Modified closed-ended DNA (CEDNA) vectors, compositions, and uses thereof
Non-viral, capsid-free DNA vectors with synthetic stem-loop structures overcome the limitations of rAAV vectors by eliminating ITR sequences, achieving efficient and enhanced gene expression for therapeutic applications.
Patent Information
- Application Number
- PCT/US2024/030986
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-04-19
- Filing Date
- 2024-05-24
- Publication Date
- 2024-12-05
AI Technical Summary
Current gene therapy using recombinant adeno-associated virus (rAAV) vectors faces limitations due to limited viral packaging capacity, immunogenicity, and immune response, which restricts the size of transgene capacity, re-administration, and efficiency of gene expression.
Development of non-viral, capsid-free DNA vectors with covalently-closed ends (ceDNA vectors) that lack viral inverted terminal repeat (ITR) sequences, utilizing synthetic stem-loop structures for transgene expression, allowing for enhanced gene expression and reduced immunogenicity.
The ceDNA vectors achieve comparable or enhanced gene expression profiles without the size constraints and immunogenic issues of traditional rAAV vectors, enabling broader therapeutic applications and reduced manufacturing costs.
Smart Images

Figure IMGF000102_0001 
Figure IMGF000102_0002 
Figure IMGF000102_0003
Abstract
Description
MODIFIED CLOSED-ENDED DNA (CEDNA) VECTORS, COMPOSITIONS, AND USES THEREOF RELATED APPLICATIONS This application claims priority to U.S. Provisional Application No.63 / 469,179, filed on May 26, 2023 and U.S. Provisional Application No.63 / 636,411, filed on April 19, 2024. The entire contents of each of the foregoing applications are expressly incorporated by reference herein in their entireties. BACKGROUND Gene therapy aims to improve clinical outcomes for patients suffering from either genetic mutations or acquired diseases caused by an aberration in the gene expression profile. Gene therapy includes the treatment or prevention of medical conditions resulting from defective genes or abnormal regulation or expression, e.g., underexpression or overexpression, that can result in a disorder, disease, malignancy, etc. For example, a disease or disorder caused by a defective gene might be treated, prevented or ameliorated by delivery of a corrective genetic material to a patient resulting in the therapeutic expression of the genetic material within the patient. The basis of gene therapy is to supply a transcription cassette with an active gene product (sometimes referred to as a transgene), e.g., that can result in a positive gain-of-function effect, a negative loss-of-function effect, or another outcome, such as, e.g., an oncolytic effect. Such outcomes can be attributed, e.g., to expression of an activating antibody, therapeutic protein, fusion protein, an inhibitory (neutralizing) antibody. Gene therapy can also be used to treat a disease or malignancy caused by other factors. Human monogenic disorders can be treated by the delivery and expression of a normal gene to the target cells. Delivery and expression of a corrective gene in the patient's target cells can be carried out via numerous methods, including the use of engineered viruses and viral gene delivery vectors. Among the many virus-derived vectors available (e.g., recombinant retrovirus, recombinant lentivirus, recombinant adenovirus, and the like), recombinant adeno-associated virus (rAAV) is gaining popularity as a versatile vector in gene therapy. However, as technology improves, and high efficiency gene transfer and expression is achieved, the ability to regulate such expression on both a temporal and spatial level becomes increasingly important. There remain several major deficiencies in using AAV vectors as a gene delivery vehicle. One major drawback associated with rAAV is its limited viral packaging capacity of about 4.5 kb of heterologous DNA (Dong et al., 1996; Athanasopoulos et al., 2004; Lai et al., 2010). As a result, use of AAV vectors has been limited to less than 150,000 Da protein coding capacity. The second drawback is that as a result of the prevalence of wild-type AAV infection in the population, candidates for rAAV gene therapy have to be screened for the presence of neutralizing antibodies that eliminate the vector from the patient before a therapeutic effect is achieved. A third drawback is 1 ME148589913v.1related to the capsid immunogenicity that prevents re-administration to patients that were not excluded from an initial treatment. The immune system in the patient can respond to the vector which effectively acts as a “booster” shot to stimulate the immune system generating high titer anti-AAV antibodies that preclude future treatments. Some recent reports indicate concerns with immunogenicity in high dose situations. Another notable drawback is that the onset of AAV-mediated gene expression is relatively slow, given that single-stranded AAV DNA must be converted to double-stranded DNA prior to heterologous gene expression. Additionally, conventional AAV virions with capsids must be produced in cultured cells, which is inefficient and introduces additional risks, including contamination by infectious agents, including other viruses. Recombinant capsid-free AAV vectors can be obtained as an isolated linear nucleic acid molecule comprising an expressible transgene and promoter regions flanked by two wild-type AAV inverted terminal repeat sequences (ITRs) including the Rep binding and terminal resolution sites. Although they avoid many of the problems of AAV-mediated gene therapy in that the transgene capacity is much higher, transgene expression onset is rapid, they still contain the attributes of the AAV-based vectors like the ITR palindromic sequences (e.g., trs, RBE, A, A’, B, B’, C, C’, D and / or D’ regions of AAV ITRs) that are found in the wild-type AAV. There remains an important unmet need for closed-ended DNA (ceDNA) with improved expression properties and reduced immunogenicity that does not comprise (is devoid of) any AAV ITR sequences. SUMMARY The present disclosure provides non-viral capsid-free DNA vectors with covalently-closed ends (referred to herein as a “closed-ended DNA vector” or a “ceDNA vector”), whereby the ceDNA vectors are devoid of or do not comprise a viral inverted terminal repeat (ITR) sequence. As is known in the art, typical AAV ITR structures comprise a palindromic double-stranded T-shaped hairpin structure, in which the double-stranded A-A’ region forms the stem, and the double- stranded B-B’ and C-C’ regions form the cross-arms of the T-shaped structure (see, for example, Ling et al., J. Virology, 89(2):952-961, 2015). The other nucleotides of the typical AAV ITR remain single stranded and are referred to as the single-stranded D(-) sequence (on the 3’ end of the ITR) and the single-stranded D(+) sequence (on the 5’ end of the ITR). Once in cells, the single-stranded regions of the D(+) region and D(-) region undergo second-strand DNA synthesis to turn them into double- stranded D and D’ regions. Prior to the instant disclosure, it was commonly believed in the art that at least some amount of viral ITR sequence was required for the replication and packaging of both AAV and ceDNA vectors used in gene therapy applications. More specifically, it was believed that a ceDNA vector minimally required at least one Rep-binding element (RBE) and at least one terminal resolution sequence (trs). The ITR is the only element of the AAV genome that is required in cis to produce viral particles. At the time of the filing, it was known in the field of gene therapy that the ITR regions D 2 ME148589913v.1and D’ contain sequences that act as binding sites for host transcription factors, including human transcription factors. Wang et al. in 1996 (J. Virol.70:1668-1677, 1996) reported that the D sequence plays a crucial role in high-efficiency rescue, selective replication, and encapsidation of the AAV genome and that a host cell protein, designated the D sequence-binding protein (D-BP), specifically interacts with this sequence. Wang et al. in 1997 (J Virol.1997 Apr; 71(4): 3077-82) further performed mutational analyses of the D sequences to evaluate their role in viral DNA rescue, replication, and packaging, and reported that 10 nucleotides proximal to the hairpin structure in each of the D sequences are necessary and sufficient to mediate high-efficiency rescue, replication, and encapsidation of the viral genome in vivo. In in vitro studies, Wang showed that the same 10 nucleotides were found to be required for specific interaction with D- sequence binding proteins. Julien et al. later reported that human transcription factors interact with the D sequence of AAV ITR (Scientific Reports (2018):8:210, pp.1-11), and knockdown of a particular transcription factor, RFX1, resulted in the absence of interaction with the D sequence of the ITR, was associated with reduced transgene expression. Further, based on work by Ling et al, it was thought by one of ordinary skill in the art that at least one of the D(+) or D(-) single-stranded regions was absolutely necessary for replication and encapsidation of AAV (see, e.g., Ling et al., J. Virology, 89(2):952-961, 2015). However, the present disclosure surprisingly demonstrated that ceDNA vectors comprising synthetic ITRs comprising no viral sequences showed comparable or even, in some embodiments, enhanced gene expression profiles for their respective transgenes. Furthermore, the ceDNA vectors of the instant disclosure have advantages over ceDNA vectors comprising viral ITRs. Removing such sequences reduced the size of a ceDNA molecule, which may be advantageous for a variety of reasons. For example, it may allow for the inclusion of other desirable sequences or motifs (e.g., functional sequences such as aptamers) without increasing the size of the ceDNA molecule. It may also reduce the cost of manufacturing by reducing the amount of raw materials needed for ceDNA production. It may also reduce the likelihood of provoking an immune response when administered to a subject. Accordingly, in one aspect, the disclosure provides a composition comprising a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structre comprising a partial duplex and at least one loop, and a lipid. In one embodiment, the stem-loop structures do not comprise any viral inverted terminal repeat (ITR) sequences. In one embodiment, the stem-loop structures do not comprise any AAV ITR sequences. In one embodiment, the stem-loop structures do not comprise any wild-type (or naturally occurring) viral inverted terminal repeat (ITR) sequences. In one embodiment, the stem-loop structures do not comprise any wild-type (or naturally occurring) AAV inverted terminal repeat (ITR) sequences. 3 ME148589913v.1In one aspect, disclosed herein is a composition comprising: a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise a viral inverted terminal repeat (ITR) sequence, and a lipid. In one embodiment, the composition further comprises a pharmaceutically acceptable excipient or carrier. In one embodiment, the ceDNA vector is encapsulated by a lipid nanoparticle (LNP). In one embodiment, the ceDNA vector is associated with an LNP. In another aspect, disclosed herein is a pharmaceutical composition comprising: a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise a viral inverted terminal repeat (ITR) sequence, an LNP, and a pharmaceutically acceptable excipient or carrier. In one embodiment, the ceDNA vector is encapsulated by a lipid nanoparticle (LNP). In one embodiment, the ceDNA vector is associated with an LNP. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising a sequence selected from the group consisting of a Rep binding element (RBE), a RBE’, a terminal resolution site (trs), an A ITR region, an A’ ITR region, a B ITR region, a B’ ITR region, a C ITR region, a C’ ITR region, a D ITR region, a D’ ITR region, and a combination thereof. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising a Rep binding element (RBE). In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising an RBE’. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising a trs. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising an A ITR region. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising an A’ ITR region. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising a B ITR region. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising a B’ ITR region. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising a C ITR region. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising a C’ ITR region. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising a D ITR region. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising a D’ ITR region. In one embodiment, the stem-loop structures do not comprise a viral ITR sequence comprising any of a Rep binding element (RBE), a RBE’, a terminal resolution site (trs), an A ITR region, an A’ ITR region, a B ITR region, a B’ ITR region, a C ITR region, a C’ ITR region, a D ITR region, or a D’ ITR region. 4 ME148589913v.1In one embodiment, the ceDNA vector does not comprise a wild-type (or naturally occurring) viral ITR sequence from a virus, e.g., an adeno-associated virus (AAV). In one embodiment, the ceDNA vector does not comprise a fragment of a wild-type (or naturally occurring) viral ITR sequence from a virus, e.g., an adeno-associated virus (AAV). In one embodiment, the at least one transgene expression cassette comprises at least one liver- specific regulatory element operably linked to at least one transgene. In one embodiment, the first stem-loop structure is located upstream of the 5’ end of the at least one transgene expression cassette and the second stem-loop structure is located downstream of the 3’ end of the at least one transgene expression cassette. In one embodiment, the first stem-loop structure and the second stem-loop structure are symmetric with respect to each other. In one embodiment, the first stem-loop structure and the second stem-loop structure are asymmetric with respect to each other. In one embodiment, the first stem-loop structure and the second stem-loop structure each comprise at least one double-stranded stem region and at least one single-stranded loop region. In one embodiment, the at least one loop is a single-stranded loop region. In one embodiment, the partial duplex comprises the double-stranded stem region. In one embodiment, each double-stranded stem region comprises about 1 to about 50 base pairs (bp), or about 1 to about 40 bp, or about 1 to about 30 bp, or about 1 to about 25 bp, or about 1 to about 20 bp, or about 1 to about 15 bp, or about 2 to about 20 bp, or about 2 to about 15 bp, or about 3 to about 20 bp, or about 3 to about 15 bp, or about 4 to about 20 bp, or about 4 to about 15 bp, or about 5 to about 20 bp, or about 5 to about 15 bp, or about 1 bp, or about 2 bp, or about 3 bp, or about 4 bp, or about 5 bp, or about 6 bp, or about 7 bp, or about 8 bp, or about 9 bp, or about 10 bp, or about 11 bp, or about 12 bp, or about 13 bp, or about 14 bp, or about 15 bp. In one embodiment, each single-stranded loop comprises about 2 to about 100 nucleotides (nt), about 2 to about 90 nt, about 2 to about 80 nt, about 2 to about 70 nt, about 2 to about 60 nt, about 2 to about 50 nt, about 2 to about 40 nt, about 2 to about 30 nt, about 2 to about 20 nt, about 2 to about 15 nt, about 2 to about 12 nt, about 2 to about 10 nt, about 2 to about 8 nt, about 3 to about 20 nt, about 3 to about 15 nt, about 3 to about 12 nt, about 3 to about 10 nt, about 3 to about 8 nt, or about 2 nt, or about 3 nt, or about 4 nt, or about 5 nt, or about 6 nt, or about 7 nt, or about 8 nt, or about 9 nt, or about 10 nt, or about 11 nt, or about 12 nt, or about 13 nt, or about 14 nt, or about 15 nt. In one embodiment, each stem-loop structure comprises at least one loop structure. In one embodiment, at least one stem-loop structure comprises an aptamer. In one embodiment, each stem- loop structure comprises an aptamer. In one embodiment, each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO:1 (5’- CTCATCAGAATCACTTTGTGATTCTGA-3’), SEQ ID NO:2 (5’- 5 ME148589913v.1TCAGAATCACAAAGTGATTCTGATGAG-3’), and SEQ ID NO:4 (5’- CACTCATCAGAATCACTTTGTGATTCTGATG-3’). In one embodiment, each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO:12 (5’- TGAGCCTTGATACCACACTTACCTTTCAAGCTTAATACCTTTAGGAGAGCAATTGCAT-3’) and SEQ ID NO:13 (5’- ATGCAATTGCTCTCCTAAAGGTATTAAGCTTGAAAGGTAAGTGTGGTATCAAGGCTCA- 3’). In one embodiment, the ceDNA vector further comprises at least one spacer region, wherein the at least one spacer region comprises an artificial nucleic acid sequence and does not comprise a viral ITR sequence. In one embodiment, the at least one spacer region is adjacent to the 5’ end of the at least one transgene expression cassette, or the at least one spacer region is adjacent to the 3’ end of the at least one transgene expression cassette, or both. In one embodiment, the at least one spacer region comprises about 1 to 200 bp, or about 5 to 150 bp, or about 10 to 100 bp, or about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 bp. In one embodiment,the at least one liver-specific regulatory element is selected from the group consisting of a liver-specific promoter, a liver-specific enhancer, a liver-specific riboswitch, a liver-specific insulator, a liver-specific mir-regulatable element, a liver-specific post-transcriptional regulatory element, a liver-specific transcription factor binding site (or consensus site), and a combination thereof. In one embodiment, the at least one liver-specific transcription factor consensus site is FoxA, HNF4, or both. In one embodiment, the at least one liver-specific promoter is selected from the group consisting of: a transthyretin (TTR) promoter, minimal TTR promotor (TTRm), an AAT promoter, an albumin (ALB) promotor or minimal promoter, an apolipoprotein A1 (APOA1) promoter or minimal promoter, a complement factor B (CFB) promoter, a ketohexokinase (KHK) promoter, a hemopexin (HPX) promoter or minimal promoter, a nicotinamide N-methyltransferase (NNMT) promoter or minimal promoter, a carboxylesterase 1 (CES1) promoter or minimal promoter, a protein C (PROC) promoter or minimal promoter, an apolipoprotein C3 (APOC3) promoter or minimal promoter, a mannan-binding lectin serine protease 2 (MASP2) promoter or minimal promoter, a hepcidin antimicrobial peptide (HAMP) promoter or minimal promoter, and a serpin peptidase inhibitor, clade C (antithrombin), member 1 (SERPINCl) promoter or minimal promoter. In one embodiment, the ceDNA vector produces an in vivo expression level of the at least one transgene expression cassette that is equivalent to or higher than the in vivo expression level produced by a reference ceDNA vector comprising a viral ITR sequence. In one embodiment, the ceDNA vector produces an in vivo liver expression level of the at least one transgene that is equivalent to or higher than the in vivo liver expression level produced by a reference ceDNA vector comprising a 6 ME148589913v.1viral ITR sequence. In one embodiment, the ceDNA vector elicits an equivalent or lower pro- inflammatory cytokine response than a reference ceDNA vector comprising a viral ITR sequence. In one embodiment, the ceDNA vector produces an expression level of the at least one transgene in a cell that is equivalent to or higher than the expression level of the at least one transgene produced by a reference ceDNA vector comprising the same transgene expression cassette and at least one stem-loop structure comprising a viral ITR sequence. In one embodiment, the cell is selected from the group consisting of a liver cell, a muscle cell, a T cell, a B cell, a natural killer (NK) cell, and a dendritic cell. In one embodiment, the cell is in vitro. In one embodiment, the cell is in vivo. In one embodiment, the cell is ex vivo. In one embodiment, the ceDNA vector is synthetically produced in a cell-free environment. In one embodiment, the ceDNA vector is produced using a method comprising: (a) contacting a double-stranded DNA construct having a sense strand and an antisense strand with at least a first restriction endonuclease and at least a second restriction endonuclease, wherein: the double-stranded DNA construct comprises: a transgene expression cassette, a first non-palindromic restriction endonuclease recognition site and a corresponding first cleavage site upstream of the transgene expression cassette, and a second non-palindromic restriction endonuclease recognition site and a corresponding second cleavage site downstream of the transgene expression cassette; and wherein the first restriction endonuclease is capable of cleaving the double-stranded DNA construct at the first cleavage site, and wherein the second restriction endonuclease is capable of cleaving the double- stranded DNA construct at the second cleavage site, and wherein contacting the double-stranded DNA construct with the first restriction endonuclease and the second restriction endonuclease releases an insert having a first end comprising a first single-stranded overhang and a second end comprising a second single-stranded overhang; (b) ligating the first end to a first oligonucleotide comprising one or more stem-loop structures, wherein the first oligonucleotide does not comprise a viral inverted terminal repeat (ITR) sequence; and (c) ligating the second end to a second oligonucleotide comprising one or more stem-loop structures, wherein the second oligonucleotide does not comprise a viral ITR sequence; thereby producing the ceDNA vector. In one embodiment, the first oligonucleotide and the second oligonucleotide are symmetric with respect to each other. In one embodiment, the first oligonucleotide and the second oligonucleotide are asymmetric with respect to each other. In one embodiment, the first oligonucleotide and the second oligonucleotide each self-anneal to form the one or more stem-loop structures and a single-stranded overhang at the 5’ end of each oligonucleotide or the 3’ end of each oligonucleotide. In one embodiment, the single-stranded overhang of the first oligonucleotide and / or the single-stranded overhang of the second oligonucleotide each comprise a 5’ to 3’ nucleic acid sequence selected from the group consisting of CTCT, CTCA, CACT, CTC, and GCT. In one embodiment, the first oligonucleotide corresponds to the first stem-loop region in the ceDNA vector and the second oligonucleotide corresponds to the second stem-loop region in the ceDNA vector. 7 ME148589913v.1In one embodiment, at least one of the first and second restriction endonucleases or wherein each of the first and second restriction endonucleases is a Type IIS restriction endonuclease. In one embodiment, the first restriction endonuclease and the second restriction endonuclease are the same restriction endonuclease. In one embodiment, the first restriction endonuclease and the second restriction endonuclease are different restriction endonucleases. In one embodiment, the Type IIS restriction endonuclease is selected from group consisting of AcuI, AlwI, Alw26I, BasI, BbsI, BbvI, BceAI, BcgI, BciVI, BcoDI, BruAI, BmrI, BpiI, BpuEI, BsaI, BsaXI, BseGI, BseRI, BsgI, BsmAI, BsmBI, BsmFI, BsmI, BspCNI, BspMI, BspQI, BsrDI, BsrI, BtgZI, BtsCI, BtsI, MutI, CspCI, EarI, EciI, Eco31I, Esp3I, FauI, FokI, HgaI, HphI, HpyAV, LguI, MboII, MlyI, MmeI, MnlI, Mva1269I, NmeAIII, PaqCI, PleI, SapI, SfaNI, and an isoschizomer thereof. In one embodiment, the Type IIS restriction endonuclease is selected from group consisting of BbsI, BsaI, BsmBI, Esp3I, and SapI, and an isoschizomer thereof. In one embodiment, the Type IIS restriction endonuclease is BsmBI or an isoschizomer thereof; or wherein each of the first and second restriction endonucleases is BsmBI or an isoschizomer thereof. In one embodiment, the lipid or LNP comprises at least one lipid selected from the group consisting of an ionizable lipid, a sterol, non-cationic lipid, and a lipid-anchored polymer. In one embodiment, the LNP comprises a sterol. In one embodiment, the sterol is cholesterol or beta-sitosterol. In one embodiment, the LNP comprises a non-cationic lipid. In one embodiment, the non- cationic lipid is selected from the group consisting of distearoyl-sn-glycero-phosphoethanolamine (DSPE), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), monomethyl-phosphatidylethanolamine (such as 16- O-monomethyl PE), dimethyl-phosphatidylethanolamine (such as 16-O-dimethyl PE), 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), hydrogenated soy phosphatidylcholine (HSPC), egg phosphatidylcholine (EPC), dioleoylphosphatidylserine (DOPS), sphingomyelin (SM), dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), dierucoylphosphatidylcholine (DEPC), palmitoyloleyolphosphatidylglycerol (POPG), dielaidoyl-phosphatidylethanolamine (DEPE), 1,2- dilauroyl-sn-glycero-3 -pho sphoethanolamine (DLPE); 1,2-diphytanoyl-sn-glycero-3- phosphoethanolamine (DPHyPE); lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidicacid, cerebrosides, dicetylphosphate, 8 ME148589913v.1lysophosphatidylcholine, dilinoleoylphosphatidylcholine, and mixtures thereof. In one embodiment, the non-cationic lipid is selected from the group consisting of dioleoylphosphatidylcholine (DOPC), distearoylphosphatidylcholine (DSPC), and dioleoyl-phosphatidylethanolamine (DOPE). In one embodiment, the non-cationic lipid is DSPC. In one embodiment, the LNP comprises a lipid-anchored polymer. In one embodiment, the lipid-anchored polymer is a PEGylated lipid. In one embodiment, the PEGylated lipid is selected from the group consisting of PEG-dilauryloxypropyl; PEG-dimyristyloxypropyl; PEG- dipalmityloxypropyl, PEG-distearyloxypropyl; l-(monomethoxy-polyethyleneglycol)-2,3- dimyristoylglycerol (DMG-PEG); PEG-dilaurylglycerol; PEG-dipalmitoylglycerol; PEG- disterylglycerol; PEG-dilaurylglycamide; PEG-dimyristylglycamide; PEG-dipalmitoylglycamide; PEG-disterylglycamide; (l-[8’-(Cholest-5-en-3[beta]-oxy)carboxamido-3’,6’-dioxaoctanyl] carbamoyl-[omega]-methyl-poly(ethylene glycol) (PEG-cholesterol); 3,4-ditetradecoxylbenzyl- [omega]- methyl-poly(ethylene glycol) ether (PEG-DMB), and l,2-dimyristoyl-sn-glycero-3- phosphoethanolamine-N- [methoxy(polyethylene glycol) (DSPE-PEG). In one embodiment, the PEGylated lipid is DMG-PEG, DSPE-PEG, or both. In one embodiment, the PEGylated lipid is DMG-PEG2000, DSPE-PEG2000, or both. In one embodiment, the LNP comprises an ionizable lipid, a sterol, and a lipid-anchored polymer. In one embodiment, the LNP comprises an ionizable lipid, a sterol, a non-cationic lipid, and a lipid-anchored polymer. In one embodiment, the LNP comprise a tissue-specific targeting ligand. In one embodiment, the tissue-specific targeting ligand is N-acetylgalactosamine (GalNAc) or a GalNAc derivative. In one embodiment, the tissue-specific targeting ligand is covalently linked to the PEGylated lipid to form a PEGylated lipid conjugate. In one embodiment, the PEGylated lipid conjugate comprises tetra- or tri-antennary GalNAc covalently linked to the PEGylated lipid. In one embodiment, the PEGylated lipid is DSPE-PEG2000 In one embodiment, the ionizable lipid is present in the LNP at a molar percentage of about 30% to about 70%. In one embodiment, the sterol is present in the LNP at a molar percentage of about 20% to about 50%. In one embodiment, the non-cationic lipid is present in the LNP at a molar percentage of about 2% to about 20%. In one embodiment, the lipid-anchored polymer or PEGylated lipid is present in the LNP at a molar percentage of about 2.1% to about 10%. In one embodiment, the PEGylated lipid conjugate is present in the LNP at a molar percentage of about 0.1% to about 10%. In one embodiment, the LNP comprises an ionizable lipid, a sterol, a non-cationic lipid, a PEGylated lipid, and a PEGylated lipid conjugate. 9 ME148589913v.1In one embodiment, the LNP has an average diameter ranging from about 40 nm to about 120 nm. In one embodiment, the LNP has an average diameter of less than about 100 nm. In one embodiment, the LNP has an average diameter of about 50 nm to about 80 nm. In one aspect, disclosed herein is an isolated host cell comprising a ceDNA vector of the composition or pharmaceutical compositions disclosed herein. In one aspect, disclosed herein is an isolated host cell comprising: a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise any viral ITR sequences. In one aspect, disclosed herein is a transgenic animal comprising a ceDNA vector or an isolated host cell. In one aspect, disclosed herein is a transgenic animal comprising: a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise any viral ITR sequences. In one aspect, disclosed herein is a method of treating a disorder, disease, or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of a composition or pharmaceutical composition disclosed herein. In one aspect, disclosed herein is a method of treating a disorder, disease, or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise any viral ITR sequence, wherein the ceDNA vector is encapsulated by an LNP. In one embodiment, the disorder, disease, or condition is a genetic disorder, disease, or condition. In one aspect, disclosed herein is a method of delivering a therapeutic protein to a subject, the method comprising administering to the subject a therapeutically effective amount of the composition or pharmaceutical composition disclosed herein. In one aspect, disclosed herein is a method of delivering a therapeutic protein to a subject, the method comprising administering to the subject a therapeutically effective amount of a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise any viral ITR sequences, and wherein the 10 ME148589913v.1ceDNA vector is encapsulated by an LNP. In one embodiment, therapeutic protein is selected from the group consisting of an enzyme, a coagulation factor or co-factor, an antibody or an antigen- binding fragment thereof, an antigen, a gene-editing protein, and a cytotoxic protein. In one aspect, disclosed herein is a method of producing the ceDNA vector of any one of claims 1 to 72, the method comprising: (a) contacting a double-stranded DNA construct having a sense strand and an antisense strand with at least a first restriction endonuclease and at least a second restriction endonuclease, wherein: the construct comprises: a transgene expression cassette, a first non-palindromic restriction endonuclease recognition site and a corresponding first cleavage site upstream of the transgene expression cassette, and a second non-palindromic restriction endonuclease recognition site and a corresponding second cleavage site downstream of the transgene expression cassette; and wherein the first restriction endonuclease is capable of cleaving the double-stranded DNA construct at the first cleavage site, and wherein the second restriction endonuclease is capable of cleaving the double-stranded DNA construct at the second cleavage site, and wherein contacting the double-stranded DNA construct with the first restriction endonuclease and the second restriction endonuclease releases an insert having a first end comprising a first single-stranded overhang and a second end comprising a second single-stranded overhang; (b) ligating the first end to a first oligonucleotide comprising one or more stem-loop structures, wherein the first oligonucleotide does not comprise a viral inverted terminal repeat (ITR) sequence; and (c) ligating the second end to a second oligonucleotide comprising one or more stem-loop structures, wherein the second oligonucleotide does not comprise a viral ITR sequence; thereby producing the ceDNA vector. In one embodiment, the first oligonucleotide and the second oligonucleotide are symmetric with respect to each other. In one embodiment, the first oligonucleotide and the second oligonucleotide are asymmetric with respect to each other. In one embodiment, the first oligonucleotide and the second oligonucleotide each self-anneal to form the one or more stem-loop structures and a single-stranded overhang at the 5’ end of each oligonucleotide or the 3’ end of each oligonucleotide. In one embodiment, the single-stranded overhang of the first oligonucleotide and / or the single-stranded overhang of the second oligonucleotide each comprise a 5’ to 3’ nucleic acid sequence selected from the group consisting of CTCT, CTCA, CACT, CTC, and GCT. In one embodiment, the first oligonucleotide corresponds to the first stem-loop region in the ceDNA vector and the second oligonucleotide corresponds to the second stem-loop region in the ceDNA vector. In one embodiment, at least one of the first and second restriction endonucleases or wherein each of the first and second restriction endonucleases is a Type IIS restriction endonuclease. In one embodiment, the first restriction endonuclease and the second restriction endonuclease are the same restriction endonuclease. In one embodiment, the first restriction endonuclease and the second restriction endonuclease are different restriction endonucleases. In one embodiment, the Type IIS restriction endonuclease is selected from group consisting of AcuI, AlwI, Alw26I, BasI, BbsI, BbvI, BceAI, BcgI, BciVI, BcoDI, BruAI, BmrI, BpiI, BpuEI, BsaI, BsaXI, BseGI, BseRI, BsgI, BsmAI, 11 ME148589913v.1BsmBI, BsmFI, BsmI, BspCNI, BspMI, BspQI, BsrDI, BsrI, BtgZI, BtsCI, BtsI, MutI, CspCI, EarI, EciI, Eco31I, Esp3I, FauI, FokI, HgaI, HphI, HpyAV, LguI, MboII, MlyI, MmeI, MnlI, Mva1269I, NmeAIII, PaqCI, PleI, SapI, SfaNI, and an isoschizomer thereof. In one embodiment, the Type IIS restriction endonuclease is selected from group consisting of BbsI, BsaI, BsmBI, Esp3I, and SapI, and an isoschizomer thereof. In one embodiment, the Type IIS restriction endonuclease is BsmBI or an isoschizomer thereof; or wherein each of the first and second restriction endonucleases is BsmBI or an isoschizomer thereof. These and other aspects of the disclosure are described in further detail below. BRIEF DESCRIPTION OF THE DRAWINGS The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing(s) will be provided by the Office upon request and payment of the necessary fee. Embodiments of the present disclosure, briefly summarized above and discussed in greater detail below, can be understood by reference to the illustrative embodiments of the disclosure depicted in the appended drawings. However, the appended drawings illustrate only typical embodiments of the disclosure and are therefore not to be considered limiting of scope, for the disclosure may admit to other equally effective embodiments. FIG.1A and FIG.1B are schematic diagrams showing, respectively, ceDNAs 384 and ceDNA 558, each representing non-limiting embodiments of non-viral and capsid-free DNA vectors having covalently-closed ends (ceDNA) that contain no viral inverted terminal repeat (ITR) sequences. FIG.2A and FIG.2B are schematic diagrams showing the cell-free synthetic production of, respectively, ceDNA 384 and ceDNA 558, which includes a one-step restriction digestion and ligation reaction. FIG.3A is a graph comparing the in vitro expression of green fluorescence protein (GFP) in human embryonic kidney cells (293T cells) transfected with 30 ng, 90 ng, or 180 ng of reference ceDNA 382 (with 5’ AAV2 ITR and 3’ AAV2 ITR) and ceDNA 558A (with no viral ITR sequences), where the ceDNA vectors each carry a gfp transgene. FIG.3B is a graph comparing the in vitro expression of GFP in human fibroblasts (HFF1) transfected with reference ceDNA 382 or ceDNA 558A. FIG.4A and FIG.4B are graphs comparing the in vivo expression of luciferase in C57 mice and Rag2KO mice at Day 7 and Day 14, respectively, after being dosed via intravenous administration with reference ceDNA 382 (with 5’ AAV2 ITR and 3’ AAV2 ITR) and ceDNA 558 (with no viral ITR sequences) that were each formulated as lipid nanoparticles (LNPs). 12 ME148589913v.1FIGS.5A-5F and FIGS.5G-5L are images taken using the in vivo imaging system at Day 7 and Day 14 post-dosing, indicating that the luciferase expression was detected in the abdominal area of the mice where the liver is located. FIG.6A and FIG.6B are graphs showing the longitudinal body weight change in C57 mice and Rag2KO mice from Day 0 through Day 28 after being dosed via intravenous administration with reference ceDNA 382 (with 5’ AAV2 ITR and 3’ AAV2 ITR) and ceDNA 558 (with no viral ITR sequences) that were each formulated as lipid nanoparticles (LNPs). FIGS.7A-7E depict, respectively, blood serum levels of IFN-γ (FIG.7A), IL-18 (FIG.7B), IFN-α (FIG.7C), TNF-α (FIG.7D), and IL-6 (FIG.7E) in C57 mice and Rag2KO mice at 6 hours pose-dose following injection of reference ceDNA 382 (with 5’ AAV2 ITR and 3’ AAV2 ITR) and ceDNA 558 (with no viral ITR sequences) that were each formulated as lipid nanoparticles (LNPs). FIG.8 provides a schematic diagram of the ITR structures of various synthetic ceDNA constructs with one or more complete sections of the ITR regions A and A’, B and B’, C and C’, or D and D’ removed. The structural ITR variant constructs were designated as follows: ceDNA178 (wt- wt); ceDNA4 (wt-wt); ceDNA14 (wt-mu); ceDNA15 (mu-mu); ceDNA16 (blunt-blunt); ceDNA17 (hpin-hpin); ceDNA18 (blunt-wt); ceDNA19 (blunt-mu); ceDNA20 (hpin-wt); ceDNA35 (wt-hpin). FIG.9A and FIG.9B show the results of transfection and expression of ceDNA variants in human leukemia monocytic cells (THP-1) and human fibroblast cell line (HFF1) cells. FIG.10 is a graph that shows expression of ceDNA transgene in 293T cells in suspension. FIG.11 is a graph that shows expression of ceDNA transgene in adherent HFF1 cells. FIG.12 is a graph that shows the results of analysis of different ceDNA constructs shown in FIG.8 by IFN bioassay in THP1-ISG reporter cell. ISG promoter activation was determined by transferring supernatant from 293T cells and supernatant transferred from HFF1 cells. Expression of ceDNA transgene in 293T cells did not induce IFN-I, but did induce IFN-I in HFF1 cells. FIG.13A and FIG.13B are graphs that show the results of analysis of ceDNA constructs shown in FIG.8 by Bioassay, and a correlation of transgene expression and IFN response. FIG.14A and FIG.14B are graphs that show the correlation of expression and innate immune response in ceDNA4 (wt-wt) and ceDNA20 (hpin-wt) constructs. FIG.15A is a graph that shows GFP expression of ceDNA20 (hpin-wt) having 3’ left, wt-ITR and ceDNA35 with opposing ITR (wt-hpin) having 5’ right wt-ITR configurations in HFF1 cells. FIG.15B is a graph that shows results obtained in the interferon bioassay in THP1 -ISG reporter cells. FIG.16A and FIG.16B are graphs that show the results of ceDNA expression analysis in retinal pigment epithelial (RPE) for ceDNA4 (wt-wt), ceDNA17 (hpin-hpin), ceDNA20 (hpin-wt) and ceDNA35 (wt-hpin). FIG.16A shows GFP intensity. FIG.16B shows GFP expression over time. FIG.17A and FIG.17B are graphs that show the results of GFP expression analysis in RAW-ISG murine macrophage cell line for ceDNA4 (wt-wt), ceDNA17 (hpin-hpin), ceDNA20 (hpin- 13 ME148589913v.1wt) and ceDNA35 (wt-hpin). FIG.17A shows GFP intensity. FIG.17B shows GFP expression over time. FIG.18 is a graph that shows GFP expression in HEPaRG cells over time. As shown in FIG. 18, synthetic ceDNA (ceDNA4) recapitulated the long-term expression observed with the Sf9-ceDNA (ceDNA178). FIG.19 is a Western blot that shows the results of synthetic ceDNA production in insect cells by transient transfection and the absence of detectable non-ceDNA species. FIG.20 is a Western blot that shows the results of amplification of ceDNA with one ITR (right) in SF9 cells. DETAILED DESCRIPTION One of the biggest hurdles in the development of therapeutics, particularly in rare diseases, is the large number of individual conditions. Around 350 million people on earth are living with rare disorders, defined by the National Institutes of Health as a disorder or condition with fewer than 200,000 people diagnosed. About 80 percent of these rare disorders are genetic in origin, and about 95 percent of them do not have treatment approved by the FDA. Among the advantages of the ceDNA vectors described herein is in providing an approach that can be rapidly adapted to multiple diseases, and particularly to rare monogenic diseases, and allow for the treatment of a wider range of rare and prevalent diseases than what is currently possible with viral gene therapy. According to some aspects, the disclosure provides a composition comprising a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise any viral ITR sequences, and a lipid. According to some aspects, the disclosure provides a method of delivering a therapeutic protein to a subject, the method comprising administering to the subject a therapeutically effective amount of ceDNA vector, wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise any viral ITR sequences. In some embodiments, the ceDNA vectors described herein can be used for gene editing. In some embodiments, the ceDNA vectors described herein comprise an antibody, or an antigen binding fragment thereof. In some embodiments, the ceDNA vectors described herein comprise an aptamer. In some embodiments, the ceDNA vectors described herein comprise a regulatory switch, thus allowing for controllable gene expression after delivery. 14 ME148589913v.1I. Definitions Unless otherwise defined herein, scientific and technical terms used in connection with the present application shall have the meanings that are commonly understood by those of ordinary skill in the art to which this disclosure belongs. It should be understood that this disclosure is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present disclosure, which is defined solely by the claims. Definitions of common terms in immunology and molecular biology can be found in The Merck Manual of Diagnosis and Therapy, 19th Edition, published by Merck Sharp & Dohme Corp., 2011 (ISBN 978-0- 911910-19-3); Robert S. Porter et al. (eds.), Fields Virology, 6thEdition, published by Lippincott Williams & Wilkins, Philadelphia, PA, USA (2013), Knipe, D.M. and Howley, P.M. (ed.), The Encyclopedia of Molecular Cell Biology and Molecular Medicine, published by Blackwell Science Ltd., 1999-2012 (ISBN 9783527600908); and Robert A. Meyers (ed.), Molecular Biology and Biotechnology: a Comprehensive Desk Reference, published by VCH Publishers, Inc., 1995 (ISBN 1- 56081-569-8); Immunology by Werner Luttmann, published by Elsevier, 2006; Janeway's Immunobiology, Kenneth Murphy, Allan Mowat, Casey Weaver (eds.), Taylor & Francis Limited, 2014 (ISBN 0815345305, 9780815345305); Lewin's Genes XI, published by Jones & Bartlett Publishers, 2014 (ISBN-1449659055); Michael Richard Green and Joseph Sambrook, Molecular Cloning: A Laboratory Manual, 4thed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA (2012) (ISBN 1936113414); Davis et al., Basic Methods in Molecular Biology, Elsevier Science Publishing, Inc., New York, USA (2012) (ISBN 044460149X); Laboratory Methods in Enzymology: DNA, Jon Lorsch (ed.) Elsevier, 2013 (ISBN 0124199542); Current Protocols in Molecular Biology (CPMB), Frederick M. Ausubel (ed.), John Wiley and Sons, 2014 (ISBN 047150338X, 9780471503385), Current Protocols in Protein Science (CPPS), John E. Coligan (ed.), John Wiley and Sons, Inc., 2005; and Current Protocols in Immunology (CPI) (John E. Coligan, ADA M Kruisbeek, David H Margulies, Ethan M Shevach, Warren Strobe, (eds.) John Wiley and Sons, Inc., 2003 (ISBN 0471142735, 9780471142737), the contents of which are all incorporated by reference herein in their entireties. As used herein, the term “AAV” or “adeno-associated virus” refer to single-stranded DNA parvoviruses that grow only in cells. Certain functions of AAV are provided only by co-infecting a helper virus. Thirteen serotypes of AAV have been identified. General information and review of AAV can be found, e.g., in Carter, 1989, Handbook of Parvoviruses, Vol.1, p.169-228, and Berns, 1990, Virology, pp.1743-1764, Raven Press, (New York). As used herein the terms, “administration,” “administering” and variants thereof refers to introducing a composition or agent (e.g., nucleic acids, in particular ceDNA) into a subject and includes concurrent and sequential introduction of one or more compositions or agents. “Administration” can refer, e.g., to therapeutic, pharmacokinetic, diagnostic, research, placebo, and 15 ME148589913v.1experimental methods. “Administration” also encompasses in vitro and ex vivo treatments. The introduction of a composition or agent into a subject is by any suitable route known in the art, including, but not limited to, orally, pulmonarily (e.g., via inhalation), intranasally, parenterally (intravenously, intramuscularly, intraperitoneally, or subcutaneously), rectally, intralymphatically, intratumorally, or topically. Administration includes self-administration and the administration by another. Administration can be carried out by any suitable route. A suitable route of administration allows the composition or the agent to perform its intended function. For example, if a suitable route is intravenous, the composition is administered by introducing the composition or agent into a vein of the subject. As used herein, the term “antibody” is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity. An “antibody fragment” refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the same antigen to which the intact antibody binds. In one embodiment, the antibody or antibody fragment comprises an immunoglobulin chain or antibody fragment and at least one immunoglobulin variable domain sequence. Examples of antibodies or fragments thereof include, but are not limited to, an Fv, an scFv, a Fab fragment, a Fab’, a F(ab’)2, a Fab’-SH, a single domain antibody (dAb), a heavy chain, a light chain, a heavy and light chain, a full antibody (e.g., includes each of the Fc, Fab, heavy chains, light chains, variable regions etc.), a bispecific antibody, a diabody, a linear antibody, a single chain antibody, an intrabody, a monoclonal antibody, a chimeric antibody, a multispecific antibody, or a multimeric antibody. An antibody or fragment thereof can be of any class, including but not limited to IgA, IgD, IgE, IgG, and IgM, and of any subclass thereof including but not limited to IgG1, IgG2, IgG3, IgG4, IgA1 and IgA2. In addition, an antibody can be derived from any mammal, for example, primates, humans, rats, mice, horses, goats etc. In one embodiment, the antibody is human or humanized. In some embodiments, the antibody is a modified antibody. In some embodiments, the components of an antibody can be expressed separately such that the antibody self-assembles following expression of the protein components. In some embodiments, the antibody is “humanized” to reduce immunogenic reactions in a human. In some embodiments, the antibody has a desired function, for example, interaction and inhibition of a desired protein for the purpose of treating a disease or a symptom of a disease. In one embodiment, the antibody or antibody fragment comprises a framework region or an Fcregion. As used herein, the term “antigen-binding domain” of an antibody molecule refers to the part of an antibody molecule, e.g., an immunoglobulin (Ig) molecule, that participates in antigen binding. In embodiments, the antigen binding site is formed by amino acid residues of the variable (V) regions of the heavy (H) and light (L) chains. Three highly divergent stretches within the variable regions of the heavy and light chains, referred to as hypervariable regions, are disposed between more conserved 16 ME148589913v.1flanking stretches called “framework regions,” (FRs). FRs are amino acid sequences that are naturally found between, and adjacent to, hypervariable regions in immunoglobulins. In embodiments, in an antibody molecule, the three hypervariable regions of a light chain and the three hypervariable regions of a heavy chain are disposed relative to each other in three-dimensional space to form an antigen- binding surface, which is complementary to the three-dimensional surface of a bound antigen. The three hypervariable regions of each of the heavy and light chains are referred to as “complementarity- determining regions,” or “CDRs.” The framework region and CDRs have been defined and described, e.g., in Kabat, E. A., et al. (1991) Sequences of Proteins of Immunological Interest, Fifth Edition, U.S. Department of Health and Human Services, NIH Publication No.91-3242, and Chothia, C. et al. (1987) J. Mol. Biol.196:901-917. Each variable chain (e.g., variable heavy chain and variable light chain) is typically made up of three CDRs and four FRs, arranged from amino-terminus to carboxy- terminus in the amino acid order: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. As used herein, the phrase “anti-therapeutic nucleic acid immune response,” “anti-transfer vector immune response,” “immune response against a therapeutic nucleic acid,” “immune response against a transfer vector,” or the like refers to any undesired immune response against a therapeutic nucleic acid, viral or non-viral in its origin. In some embodiments, the undesired immune response is an antigen-specific immune response against the viral transfer vector itself. In some embodiments, the immune response is specific to the transfer vector which can be double stranded DNA, single stranded RNA, or double stranded RNA. In other embodiments, the immune response is specific to a sequence of the transfer vector. In other embodiments, the immune response is specific to the CpG content of the transfer vector. As used herein, the term “aptamer” refers to a nucleic acid molecule that is capable of binding to a particular molecule of interest with high affinity and specificity (Tuerk and Gold, Science 249:505 (1990); Ellington and Szostak, Nature 346:818 (1990)). For example, aptamers may be composed of DNA or RNA, or may comprise nonnatural nucleotides and nucleotide analogs (e.g., locked DNA or peptide nucleic acids [PNAs]) that have high affinity to a protein localized in the nucleus or the membrane thereof. As used herein, “carrier” includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like. The use of such media and agents for pharmaceutically active substances is well known in the art. Supplementary active ingredients can also be incorporated into the compositions. The phrase “pharmaceutically-acceptable” refers to molecular entities and compositions that do not produce a toxic, an allergic, or similar untoward reaction when administered to a host. As used herein, the term “ceDNA” refers to capsid-free closed-ended linear double stranded (ds) duplex DNA for non-viral gene transfer, synthetic or otherwise. Detailed description of ceDNA is described in International Patent Application No. PCT / US2017 / 020828, filed March 3, 2017, the 17 ME148589913v.1entire contents of which are expressly incorporated herein by reference. Certain methods for the production of ceDNA comprising various inverted terminal repeat (ITR) sequences and configurations using cell-based methods are described in Example 1 of International applications PCT / US18 / 49996, filed September 7, 2018, and PCT / US2018 / 064242, filed December 6, 2018 each of which is incorporated herein in its entirety by reference. Certain methods for the production of synthetic ceDNA vectors comprising various ITR sequences and configurations are described, e.g., in International application PCT / US2019 / 14122, filed January 18, 2019, the entire content of which is incorporated herein by reference. As used herein, the terms “ceDNA vector” and “ceDNA” are used interchangeably. In one embodiment, the ceDNA is a closed-ended linear duplex (CELiD) CELiD DNA. In one embodiment, the ceDNA is a DNA-based minicircle. In one embodiment, the ceDNA is a minimalistic immunological-defined gene expression (MIDGE)-vector. In one embodiment, the ceDNA is a ministering DNA. In one embodiment, the ceDNA is a doggybone™ DNA. With the exception of the reference ceDNA vectors that are described herein in the Examples and any other non-inventive ceDNA vectors referred herein, the ceDNA vectors of this disclosure contain no viral ITR sequences. As used herein, the term “reference ceDNA” or “reference ceDNA vector” refers to a ceDNA that contains a viral ITR sequence, e.g., a 5’ AAV derived wt-ITR and a 3’ AAV derived wt- ITR, or a partial or a modified AAV-derived ITR sequence. For example, a reference ceDNA may comprise an AAV-derived ITR sequence with a deletion, substitution, or deletion as compared to a wild-type ITR sequence (e.g., a wild-type AAV ITR sequence). A reference ceDNA comprising a partial AAV-derived ITR sequence may comprise, for example, at least one viral ITR sequence, including, but not limited to, a trs, Rep binding element (RBE), A, A’, B, B’, C, C’, D and / or D’ regions of AAV ITRs. A reference ceDNA vector may be prepared using conventional cell-based production methods, such as Sf9 insect cell-based production method, or the reference ceDNA vector may be synthetically produced in a cell-free environment. As used herein, the terms “closed-ended DNA vector”, “ceDNA vector” and “ceDNA” are used interchangeably and refer to a synthetically made, capsid-free DNA vector, with at least one covalently-closed end (i.e., an intramolecular duplex). In some embodiments, the ceDNA comprises two covalently-closed ends. As used herein, the term “ceDNA (vector) of this invention / disclosure,” “ceDNA (vector) of the present invention / disclosure” refers to an inventive ceDNA provided herein that contains no viral sequences (e.g., ITR sequences, e.g., does not comprise (is devoid of) any viral ITR sequences, including, but not limited to, trs, RBE, A, A’, B, B’, C, C’, D, and / or D’ regions (e.g., trs, RBE, A and A’, B and B’, C and C’ and / or D and D’ regions of an AAV ITR)). Replacing all of the elements and regions of AAV ITRs with a stem-loop structure, the ceDNA vectors of this disclosure are synthetically produced in a cell-free environment, such as using the procedures as described in Example 1 of this disclosure and also in Examples 2-6 of International Patent Application No. 18 ME148589913v.1PCT / US2019 / 014122, filed January 18, 2019, and also in International Patent Application No. PCT / US2022 / 053868, filed December 22, 2022, each of which is incorporated herein in its entirety by reference. As used herein, the terms “cell-free,” “cell-free synthesis,” “cell-free production,” “synthetic closed-ended DNA vector production” and “synthetic production” and all other related counterparts are used interchangeably and refer to the production of one or more molecules in a manner that does not involve replication or other multiplication of the molecule by or inside of a cell or using a cellular extract. Synthetic production avoids contamination of the produced molecule with cellular contaminants (e.g., cellular proteins or cellular nucleic acids) and further avoids unwanted cellular- specific modification of the molecule during the production process (e.g., methylation or glycosylation or other post-translational modification). As used herein, the terms “inverted terminal repeat” or “ITR” are meant to refer to a nucleic acid sequence located at the 5’ and / or 3’ terminus of an AAV molecule or ceDNA molecule and which comprise at least one stem-loop structure comprising a partial duplex and at least one loop. As used herein, a “wild-type ITR” or “WT-ITR” refers to the viral sequence of a naturally occurring ITR sequence in an AAV genome or other dependovirus that retains, e.g., Rep binding activity and Rep nicking ability. The nucleotide sequence of a WT-ITR from any AAV serotype may slightly vary from the canonical naturally occurring sequence due to degeneracy of the genetic code or drift. A wild-type ITR comprises trs, RBE, A, A’, B, B’, C, C’, D, and / or D’ regions (e.g., trs, RBE, A and A’, B and B’, C and C’ and / or D and D’ regions of an AAV ITR). As used herein, the term “viral inverted terminal repeat,” “viral ITR,” “viral inverted terminal repeat sequence,” “viral ITR sequence,” “virally-derived inverted terminal repeat (ITR)” or “virally- derived ITR sequence” refers to an ITR sequence that is a wild-type ITR sequence, or a fragment thereof, e.g., an AAV wild-type ITR sequence or a fragment thereof. In some embodiments, a viral ITR can be, e.g., a naturally occurring ITR sequence or ITR sequence fragment from, e.g., AAV. In other embodiments, a viral ITR can be, e.g., a modified ITR sequence or fragment thereof derived from a virus, e.g., wherein the virus is an AAV. In some embodiments, a modified ITR sequence derived from a virus can have at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identity with a wild-type ITR sequence, e.g., wherein the virus is an AAV. For example, the ITR can be from (i.e., originates from) the family Parvoviridae, which encompasses parvoviruses and dependoviruses (e.g., canine parvovirus, bovine parvovirus, mouse parvovirus, porcine parvovirus, human parvovirus B-19), or the SV40 hairpin that serves as the origin of SV40 replication can be used as an ITR, which can further be modified by truncation, substitution, deletion, insertion and / or addition. Parvoviridae family viruses consist of two subfamilies: Parvovirinae, which infect vertebrates, and Densovirinae, which infect invertebrates. Typically, these ITRs are about 145 nucleotides in length and in nature are inverted with respect to the other. Dependoparvoviruses include the viral family of the adeno-associated viruses (AAV) which are capable of replication in 19 ME148589913v.1vertebrate hosts including, but not limited to, human, primate, bovine, canine, equine and ovine species. The terminal 125 nucleotides in each ITR form a palindromic double-stranded T-shaped hairpin structure, in which the A-A' palindrome forms the stem, and the two smaller palindromes, B- B' and the C-C', form the cross-arms of the T. For example, a cell-dependent AAV-derived vector typically contains two ITR sequences with trs, RBE, A and A’, B and B’, C and C’ and / or D and / or D’ regions. In one embodiment, a viral ITR may comprise one or more of trs, RBE, A, A’, B, B’, C, C’, D, and / or D’ ITR regions (e.g., trs, RBE, A and A’, B and B’, C and C’ and / or D and D’ regions of an AAV ITR). As used herein, the terms “spacer” or “spacer region” refer to an intervening sequence that separates functional elements in the ceDNA vector. In some embodiments, ceDNA spacer regions keep two functional elements at a desired distance for optimal functionality. In some embodiments, ceDNA spacer regions provide or add to the genetic stability of the ceDNA within e.g., a plasmid or baculovirus. In some embodiments, ceDNA spacer regions facilitate ready genetic manipulation of the ceDNA molecule by providing a convenient location for cloning sites and the like. For example, in certain aspects, an oligonucleotide “polylinker” containing several restriction endonuclease sites, or a non-open reading frame sequence designed to have no known protein (e.g., transcription factor) binding sites can be positioned in the ceDNA molecule to separate the cis – acting factors, e.g., inserting a 6mer, 12mer, 18mer, 24mer, 48mer, 86mer, 176mer, etc. between the terminal resolution site and the upstream transcriptional regulatory element. Similarly, the spacer may be incorporated between the polyadenylation signal sequence and the 3’-terminal resolution site. In some embodiments, the 5’ or 3’ end of the spacer region of a ceDNA vector contains partial sequences of one or more recognition sites for a restriction endonuclease, such as a Type IIS restriction endonuclease. As used herein, the term “exogenous” refers to a substance present in a cell other than its native source. The term “exogenous” when used herein can refer to a nucleic acid (e.g., a nucleic acid encoding a polypeptide) or a polypeptide that has been introduced by a process involving the hand of man into a biological system such as a cell or organism in which it is not normally found and one wishes to introduce the nucleic acid or polypeptide into such a cell or organism. Alternatively, “exogenous” can refer to a nucleic acid or a polypeptide that has been introduced by a process involving the hand of man into a biological system such as a cell or organism in which it is found in relatively low amounts and one wishes to increase the amount of the nucleic acid or polypeptide in the cell or organism, e.g., to create ectopic expression or levels. In contrast, as used herein, the term “endogenous” refers to a substance that is native to the biological system or cell. As used herein, the term “effector protein” refers to a polypeptide that provides a detectable read-out, either as, for example, a reporter polypeptide, or more appropriately, as a polypeptide that kills a cell, e.g., a toxin, or an agent that renders a cell susceptible to killing with a chosen agent or lack thereof. Effector proteins include any protein or peptide that directly targets or damages the host 20 ME148589913v.1cell’s DNA and / or RNA. For example, effector proteins can include, but are not limited to, a restriction endonuclease that targets a host cell DNA sequence (whether genomic or on an extrachromosomal element), a protease that degrades a polypeptide target necessary for cell survival, a DNA gyrase inhibitor, and a ribonuclease-type toxin. In some embodiments, the expression of an effector protein controlled by a synthetic biological circuit as described herein can participate as a factor in another synthetic biological circuit to thereby expand the range and complexity of a biological circuit system’s responsiveness. As used herein, the terms “transgene expression cassette,” “expression cassette,” “transcription cassette” and “gene expression unit” are used interchangeably and refer to a linear stretch of nucleic acids that includes a transgene that is operably linked to one or more regulatory elements such as promoters or other regulatory sequences sufficient to direct transcription of the transgene, but which does not comprise capsid-encoding sequences, other vector sequences or inverted terminal repeat regions. An expression cassette may additionally comprise one or more regulatory genetic elements including cis-acting sequences (e.g., promoters, enhancers, or repressors), one or more introns, one or more polyadenylation signals and one or more post-transcriptional regulatory elements such as a WHP post-transcriptional regulatory element (WPRE). As used herein, the term “flanking” refers to a relative position of one nucleic acid sequence with respect to another nucleic acid sequence. Generally, in the sequence ABC, B is flanked by A and C. The same is true for the arrangement AxBxC. Thus, a flanking sequence precedes or follows a flanked sequence but need not be contiguous with, or immediately adjacent to the flanked sequence. In one embodiment, the term flanking refers to terminal repeats at each end of the linear single strand synthetic AAV vector. As used herein, the term “full length antibody” refers to an immunoglobulin (Ig) molecule (e.g., an IgG antibody), for example, that is naturally occurring, and formed by normal immunoglobulin gene fragment recombinatorial processes. As used herein, the term “functional antibody fragment” refers to a fragment that binds to the same antigen as that recognized by the intact (e.g., full-length) antibody. The terms “antibody fragment” or “functional fragment” also include isolated fragments consisting of the variable regions, such as the “Fv” fragments consisting of the variable regions of the heavy and light chains or recombinant single chain polypeptide molecules in which light and heavy variable regions are connected by a peptide linker (“scFv proteins”). In some embodiments, an antibody fragment does not include portions of antibodies without antigen binding activity, such as Fc fragments or single amino acid residues. As used herein, the term “gene” is used broadly to refer to any segment of nucleic acid associated with expression of a given RNA or protein, in vitro or in vivo. Thus, genes include regions encoding expressed RNAs (which typically include polypeptide coding sequences) and, often, the 21 ME148589913v.1regulatory sequences required for their expression. Genes can be obtained from a variety of sources, including cloning from a source of interest or synthesizing from known or predicted sequence information, and may include sequences designed to have specifically desired parameters. As used herein, the phrase “genetic disease” or “genetic disorder” refers to a disease, partially or completely, directly or indirectly, caused by one or more abnormalities in the genome, including and especially a condition that is present from birth. The abnormality may be a mutation, an insertion or a deletion in a gene. The abnormality may affect the coding sequence of the gene or its regulatory sequence. As used herein, the term “heterologous” refers to a nucleotide or polypeptide sequence that is not found in the native nucleic acid or protein, respectively. As used herein, the terms “heterologous nucleotide sequence” and “transgene” are used interchangeably and refer to a nucleic acid of interest (other than a nucleic acid encoding a capsid polypeptide) that is incorporated into and may be delivered and expressed by a ceDNA vector as disclosed herein. A heterologous nucleic acid sequence may be linked to a naturally occurring nucleic acid sequence (or a variant thereof) (e.g., by genetic engineering) to generate a chimeric nucleotide sequence encoding a chimeric polypeptide. A heterologous nucleic acid sequence may be linked to a variant polypeptide (e.g., by genetic engineering) to generate a nucleotide sequence encoding a fusion variant polypeptide. Transgenes of interest include, but are not limited to, nucleic acids encoding polypeptides, preferably therapeutic (e.g., for medical, diagnostic, or veterinary uses) or immunogenic polypeptides (e.g., for vaccines). In some embodiments, nucleic acids of interest include nucleic acids that are transcribed into therapeutic RNA. Transgenes included for use in the ceDNA vectors of the disclosure include, but are not limited to, those that express or encode one or more polypeptides, peptides, ribozymes, aptamers, peptide nucleic acids, siRNAs, RNAis, miRNAs, lncRNAs, antisense oligo- or polynucleotides, antibodies, antigen binding fragments, or any combination thereof. As used herein, the term “sequence identity” refers to the relatedness between two nucleic acid sequences, that is to the percentage of nucleotide or amino acid residues that are identical to the nucleotide or amino acid residues in another nucleotide or amino acid sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity. Alignment for purposes of determining percent nucleotide sequence homology can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN, ClustalW2 or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. In some embodiments, a nucleic acid sequence (e.g., DNA sequence), for example of a homology arm of a repair template, is considered “homologous” when the sequence is at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or more, identical to the 22 ME148589913v.1corresponding native or unedited nucleic acid sequence (e.g., genomic sequence) of the host cell. In some embodiments (e.g., in the context of a homology arm used in gene editing), the terms “homology” or “homologous” may be used interchangeably with the terms “identity” or “identical”, respectively. As used herein, the term “host cell” refers to any cell type that is susceptible to transformation, transfection, transduction, and the like with nucleic acid therapeutics of the present disclosure. As non-limiting examples, a host cell can be an isolated primary cell, pluripotent stem cells, CD34+cells, induced pluripotent stem cells, or any of a number of immortalized cell lines (e.g., HepG2 cells). Alternatively, a host cell can be an in situ or in vivo cell in a tissue, organ or organism. Furthermore, a host cell can be a target cell of, for example, a mammalian subject (e.g., human patient in need of gene therapy). As used herein, an “immunoglobulin variable domain sequence” refers to an amino acid sequence which can form the structure of an immunoglobulin variable domain. For example, the sequence may include all or part of the amino acid sequence of a naturally-occurring variable domain. For example, the sequence may or may not include one, two, or more N- or C-terminal amino acids, or may include other alterations that are compatible with formation of the protein structure. As described herein, an “inducible promoter” is one that is characterized by initiating or enhancing transcriptional activity when in the presence of, influenced by, or contacted by an inducer or inducing agent. An “inducer” or “inducing agent,” as defined herein, can be endogenous, or a normally exogenous compound or protein that is administered in such a way as to be active in inducing transcriptional activity from the inducible promoter. In some embodiments, the inducer or inducing agent, i.e., a chemical, a compound or a protein, can itself be the result of transcription or expression of a nucleic acid sequence (i.e., an inducer can be an inducer protein expressed by another component or module), which itself can be under the control or an inducible promoter. In some embodiments, an inducible promoter is induced in the absence of certain agents, such as a repressor. Examples of inducible promoters include, but are not limited to, tetracycline, metallothionine, ecdysone, mammalian viruses (e.g., the adenovirus late promoter; and the mouse mammary tumor virus long terminal repeat (MMTV-LTR)) and other steroid-responsive promoters, rapamycin responsive promoters and the like. As used herein, an “input agent responsive domain” is a domain of a transcription factor that binds to or otherwise responds to a condition or input agent in a manner that renders a linked DNA binding fusion domain responsive to the presence of that condition or input. In one embodiment, the presence of the condition or input results in a conformational change in the input agent responsive domain, or in a protein to which it is fused, that modifies the transcription-modulating activity of the transcription factor. The term “in vivo” refers to assays or processes that occur in or within an organism, such as a multicellular animal. In some of the aspects described herein, a method or use can be said to occur 23 ME148589913v.1“in vivo” when a unicellular organism, such as a bacterium, is used. The term “ex vivo” refers to methods and uses that are performed using a living cell with an intact membrane that is outside of the body of a multicellular animal or plant, e.g., explants, cultured cells, including primary cells and cell lines, transformed cell lines, and extracted tissue or cells, including blood cells, among others. The term “in vitro” refers to assays and methods that do not require the presence of a cell with an intact membrane, such as cellular extracts, and can refer to the introducing of a programmable synthetic biological circuit in a non-cellular system, such as a medium not comprising cells or cellular systems, such as cellular extracts. As used herein, the term “local delivery” refers to delivery of an active agent such as ceDNA or LNP encapsulating a ceDNA molecule directly to a target site within an organism. For example, an agent can be locally delivered by direct injection into a disease site such as a tumor or other target site such as a site of inflammation or a target organ such as the liver, heart, pancreas, kidney, skin, and the like. As used herein, the term “neDNA” or “nicked ceDNA” refers to a closed-ended DNA having a nick or a gap of 1-100 bases in a stem region or spacer region 5’ upstream of an open reading frame (e.g., a promoter and transgene to be expressed). As used herein, the term “nucleic acid” refers to a polymer containing at least two nucleotides (i.e., deoxyribonucleotides or ribonucleotides) in either single- or double-stranded form and includes DNA, RNA, and hybrids thereof. DNA may be in the form of, e.g., antisense molecules, plasmid DNA, DNA-DNA duplexes, pre-condensed DNA, PCR products, vectors (P1, PAC, BAC, YAC, artificial chromosomes), expression cassettes, chimeric sequences, chromosomal DNA, or derivatives and combinations of these groups. DNA may be in the form of minicircle, plasmid, bacmid, minigene, ministring DNA (linear covalently closed DNA vector), closed-ended linear duplex DNA (CELiD or ceDNA), doggybone™ DNA, dumbbell shaped DNA, minimalistic immunological-defined gene expression (MIDGE)-vector, viral vector or nonviral vectors. RNA may be in the form of small interfering RNA (siRNA), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), mRNA, gRNA, rRNA, tRNA, viral RNA (vRNA), and combinations thereof. Nucleic acids include nucleic acids containing known nucleotide analogs or modified backbone residues or linkages, which are synthetic, naturally occurring, and non-naturally occurring, and which have similar binding properties as the reference nucleic acid. Examples of such analogs and / or modified residues include, without limitation, phosphorothioates, phosphorodiamidate morpholino oligomer (morpholino), phosphoramidates, methyl phosphonates, chiral-methyl phosphonates, 2’-O-methyl ribonucleotides, locked nucleic acid (LNA™), and peptide nucleic acids (PNAs). Unless specifically limited, the term encompasses nucleic acids containing known analogues of natural nucleotides that have similar binding properties as the reference nucleic acid. Unless otherwise indicated, a particular nucleic acid sequence also implicitly encompasses conservatively 24 ME148589913v.1modified variants thereof (e.g., degenerate codon substitutions), alleles, orthologs, SNPs, and complementary sequences as well as the sequence explicitly indicated. As used herein, “nucleotides” contain a sugar deoxyribose (DNA) or ribose (RNA), a base, and a phosphate group. Nucleotides are linked together through the phosphate groups. As used herein, the phrases “nucleic acid therapeutic”, “therapeutic nucleic acid” and “TNA” are used interchangeably and refer to any modality of therapeutic using nucleic acids as an active component of therapeutic agent to treat a disease or disorder. As used herein, these phrases refer to RNA-based therapeutics and DNA-based therapeutics. Non-limiting examples of RNA-based therapeutics include mRNA, antisense RNA and oligonucleotides, ribozymes, aptamers, interfering RNAs (RNAi), Dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA). Non-limiting examples of DNA-based therapeutics include minicircle DNA, minigene, viral DNA (e.g., Lentiviral or AAV genome) or non-viral synthetic DNA vectors, closed-ended linear duplex DNA (ceDNA / CELiD), plasmids, bacmids, doggybone™ DNA vectors, minimalistic immunological-defined gene expression (MIDGE)-vector, nonviral ministring DNA vector (linear-covalently closed DNA vector), or dumbbell-shaped DNA minimal vector (“dumbbell DNA”).As used herein, the term “liver-specific regulatory element” refers to a genetic element, including but not limited to a promoter, an enhancer, a riboswitch, an insulator, a mir- regulatable element, a post-transcriptional regulatory element, a transcription factor binding site (or consensus site), that confers or enhances liver-specific expression (e.g., in vivo expression) of a (trans)gene, i.e. expression (e.g., in vivo expression) of the (trans)gene in the liver; or alternatively, the at least one liver-specific regulatory element is selected from the group consisting of a liver-specific promoter, a liver-specific enhancer, a liver-specific riboswitch, a liver-specific insulator, a liver- specific mir-regulatable element, a liver-specific post-transcriptional regulatory element, a liver- specific transcription factor binding site (or consensus site), and a combination thereof. Non-limiting examples of liver-specific regulatory elements are as described in International Patent Application Publication No. WO2023 / 044059 (including any one of SEQ ID NOs: 1-80, 138, 139 and 155-1689 as disclosed therein), which is incorporated herein by reference in its entirety. The term “promoter,” as used herein, refers to any nucleic acid sequence that regulates the expression of another nucleic acid sequence by driving transcription of the nucleic acid sequence, which can be a heterologous target gene encoding a protein or an RNA. Promoters can be constitutive, inducible, repressible, tissue-specific, or any combination thereof. A promoter is a control region of a nucleic acid sequence at which initiation and rate of transcription of the remainder of a nucleic acid sequence are controlled. A promoter can also contain genetic elements at which regulatory proteins and molecules can bind, such as RNA polymerase and other transcription factors. In some embodiments of the aspects described herein, a promoter can drive the expression of a transcription factor that regulates the expression of the promoter itself, or that of another promoter used in another modular component of the synthetic biological circuits described herein. Within the promoter 25 ME148589913v.1sequence will be found a transcription initiation site, as well as protein binding domains responsible for the binding of RNA polymerase. Eukaryotic promoters will often, but not always, contain “TATA” boxes and “CAT” boxes. Various promoters, including inducible promoters, may be used to drive the expression of transgenes in the ceDNA vectors disclosed herein. The term "liver-specific promoter" encompasses any promoter that confers or enhances liver- specific expression (e.g., in vivo expression) of a (trans)gene, i.e., expression (e.g., in vivo expression) of the (trans)gene in the liver. Non-limiting examples of liver-specific promoters are provided on the Liver-specific Gene Promoter Database (LSPD, rulai.cshl.edu / LSPD / ), and include, for example, the transthyretin (TTR) promoter or TTR-minimal promoter (TTRm), the alpha 1-antitrypsin (AAT) promoter, the albumin (ALB) promotor or minimal promoter, the apolipoprotein A1 (APOA1) promoter or minimal promoter, the complement factor B (CFB) promoter, the ketohexokinase (KHK) promoter, the hemopexin (HPX) promoter or minimal promoter, the nicotinamide N- methyltransferase (NNMT)promoter or minimal promoter, the (liver) carboxylesterase 1 (CES1) promoter or minimal promoter, the protein C (PROC) promoter or minimal promoter, the apolipoprotein C3 (APOC3) promoter or minimal promoter, the mannan-binding lectin serine protease 2 (MASP2) promoter or minimal promoter, the hepcidin antimicrobial peptide (HAMP) promoter or minimal promoter, and the serpin peptidase inhibitor, clade C (antithrombin), member 1 (SERPINCI) promoter or minimal promoter. The term “enhancer” as used herein refers a cis-acting regulatory sequence (e.g., about 50- 1000 base pairs) that bind one or more proteins (e.g., activator proteins or transcription factors) to increase transcriptional activation of a nucleic acid sequence. Endogenous enhancers may be positioned up to 1,000,000 base pairs upstream of the gene start site or downstream of the gene start site that they regulate. An enhancer can be positioned within an intronic region, or in the exonic region of an unrelated gene. In the ceDNA vectors as described herein, an enhancer may be located anywhere within the expression cassette (e.g., upstream or downstream, with or without spacers, etc.). A promoter can be said to drive expression or drive transcription of the nucleic acid sequence that it regulates. As used herein, “operably linked” refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For instance, a promoter is operably linked to a coding sequence if the promoter affects its transcription or expression. The phrases “operably linked,” “operatively positioned,” “operatively linked,” “under control,” and “under transcriptional control” indicate that a promoter is in a correct functional location and / or orientation in relation to a nucleic acid sequence it regulates to control transcriptional initiation and / or expression of that sequence. An “inverted promoter,” as used herein, refers to a promoter in which the nucleic acid sequence is in the reverse orientation, such that what was the coding strand is now the non-coding strand, and vice versa. Inverted promoter sequences can be used in various embodiments to regulate the state of a switch. In addition, in various embodiments, a promoter can be used in conjunction with an enhancer. 26 ME148589913v.1A promoter can be one naturally associated with a gene or sequence, as can be obtained by isolating the 5' non-coding sequences located upstream of the coding segment and / or exon of a given gene or sequence. Such a promoter can be referred to as “endogenous.” Similarly, in some embodiments, an enhancer can be one naturally associated with a nucleic acid sequence, located either downstream or upstream of that sequence. In some embodiments, a coding nucleic acid segment is positioned under the control of a “recombinant promoter” or “heterologous promoter,” both of which refer to a promoter that is not normally associated with the encoded nucleic acid sequence it is operably linked to in its natural environment. A recombinant or heterologous enhancer refers to an enhancer not normally associated with a given nucleic acid sequence in its natural environment. Such promoters or enhancers can include promoters or enhancers of other genes; promoters or enhancers isolated from any other prokaryotic, viral, or eukaryotic cell; and synthetic promoters or enhancers that are not “naturally occurring,” i.e., comprise different elements of different transcriptional regulatory regions, and / or mutations that alter expression through methods of genetic engineering that are known in the art. In addition to producing nucleic acid sequences of promoters and enhancers synthetically, promoter sequences can be produced using recombinant cloning and / or nucleic acid amplification technology, including PCR, in connection with the synthetic biological circuits and modules disclosed herein (see, e.g., U.S. Pat. No.4,683,202, U.S. Pat. No.5,928,906, each incorporated herein by reference). Furthermore, it is contemplated that control sequences that direct transcription and / or expression of sequences within non-nuclear organelles such as mitochondria, chloroplasts, and the like, can be employed as well. As used herein, the terms “Rep binding site, “Rep binding element, “RBE” and “RBS” are used interchangeably and refer to a binding site for Rep protein (e.g., AAV Rep 78 or AAV Rep 68) which upon binding by a Rep protein permits the Rep protein to perform its site-specific endonuclease activity on the sequence incorporating the RBS. An RBS sequence and its inverse complement together form a single RBS. RBS sequences are known in the art, and include, for example, 5’- GCGCGCTCGCTCGCTC-3′, an RBS sequence identified in AAV2. Without being bound by theory it is thought that he nuclease domain of a Rep protein binds to the duplex nucleotide sequence GCTC, and thus the two known AAV Rep proteins bind directly to and stably assemble on the duplex oligonucleotide, 5’-(GCGC)(GCTC)(GCTC)(GCTC)-3’. Because the ceDNA vectors of the instant disclosure are devoid of any viral ITR sequences, and because RBE sequences are located within viral ITRs (e.g., AAV ITRs), the ceDNA vectors of the instant disclosure should not comprise any RBE sequences. However, reference ceDNA vectors (e.g., reference ceDNA vectors used as controls for comparison purposes), may include an RBE sequence. As used herein, the term “reporter” refers to a nucleic acid or protein sequence that can be used to provide a detectable read-out. Reporters generally produce a measurable signal such as fluorescence, color, or luminescence. Reporter protein coding sequences encode proteins whose 27 ME148589913v.1presence in the cell or organism is readily observed. For example, fluorescent proteins cause a cell to fluoresce when excited with light of a particular wavelength, luciferases cause a cell to catalyze a reaction that produces light, and enzymes such as β-galactosidase convert a substrate to a colored product. Exemplary reporter polypeptides useful for experimental or diagnostic purposes include, but are not limited to, β-lactamase, β -galactosidase (LacZ), alkaline phosphatase (AP), thymidine kinase (TK), green fluorescent protein (GFP) and other fluorescent proteins, chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art. As used herein, a “repressor protein” or “inducer protein” is a protein that binds to a regulatory sequence element and represses or activates, respectively, the transcription of sequences operatively linked to the regulatory sequence element. Preferred repressor and inducer proteins as described herein are sensitive to the presence or absence of at least one input agent or environmental input. Preferred proteins as described herein are modular in form, comprising, for example, separable DNA-binding and input agent-binding or responsive elements or domains. As used herein, the terms “sense” and “antisense” are meant to refer to the orientation of the structural element on the polynucleotide. The sense and antisense versions of an element are the reverse complement of each other. The term “subject” as used herein refers to a human or animal, to whom treatment, including prophylactic treatment, with the ceDNA vector according to the present disclosure, is provided. Usually, the animal is a vertebrate such as, but not limited to, a primate, rodent, domestic animal or game animal. Primates include, but are not limited to, chimpanzees, cynomolgus monkeys, spider monkeys, and macaques, e.g., Rhesus. Rodents include, but are not limited to, mice, rats, woodchucks, ferrets, rabbits and hamsters. Domestic and game animals include, but are not limited to, cows, horses, pigs, goats, deer, bison, buffalo, feline species (e.g., domestic cat), canine species (e.g., dog, fox, wolf), avian species (e.g., chicken, emu, ostrich), fish (e.g., zebrafish, trout, catfish and salmon), or amphibians (e.g., frogs such as Xenopus laevis). In certain embodiments, the subject is a mammal, e.g., a non-human primate or a human. A subject can be male or female. Additionally, a subject can be an infant or a child. In some embodiments, the subject can be a neonate or an unborn subject, e.g., the subject is in utero. Mammals other than humans can be advantageously used as subjects that represent animal models of diseases and disorders. In addition, the methods and compositions described herein can be used for domesticated animals and / or pets. A human subject can be of any age, gender, race or ethnic group, e.g., Caucasian (white), Asian, African, black, African American, African European, Hispanic, Mideastern, etc. In some embodiments, the subject can be a patient or other subject in a clinical setting. In some embodiments, the subject is already undergoing treatment. As used herein, the term “suppress,” “decrease,” “interfere,” “inhibit” and / or “reduce” (and like terms) generally refers to the act of reducing, either directly or indirectly, a concentration, 28 ME148589913v.1level, function, activity, or behavior relative to the natural, expected, or average, or relative to a control condition. As used herein, the term “asymmetric ITRs” also referred to as “asymmetric ITR pairs” refers to a pair of ITRs within a single ceDNA or reference ceDNA vector that are not inverse complements across their full length. As one non-limiting example, an asymmetric ITR pair does not have a symmetric three-dimensional spatial organization to their cognate ITR such that their 3D structures are different shapes in geometrical space. As used herein, the term “symmetric ITRs” refers to a pair of ITRs within a single ceDNA molecule or reference ceDNA vector that are inverse complements across their full length. As one non-limiting example, a symmetric ITR pair has a symmetric three-dimensional spatial organization with respect to each other such that their 3D structures are the same shapes in geometrical space. For convenience herein, an ITR located 5’ to (upstream of) an expression cassette in a ceDNA vector is referred to as a “5’ ITR” or a “left ITR”, and an ITR located 3’ to (downstream of) an expression cassette in a ceDNA vector is referred to as a “3’ ITR” or a “right ITR”. Beyond the definitions provided above for symmetric ITRs, substantially symmetric ITRs, and asymmetric ITRs, the term “symmetric” when referring to the 5’ and 3’ stem-loop regions of the ceDNA vectors of the present disclosure refers to a pair of stem-loop regions that comprise only artificial sequences, and do not comprise viral ITR sequences, and that are inverse complements of each other across their full length. See e.g., ceDNA 384 whereby the 5’ and 3’ stem-loop regions of the vector are inverse complements of each other (e.g., SEQ ID NO: 1 and SEQ ID NO: 2). The term “asymmetric”, when referring to the 5’ and 3’ stem-loop regions of the ceDNA vectors of the present disclosure, refers to a pair of stem-loop regions that comprise only artificial sequences, and do not comprise viral ITR sequences, that are not inverse complements of each other across their full length. See e.g., ceDNA 558 whereby the 5’ and 3’ stem-loop regions of the vector are not inverse complements of each other (e.g., SEQ ID NO: 1 and SEQ ID NO: 4). Asymmetric stem-loop regions may be of the same length or different lengths. As used herein, the terms “synthetic vector”, “synthetic ceDNA vector” and “synthetic production of ceDNA vector” are meant to refer to a ceDNA vector, such as the ceDNA vectors of the present disclosure, and synthetic production methods thereof in an entirely cell-free environment. As used herein, the term “terminal repeat” or “TR” includes any viral terminal repeat or synthetic sequence that comprises at least one minimal required origin of replication and a region comprising a palindrome hairpin structure. A Rep-binding sequence (“RBS”) (also referred to as RBE (Rep-binding element)) and a terminal resolution site (“TRS”) together constitute a “minimal required origin of replication” and thus the TR comprises at least one RBS and at least one TRS. TRs that are the inverse complement of one another within a given stretch of polynucleotide sequence are typically each referred to as an “inverted terminal repeat” or “ITR”. As used herein, an ITR may generally include ITRs that are viral (e.g., wild-type or modified AAV ITRs) and ITRs that comprise no viral 29 ME148589913v.1ITR sequences. The ceDNA vectors of the instant disclosure comprise no viral ITR sequences and are preferably synthetic. ITRs comprising viral sequences may be used, for example, in ceDNA vectors as controls or comparisons in, e.g., expression studies. In some embodiments, an ITR of the disclosure may be a minimal ITR comprising only a number of nucleotides needed to close an end of a ceDNA vector. For example, an ITR may comprise a stem-loop structure comprising a stem of as few as 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 base pairs, and a loop comprising as few as 3, 4, 5, 6, 7, 8, 9, or 10 nucleotides. In other embodiments, an ITR may comprise at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120, 130, 140, 150, or more total nucleotides. In other embodiments, the stem region of an ITR may comprise at least 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 110, 120 or more base pairs. In other embodiments, the ITR may comprise more than one stem-loop region (e.g., a “doggy-bone”, “dumbbell”, “hammerhead”, or “cruciform” structure). In other embodiments, a loop region of an ITR may comprise at least 5, 10, 15, 20, 25 or more nucleotides. In other embodiments an ITR may comprise an aptamer. As used interchangeably herein, the terms “terminal resolution site” refer to a region at which Rep forms a tyrosine-phosphodiester bond with the 5’ thymidine generating a 3’ OH that serves as a substrate for DNA extension via a cellular DNA polymerase, e.g., DNA pol delta or DNA pol epsilon. In some embodiments, a TRS minimally encompasses a non-base-paired thymidine. TRS sequences are known in the art, and include, for example, 5’-GGTTGA-3’, the hexanucleotide sequence identified in AAV2. Other naturally known or synthetic TRS sequences include, for example, AGTT, GGTTGG, AGTTGG, AGTTGA, and other motifs such as RRTTRR. Because the ceDNA vectors of the instant disclosure are devoid of any viral ITR sequences, and because TRS sequences are located within viral ITRs (e.g., AAV ITRs), the ceDNA vectors of the instant disclosure should not comprise any TRS sequences. However, reference ceDNA vectors (e.g., reference ceDNA vectors used as controls for comparison purposes), may include a TRS sequence. As used herein, the term “transcriptional regulator” refers to transcriptional activators and repressors that either activate or repress transcription of a gene of interest. Promoters are regions of nucleic acid that initiate transcription of a particular gene. Transcriptional activators typically bind nearby to transcriptional promoters and recruit RNA polymerase to directly initiate transcription. Repressors bind to transcriptional promoters and sterically hinder transcriptional initiation by RNA polymerase. Other transcriptional regulators may serve as either an activator or a repressor depending on where they bind and cellular and environmental conditions. Non-limiting examples of transcriptional regulator classes include, but are not limited to, homeodomain proteins, zinc-finger proteins, winged-helix (forkhead) proteins, and leucine-zipper proteins. As used herein, the terms “treat,” “treating,” and / or “treatment” include abrogating, substantially inhibiting, slowing or reversing the progression of a condition, substantially ameliorating clinical symptoms of a condition, or substantially preventing the appearance of clinical symptoms of a condition, obtaining beneficial or desired clinical results. Treating further refers to accomplishing one 30 ME148589913v.1or more of the following: (a) reducing the severity of the disorder; (b) limiting development of symptoms characteristic of the disorder(s) being treated; (c) limiting worsening of symptoms characteristic of the disorder(s) being treated; (d) limiting recurrence of the disorder(s) in patients that have previously had the disorder(s); and (e) limiting recurrence of symptoms in patients that were previously asymptomatic for the disorder(s). Beneficial or desired clinical results, such as pharmacologic and / or physiologic effects include, but are not limited to, preventing the disease, disorder or condition from occurring in a subject that may be predisposed to the disease, disorder or condition but does not yet experience or exhibit symptoms of the disease (prophylactic treatment), alleviation of symptoms of the disease, disorder or condition, diminishment of extent of the disease, disorder or condition, stabilization (i.e., not worsening) of the disease, disorder or condition, preventing spread of the disease, disorder or condition, delaying or slowing of the disease, disorder or condition progression, amelioration or palliation of the disease, disorder or condition, and combinations thereof, as well as prolonging survival as compared to expected survival if not receiving treatment. As used herein, the terms “therapeutic amount”, "therapeutically effective amount", an "amount effective", or “pharmaceutically effective amount” of an active agent (e.g., a ceDNA lipid particle as described herein) are used interchangeably to refer to an amount that is sufficient to provide the intended benefit of treatment. However, dosage levels are based on a variety of factors, including the type of injury, the age, weight, sex, medical condition of the patient, the severity of the condition, the route of administration, and the particular active agent employed. Thus, the dosage regimen may vary widely, but can be determined routinely by a physician using standard methods. Additionally, the terms “therapeutic amount”, “therapeutically effective amounts” and “pharmaceutically effective amounts” include prophylactic or preventative amounts of the compositions of the described disclosure. In prophylactic or preventative applications of the described disclosure, pharmaceutical compositions or medicaments are administered to a patient susceptible to, or otherwise at risk of, a disease, disorder or condition in an amount sufficient to eliminate or reduce the risk, lessen the severity, or delay the onset of the disease, disorder or condition, including biochemical, histologic and / or behavioral symptoms of the disease, disorder or condition, its complications, and intermediate pathological phenotypes presenting during development of the disease, disorder or condition. It is generally preferred that a maximum dose be used, that is, the highest safe dose according to some medical judgment. The terms “dose” and “dosage” are used interchangeably herein. As used herein the term “therapeutic effect” refers to a consequence of treatment, the results of which are judged to be desirable and beneficial. A therapeutic effect can include, directly or indirectly, the arrest, reduction, or elimination of a disease manifestation. A therapeutic effect can also include, directly or indirectly, the arrest reduction or elimination of the progression of a disease manifestation. 31 ME148589913v.1For any therapeutic agent described herein therapeutically effective amount may be initially determined from preliminary in vitro studies and / or animal models. A therapeutically effective dose may also be determined from human data. The applied dose may be adjusted based on the relative bioavailability and potency of the administered compound. Adjusting the dose to achieve maximal efficacy based on the methods described above and other well-known methods is within the capabilities of the ordinarily skilled artisan. General principles for determining therapeutic effectiveness, which may be found in Chapter 1 of Goodman and Gilman's The Pharmacological Basis of Therapeutics, 10th Edition, McGraw-Hill (New York) (2001), incorporated herein by reference, are summarized below. Pharmacokinetic principles provide a basis for modifying a dosage regimen to obtain a desired degree of therapeutic efficacy with a minimum of unacceptable adverse effects. In situations where the drug's plasma concentration can be measured and related to therapeutic window, additional guidance for dosage modification can be obtained. As used herein, the terms “vector” or “expression vector” are meant to refer to a replicon, such as plasmid, bacmid, phage, virus, virion, or cosmid, to which another DNA segment, i.e., an “insert” “transgene” or “transgene expression cassette”, may be attached so as to bring about the expression or replication of the attached segment (“transgene expression cassette”) in a cell. A vector can be a nucleic acid construct designed for delivery to a host cell or for transfer between different host cells. As used herein, a vector can be viral or non-viral in origin in the final form. However, for the purpose of the present disclosure, a “vector” generally refers to synthetic AAV vector or a nicked ceDNA vector. Accordingly, the term “vector” encompasses any genetic element that is capable of replication when associated with the proper control elements and that can transfer gene sequences to cells. In some embodiments, a vector can be a recombinant vector or an expression vector. As used herein, the phrase “recombinant vector” refers to a vector that includes a heterologous nucleic acid sequence, or “transgene” that is capable of expression in vivo. It is to be understood that the vectors described herein can, in some embodiments, be combined with other suitable compositions and therapies. In some embodiments, the vector is episomal. The use of a suitable episomal vector provides a means of maintaining the nucleotide of interest in the subject in high copy number extra chromosomal DNA thereby eliminating potential effects of chromosomal integration. As used herein, the term “homologous recombination” means a type of genetic recombination in which nucleotide sequences are exchanged between two similar or identical molecules of DNA. Homologous recombination also produces new combinations of DNA sequences. These new combinations of DNA represent genetic variation. Homologous recombination is also used in horizontal gene transfer to exchange genetic material between different strains and species of viruses. 32 ME148589913v.1As used herein the term “comprising” or “comprises” is used in reference to compositions, methods, and respective component(s) thereof, that are essential to the method or composition, yet open to the inclusion of unspecified elements, whether essential or not. As used herein the term “consisting essentially of” refers to those elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristic(s) of that embodiment. The term “consisting of” refers to compositions, methods, and respective components thereof as described herein, which are exclusive of any element not recited in that description of the embodiment. As used in this specification and the appended claims, the singular forms “a,” “an,” and “the” include plural references unless the context clearly dictates otherwise. Thus, for example, references to “the method” includes one or more methods, and / or steps of the type described herein and / or which will become apparent to those persons skilled in the art upon reading this disclosure and so forth. Similarly, the word “or” is intended to include "and" unless the context clearly indicates otherwise. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. The abbreviation, “e.g.” is derived from the Latin exempli gratia, and is used herein to indicate a non- limiting example. Thus, the abbreviation “e.g.” is synonymous with the term “for example.” As used herein, the terms “such as”, “for example” and the like are intended to refer to exemplary embodiments and not to limit the scope of the present disclosure. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which the disclosure pertains. Although any methods and materials similar or equivalent to those described herein can be used in the practice for testing of the present disclosure, preferred materials and methods are described herein. Other than in the operating examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood as modified in all instances by the term “about.” The term “about” when used in connection with percentages can mean ±1%. The present disclosure is further explained in detail by the following examples, but the scope of the disclosure should not be limited thereto. It should be understood that this disclosure is not limited to the particular methodology, protocols, and reagents, etc., described herein and as such can vary. The terminology used herein is for the purpose of describing particular embodiments only, and is not intended to limit the scope of the present disclosure, which is defined solely by the claims. II. Closed-ended DNA (ceDNA) Vectors Provided herein are novel non-viral, capsid-free ceDNA vectors with covalently-closed ends (ceDNA) that are devoid of (do not comprise any) viral ITR sequences. 33 ME148589913v.1As is known in the art, typical AAV ITR structures comprise a palindromic double-stranded T-shaped hairpin structure, in which the double-stranded A-A’ region forms the stem, and the double- stranded B-B’ and C-C’ regions form the cross-arms of the T-shaped structure (see, for example, Ling et al., J. Virology, 89(2):952-961, 2015). The other nucleotides of the typical AAV ITR remain single stranded and are referred to as the single-stranded D(-) sequence (on the 3’ end of the ITR) and the single-stranded D(+) sequence (on the 5’ end of the ITR). Once in cells, the single-stranded regions of the D(+) region and D(-) region undergo second-strand DNA synthesis to turn them into double- stranded D and D’ regions. Prior to the instant disclosure, it was commonly believed in the art that at least some amount of viral ITR sequence was required for the replication and packaging of both AAV and ceDNA vectors used in gene therapy applications. More specifically, it was believed that a ceDNA vector minimally required at least one Rep-binding element (RBE) and at least one terminal resolution sequence (trs). The ITR is the only element of the AAV genome that is required in cis to produce viral particles. At the time of the filing, it was known in the field of gene therapy that the ITR regions D and D’ contain sequences that act as binding sites for host transcription factors, including human transcription factors. Wang et al. in 1996 (J. Virol.70:1668-1677, 1996) reported that the D sequence plays a crucial role in high-efficiency rescue, selective replication, and encapsidation of the AAV genome and that a host cell protein, designated the D sequence-binding protein (D-BP), specifically interacts with this sequence. Wang et al. in 1997 (J Virol.1997 Apr; 71(4): 3077-82) further performed mutational analyses of the D sequences to evaluate their role in viral DNA rescue, replication, and packaging, and reported that 10 nucleotides proximal to the hairpin structure in each of the D sequences are necessary and sufficient to mediate high-efficiency rescue, replication, and encapsidation of the viral genome in vivo. In in vitro studies, Wang showed that the same 10 nucleotides were found to be required for specific interaction with D- sequence binding proteins. Julien et al. later reported that human transcription factors interact with the D sequence of AAV ITR (Scientific Reports (2018):8:210, pp.1-11), and knockdown of a particular transcription factor, RFX1, resulted in the absence of interaction with the D sequence of the ITR, was associated with reduced transgene expression. Further, based on work by Ling et al, it was thought by one of ordinary skill in the art that at least one of the D(+) or D(-) single-stranded regions was absolutely necessary for replication and encapsidation of AAV (see, e.g., Ling et al., J. Virology, 89(2):952-961, 2015). However, the present disclosure surprisingly demonstrated that ceDNA vectors comprising synthetic stem-loop structures comprising no viral ITR sequences showed comparable or even, in some embodiments, enhanced gene expression profiles for their respective transgenes. Furthermore, the ceDNA vectors of the instant disclosure have advantages over ceDNA vectors comprising viral ITRs. Removing such sequences reduced the size of a ceDNA molecule, which may be advantageous for a variety of reasons. For example, it may allow for the inclusion of other desirable sequences or motifs (e.g., functional sequences such as aptamers) without increasing 34 ME148589913v.1the size of the ceDNA molecule. It may also reduce the cost of manufacturing by reducing the amount of raw materials needed for ceDNA production. It may also reduce the likelihood of provoking an immune response when administered to a subject. In some embodiments, the ceDNA vectors of the present disclosure also do not contain any of the following ITR sequences: a Rep binding element (RBE), RBE’, a terminal resolution site (trs), A, A’, B, B’, C, C’, D and / or D’ regions of a naturally occurring ITR sequence from, e.g., AAV, or any ITR sequences derived from a naturally occurring ITR sequence (e.g., an ITR sequence modified by an addition, deletion, or substitution in a naturally occurring ITR sequence). In some embodiments, the ceDNA vectors of the present disclosure do not contain any of the following ITR sequences: a Rep binding element (RBE), RBE’, a terminal resolution site (trs), an A- A’ region, B-B’ region, C-C’ region, or D-D’ region of a naturally occurring ITR sequence from, e.g., AAV, or any ITR sequences derived from a naturally occurring ITR sequence (e.g., an ITR sequence modified by an addition, deletion, or substitution in a naturally occurring ITR sequence). In one embodiment, the ceDNA vectors of the present disclosure do not comprise a B and B’ ITR region that would be present in a wild-type AAV ITR. In one embodiment, the ceDNA vectors of the present disclosure do not comprise a C and C’ ITR region that would be present in a wild-type AAV ITR. In one embodiment, the ceDNA vectors of the present disclosure do not comprise a B and B’ and C and C’ ITR regions that would be present in a wild-type AAV ITR. In one embodiment, the ceDNA vectors of the present disclosure do not comprise any of an A and A’, B and B’, C and C’ and D and D’ ITR region that would be present in a wild-type AAV ITR. In particular aspects, the disclosure provides non-viral, capsid-free ceDNA vectors with covalently-closed ends (ceDNA), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by at least one stem-loop structure at the 3’ end, wherein the at least one stem-loop structure at the 3’ end does not comprise any viral ITR sequences. In some embodiments, the ceDNA vector may further comprise at least one stem-loop structure at the 5’ end, wherein the at least one stem-loop structure at the 5’ end does not comprise any viral ITR sequences. In other further embodiments, the ceDNA vector may further comprise a lipid. A. 3’ end In one embodiment, the at least one stem-loop structure at the 3’ end of the ceDNA vector does not comprise a B and B’ ITR region that would be present in a wild-type AAV ITR. In one embodiment, the at least one stem-loop structure at the 3’ end of the ceDNA vector does not comprise a C and C’ ITR region that would be present in a wild-type AAV ITR. In one embodiment, the at least one stem-loop structure at the 3’ end of the ceDNA vector does not comprise a B and B’ and C and C’ ITR regions that would be present in a wild-type AAV ITR. 35 ME148589913v.1In one embodiment, the at least one stem-loop structure at the 3’ end of the ceDNA vector does not comprise any of an A and A’, B and B’, C and C’ and D and D’ ITR region that would be present in a wild-type AAV ITR. In one embodiment, the at least one stem-loop structure at the 3’ end does not comprise a rep binding element (RBE) that would be present in a wild-type ITR. In one embodiment, the at least one stem-loop structure at the 3’ end does not comprise a terminal resolution site (trs) that would be present in a wild-type ITR. In some embodiments, the at least one stem loop structure at the 3’ end is devoid of any viral capsid protein coding sequences. In one embodiment, the stem portion of the stem-loop is 4-500 nucleotides in length and the loop portion of the stem-loop is 3-500 nucleotides in length. In one embodiment, the stem portion of the stem-loop is 4-50 nucleotides in length and the loop portion of the stem-loop is 3-50 nucleotides in length. In one embodiment, the stem portion of the stem-loop is 4-20 nucleotides in length and the loop portion of the stem-loop is 3-20 nucleotides in length. In one embodiment, the stem portion of the stem-loop is 4-10 nucleotides in length and the loop portion of the stem-loop is 3-10 nucleotides in length. In one embodiment, the loop further comprises one or more nucleic acids or that are used to stabilize the ends. According to other embodiments, the loop further comprises one or more nucleic acids that may be employed in therapeutic methods. According to other embodiments, the loop further comprises one or more nucleic acids that may be employed in diagnostic methods. According to other embodiments, the loop further comprises one or more nucleic acids that that may be employed for research purposes. In one embodiment, the minimal nucleic acid structure that is necessary at the 3’ end of the ceDNA is any structure that loops back on itself, i.e., a hairpin structure. However, it is to be understood that a variety of structures are envisioned at the 3’ end, as long as there is at least one stem and one loop. For example, in some embodiments, the ceDNA described herein may comprise at least one stem-loop structure at the 3’ end. In some embodiments, the ceDNA may comprise at least two stem-loop structures at the 3’ end. In some embodiments, the ceDNA may comprise at least three stem-loop structures at the 3’ end. In some embodiments, the ceDNA may comprise at least four stem-loop structures at the 3’ end. In some embodiments, the ceDNA may comprise at least five stem-loop structures at the 3’ end. In one embodiment, the nucleotides at the 3’ end form a cruciform DNA structure. A DNA cruciform structure can be formed when both strands form a stem-loop structure at the same location in the molecule, and comprises a four-way junction and two closed hairpin-shaped points. In one embodiment, the nucleotides at the 3’ end form a hairpin DNA structure. Hairpin loop structures in nucleic acids consist of a base-paired stem structure and a loop sequence with unpaired or non-Watson-Crick-paired nucleotides. 36 ME148589913v.1In one embodiment, the nucleotides at the 3’ end form a hammerhead DNA structure, made up of three base paired helices, separated by short linkers of conserved sequence. In one embodiment, the nucleotides at the 3’ end form a quadraplex DNA structure. G- quadruplexes are four-stranded DNA secondary structures (G4s) that form from certain guanine-rich sequences. In one embodiment, the nucleotides at the 3’ end form a bulged DNA structure. In one embodiment, the nucleotides at the 3’ end form a multibranched loop. In one embodiment, the nucleotides at the 3’ end do not form a 2 stem-loop structure. B. 5’ end In one embodiment, the at least one stem-loop structure at the 5’ end of the ceDNA vector does not comprise a B and B’ ITR region that would be present in a wild-type AAV ITR. In one embodiment, the at least one stem-loop structure at the 5’ end of the ceDNA vector does not comprise a C and C’ ITR region that would be present in a wild-type AAV ITR. In one embodiment, the at least one stem-loop structure at the 5’ end of the ceDNA vector does not comprise a B and B’ and C and C’ ITR regions that would be present in a wild-type AAV ITR. In one embodiment, the at least one stem-loop structure at the 5’ end of the ceDNA vector does not comprise any of an A and A’, B and B’, C and C’ and D and D’ ITR region that would be present in a wild-type AAV ITR. In one embodiment, the at least one stem-loop structure at the 5’ end does not comprise a rep binding element (RBE) that would be present in a wild-type ITR. In one embodiment, the at least one stem-loop structure at the 5’ end does not comprise a terminal resolution site (trs) that would be present in a wild-type ITR. In some embodiments, the at least one stem loop structure at the 5’ end is devoid of any viral capsid protein coding sequences. In one embodiment, the stem portion of the stem-loop is 4-500 nucleotides in length and the loop portion of the stem-loop is 3-500 nucleotides in length. In one embodiment, the stem portion of the stem-loop is 4-50 nucleotides in length and the loop portion of the stem-loop is 3-50 nucleotides in length. In one embodiment, the stem portion of the stem-loop is 4-20 nucleotides in length and the loop portion of the stem-loop is 3-20 nucleotides in length. In one embodiment, the stem portion of the stem-loop is 4-10 nucleotides in length and the loop portion of the stem-loop is 3-10 nucleotides in length. In one embodiment, the loop further comprises one or more nucleic acids or that are used to stabilize the ends. According to other embodiments, the loop further comprises one or more nucleic acids that may be employed in therapeutic methods. According to other embodiments, the loop further comprises one or more nucleic acids that may be employed in diagnostic methods. According 37 ME148589913v.1to other embodiments, the loop further comprises one or more nucleic acids that that may be employed for research purposes. In one embodiment, the minimal nucleic acid structure that is necessary at the 5’ end of the ceDNA is any structure that loops back on itself, i.e., a hairpin structure. However, it is to be understood that a variety of structures are envisioned at the 5’ end, as long as there is at least one stem and one loop. For example, in some embodiments, the ceDNA described herein may comprise at least one stem-loop structure at the 5’ end. In some embodiments, the ceDNA may comprise at least two stem-loop structures at the 5’ end. In some embodiments, the ceDNA may comprise at least three stem-loop structures at the 5’ end. In some embodiments, the ceDNA may comprise at least four stem-loop structures at the 5’ end. In some embodiments, the ceDNA may comprise at least five stem-loop structures at the 5’ end. In one embodiment, the nucleotides at the 5’ end form a cruciform DNA structure. A DNA cruciform structure can be formed when both strands form a stem-loop structure at the same location in the molecule, and comprises a four-way junction and two closed hairpin-shaped points. In one embodiment, the nucleotides at the 5’ end form a hairpin DNA structure. Hairpin loop structures in nucleic acids consist of a base-paired stem structure and a loop sequence with unpaired or non-Watson-Crick-paired nucleotides. In one embodiment, the nucleotides at the 5’ end form a hammerhead DNA structure, made up of three base paired helices, separated by short linkers of conserved sequence. In one embodiment, the nucleotides at the 5’ end form a quadraplex DNA structure. G- quadruplexes are four-stranded DNA secondary structures (G4s) that form from certain guanine-rich sequences. In one embodiment, the nucleotides at the 5’ end form a bulged DNA structure. In one embodiment, the nucleotides at the 5’ end form a multibranched loop. In one embodiment, the nucleotides at the 5’ end do not form a 2 stem-loop structure. In one embodiment, the loop structure at either the 3’ or 5’ end further comprises one or more nucleic acids or that are used to stabilize the ends. According to other embodiments, the loop further comprises one or more nucleic acids that may be employed in therapeutic methods. According to other embodiments, the loop further comprises one or more nucleic acids that may be employed in diagnostic methods. According to other embodiments, the loop further comprises one or more nucleic acids that that may be employed for research purposes. In one embodiment, the nucleotides in the loop at either the 3’ or 5’ end are chemically modified with functional groups in order to alter their properties. In one embodiment, the loop at either the 3’ or 5’ end further comprises one or more aptamers. In one embodiment, the aptamer is identified from the Apta-index database of aptamers available to the public (aptagen.com / apta-index). 38 ME148589913v.1In one embodiment, the loop at either the 3’ or 5’ end comprises one or more synthetic ribozymes. In one embodiment, the loop at either the 3’ or 5’ end further comprises one or more antisense oligonucleotides (ASOs). In one embodiment, the loop at either the 3’ or 5’ end further comprises one or more short- interfering RNAs (siRNAs). In one embodiment, the loop at either the 3’ or 5’ end further comprises one or more antiviral nucleoside analogues (ANAs). In one embodiment, the loop at either the 3’ or 5’ end further comprises one or more triplex forming oligonucleotides. In one embodiment, the loop at either the 3’ or 5’ end further comprises one or more gRNAs or gDNAs. In one embodiment, the loop at either the 3’ or 5’ end further comprises one or more molecular probes, for example nucleic acid based fluorescent probes. In one embodiment, “click” azide-alkyne cycloaddition (Kolb et al., Angew. Chem. Int. Ed. Engl.2001, 40, 2004–2021) is used to modify the nucleotides in the loop. Click chemistry was developed to join together organic molecules under mild conditions in the presence of a diverse range of functional groups. Most click-mediated modifications are performed on the nitrogenous bases by introducing novel base analogues, attaching fluorophores or isotopic elements for molecular imaging, forming inter-strand linkages between oligonucleotides, and for the bioconjugation of molecules. The best example of click chemistry is the CuIcatalyzed version of Huisgen’s [3 + 2] azide–alkyne cycloaddition reaction (Angew. Chem., Int. Ed.1963, 2, 633–645), discovered independently by Sharpless and Meldal (the CuAAC reaction) (Angew. Chem., Int. Ed.2002, 41, 2596–2599). In one embodiment, the introduction of active amino or thiol groups into synthesized oligonucleotides provides acceptors for, e.g., subsequent chemical fluorescent labeling. In one embodiment, the stem-loop structure may comprise alternative or modified nucleotides, including, but not limited to, ribonucleic acids (RNA), peptide-nucleic acids (PNA), locked nucleic acids (LNA). In one embodiment, the loop portion of the stem-loop structure may comprise a chemical structure that does not comprise nucleic acids. In one embodiment, the DNA structure at the 5’ end is the same as the DNA structure at the 3’ end. In one embodiment, the DNA structure at the 5’ end is different from the DNA structure at the 3’ end. In some embodiments, the nucleotides at the 3’ end of the ceDNA vector do not form an AAV ITR structure. In some embodiments, the nucleotides at the 5’ end of the ceDNA vector do not form an AAV ITR structure. 39 ME148589913v.1In some embodiments, the ceDNA vector comprises at least one stem-loop structure at the 3’ end of the ceDNA vector does not comprise a C and C’ ITR region that would be present in a wild- type AAV ITR. In some embodiments, the ceDNA vector is ceDNA14. In some embodiments, the ceDNA vector comprises at least one stem-loop structure at the 5’ end that does not comprise a B and B’ ITR region that would be present in a wild-type AAV ITR and at least one stem-loop structure at the 3’ end of the ceDNA vector does not comprise a C and C’ ITR region that would be present in a wild-type AAV ITR. In some embodiments, the ceDNA vector is ceDNA15. In some embodiments, the ceDNA vector comprises at least one stem-loop structure at the 5’ end of that does not comprise a B and B’ and a C and C’ ITR region that would be present in a wild- type AAV ITR and at least one stem-loop structure at the 3’ end of the ceDNA vector that does not comprise a B and B’ and a C and C’ ITR region that would be present in a wild-type AAV ITR. In some embodiments, the ceDNA vector is ceDNA16. In some embodiments, the ceDNA vector comprises at least one stem-loop structure at the 5’ end that does not comprise any of an A and A’, B and B’, C and C’ and D and D’ ITR region that would be present in a wild-type AAV ITR and at least one stem-loop structure at the 3’ end of the ceDNA vector that does not comprise any of an A and A’, B and B’, C and C’ and D and D’ ITR region that would be present in a wild-type AAV ITR. In some embodiments, the ceDNA vector is ceDNA17. In some embodiments, the ceDNA vector comprises at least one stem-loop structure at the 5’ end of that does not comprise a B and B’ and a C and C’ ITR region that would be present in a wild- type AAV ITR and at least one stem-loop structure at the 3’ end of the ceDNA vector that comprises wild-type AAV ITR. In some embodiments, the ceDNA vector is ceDNA18. In some embodiments, the ceDNA vector comprises at least one stem-loop structure at the 5’ end that does not comprise a B and B’ and a C and C’ ITR region that would be present in a wild-type AAV ITR and at least one stem-loop structure at the 3’ end of the ceDNA vector does not comprise a C and C’ ITR region that would be present in a wild-type AAV ITR. In some embodiments, the ceDNA vector is ceDNA19. In some embodiments, the ceDNA vector comprises at least one stem-loop structure at the 5’ end that does not comprise any of an A and A’, B and B’, C and C’ and D and D’ ITR region that would be present in a wild-type AAV ITR and at least one stem-loop structure at the 3’ end of the ceDNA vector that would be present in a wild-type AAV ITR. In some embodiments, the ceDNA vector is ceDNA20. In some embodiments, the ceDNA vector comprises at least one stem-loop structure at the 5’ end that would be present in a wild-type AAV ITR and at least one stem-loop structure at the 3’ end 40 ME148589913v.1of the ceDNA vector that does not comprise any of an A and A’, B and B’, C and C’ and D and D’ ITR region that would be present in a wild-type AAV ITR. In some embodiments, the ceDNA vector is ceDNA35. The ceDNA vectors disclosed herein have no packaging constraints imposed by the limiting space within the viral capsid. ceDNA vectors represent a viable eukaryotically-produced alternative to prokaryote-produced plasmid DNA vectors, as opposed to encapsulated AAV genomes. This permits the insertion of control elements, e.g., regulatory switches as disclosed herein, large transgenes, multiple transgenes etc., and incorporation of the native genetic regulatory elements of the transgene, or a functional sequence like an aptamer, if desired. ceDNA vectors preferably have a linear and continuous structure rather than a non-continuous structure, as determined by restriction enzyme digestion assay and electrophoretic analysis. The linear and continuous structure is believed to be more stable from attack by cellular endonucleases, as well as less likely to be recombined and cause mutagenesis. The continuous, linear, single strand intramolecular duplex ceDNA vector can have covalently bound terminal ends (e.g., stem-loop hairpin structure), without viral ITR sequences or sequences encoding AAV capsid proteins. These ceDNA vectors are structurally distinct from plasmids (including ceDNA plasmids described herein), which are circular duplex nucleic acid molecules of bacterial origin. The complimentary strands of plasmids may be separated following denaturation to produce two nucleic acid molecules, whereas in contrast, ceDNA vectors, while having complimentary strands, are a single DNA molecule and, therefore, even if denatured, remain a single molecule. In some embodiments, ceDNA vectors as described herein can be produced without DNA base methylation of prokaryotic type, unlike plasmids. Therefore, the ceDNA vectors and ceDNA-plasmids are different both in terms of structure (in particular, linear versus circular) and also in view of the methods used for producing and purifying these different constructs (see below), and also in view of their DNA methylation which is of prokaryotic type for ceDNA-plasmids and of eukaryotic type for the ceDNA vector. Exemplary viral ITRs that are contained in reference ceDNA vectors (useful for, e.g., comparison purposes) described herein are discussed below in the section entitled “ITRs”, and in Table 1 herein, or in Tables 2, 3, 4, 5, 6, 7, 8, 9 or 10A-10B of PCT / US18 / 49996 filed September 7, 2018, and incorporated by reference in its entirety herein, where the flanking ITR sequence is asymmetric, symmetric (e.g., inverse complement) thereof or substantially symmetric thereto. As described throughout the instant application, the ceDNA vectors described herein do not comprise any viral ITR sequences. In some embodiments, one of ordinary skill in the art may refer to any of the viral ITR sequences as set forth above to ensure that such sequences are not included in the ceDNA vectors of the disclosure. In some embodiments, a reference ceDNA vector described herein or a ceDNA vector of this disclosure comprises a transgene expression cassette with a transgene which is a therapeutic nucleic 41 ME148589913v.1acid sequence, can be operatively linked to one or more regulatory sequence(s) that allows or controls expression of the transgene. In one embodiment of a ceDNA vector of the instant disclosure, the polynucleotide comprises a first stem-loop sequence and a second stem-loop sequence, wherein the nucleotide sequence of interest is flanked by the first and second stem-loop sequences, and the first and second stem-loop sequences are asymmetric relative to each other or are symmetric relative to each other. Instead, in one embodiment of a ceDNA vector of the disclosure, the vector comprises a first stem-loop region and a second stem-loop region, wherein both the first and second stem-loop regions contain only artificial sequences and no viral ITR sequences, wherein the nucleotide sequence of interest is flanked by the first and second stem-loop regions, and the first and second stem-loop regions are asymmetric relative to each other or are symmetric relative to each other. In one embodiment an expression cassette comprises one or more of: a promoter operably linked to a transgene, a posttranscriptional regulatory element, and a polyadenylation and termination signal. In one embodiment, the promoter is regulatable (e.g., inducible or repressible). The promoter can be any sequence that facilitates the transcription of the transgene. In one embodiment the promoter is a CAG promoter, or variation thereof. The posttranscriptional regulatory element is a sequence that modulates expression of the transgene, as a non-limiting example, any sequence that creates a tertiary structure that enhances expression of the transgene which is a therapeutic nucleic acid sequence. In one embodiment, the posttranscriptional regulatory element comprises a WPRE. In one embodiment, the polyadenylation and termination signal comprise a BGHpolyA. Any cis regulatory element known in the art, or combination thereof, can be additionally used e.g., SV40 late polyA signal upstream sequence element (USE), or other posttranscriptional processing elements including, but not limited to, the thymidine kinase gene of herpes simplex virus, or hepatitis B virus (HBV). In one embodiment, the expression cassette length in the 5’ to 3’ direction is greater than the maximum length known to be encapsidated in an AAV virion. In one embodiment, the length is greater than 4.6 kb, or greater than 5 kb, or greater than 6 kb, or greater than 7 kb. Various expression cassettes are exemplified herein. The expression cassette can comprise more than 4000 nucleotides, 5000 nucleotides, 10,000 nucleotides or 20,000 nucleotides, or 30,000 nucleotides, or 40,000 nucleotides or 50,000 nucleotides, or any range between about 4000-10,000 nucleotides or 10,000-50,000 nucleotides, or more than 50,000 nucleotides. In some embodiments, the expression cassette can comprise a transgene (e.g., a therapeutic nucleic acid sequence) in the range of 500 to 50,000 nucleotides in length. In some embodiments, the expression cassette can comprise a transgene (e.g., a therapeutic nucleic acid sequence) in the range of 500 to 75,000 nucleotides in length. In some embodiments, the expression cassette can comprise a transgene (e.g., a therapeutic nucleic acid sequence) in the range of 500 to 10,000 nucleotides in length. In some embodiments, the expression cassette can comprise a transgene 42 ME148589913v.1(e.g., a therapeutic nucleic acid sequence) in the range of 1000 to 10,000 nucleotides in length. In some embodiments, the expression cassette can comprise a transgene (e.g., a therapeutic nucleic acid sequence) in the range of 500 to 5,000 nucleotides in length. The ceDNA vectors do not have the size limitations of encapsidated AAV vectors, thus enable delivery of a large-size expression cassette to provide efficient expression of transgenes. In some embodiments, the ceDNA vector is devoid of prokaryote-specific methylation. In one embodiment, the expression cassette can also comprise an internal ribosome entry site (IRES) and / or a 2A element. The cis-regulatory elements include, but are not limited to, a promoter, a riboswitch, an insulator, a mir-regulatable element, a post-transcriptional regulatory element, a tissue- and cell type-specific promoter and an enhancer. In some embodiments the ITR can act as the promoter for the transgene. In some embodiments, the ceDNA vector comprises additional components to regulate expression of the transgene, for example, a regulatory switch, described herein in the section entitled “Regulatory Switches,” for controlling and regulating the expression of the transgene, and can include if desired, a regulatory switch which is a kill switch to enable controlled cell death of a cell comprising a ceDNA vector. A. Therapeutic Nucleic Acids The expression cassette can comprise any transgene of interest. Transgenes of interest include, but are not limited to, nucleic acids encoding polypeptides, or non-coding nucleic acids (e.g., RNAi, miRs etc.) preferably therapeutic (e.g., for medical, diagnostic, or veterinary uses) or immunogenic (e.g., for vaccines) polypeptides. In certain embodiments, the transgenes in the expression cassette encodes one or more polypeptides, peptides, ribozymes, peptide nucleic acids, siRNAs, RNAis, antisense oligonucleotides, antisense polynucleotides, antibodies, antigen binding fragments, or any combination thereof. Illustrative therapeutic nucleic acids of the present disclosure can include, but are not limited to, minigenes, plasmids, minicircles, small interfering RNA (siRNA), microRNA (miRNA), antisense oligonucleotides (ASO), ribozymes, closed ended double stranded DNA (e.g., ceDNA, CELiD, linear covalently closed DNA (“ministring”), doggybone™ DNA, protelomere closed ended DNA, or dumbbell linear DNA), dicer-substrate dsRNA, small hairpin RNA (shRNA), asymmetric interfering RNA (aiRNA), microRNA (miRNA), mRNA, tRNA, rRNA, gRNA, and DNA viral vectors, viral RNA vector, and any combination thereof. In some embodiments, the transgene is a therapeutic gene, or a marker protein. In some embodiments, the transgene is an agonist or antagonist. In some embodiments, the antagonist is a mimetic or antibody, or antibody fragment, or antigen-binding fragment thereof, e.g., a neutralizing antibody or antibody fragment and the like. In some embodiments, the transgene encodes an antibody, including a full-length antibody or antibody fragment, as defined herein. In some embodiments, the antibody is an antigen-binding domain or an immunoglobulin variable domain sequence, as that is 43 ME148589913v.1defined herein. In particular, the transgene can encode one or more therapeutic agent(s), including, but not limited to, for example, protein(s), polypeptide(s), peptide(s), enzyme(s), antibodies, antigen binding fragments, as well as variants, and / or active fragments thereof, for use in the treatment, prophylaxis, and / or amelioration of one or more symptoms of a disease, dysfunction, injury, and / or disorder. Exemplary transgenes are described herein in the section entitled “Method of Treatment”. B. Inverted Terminal Repeats (ITRs) in Reference ceDNA Vectors It is a feature of the present disclosure that the ceDNA vectors described herein contain no viral ITR sequences (e.g., trs, RBE, A and A’, B and B’, C and C’ and / or D and D’ regions of an AAV ITR). Only the reference ceDNA vectors (e.g., ceDNA vectors that may be used for comparison purposes) that are described herein contain viral ITR sequences. According to one embodiment, the reference ceDNA vectors are capsid-free, linear duplex DNA molecules formed from a continuous strand of complementary DNA with covalently-closed ends (linear, continuous and non-encapsidated structure), which comprise a synthetic 5’ inverted terminal repeat (ITR) sequence and a synthetic 3’ ITR sequence that are symmetric or asymmetric with respect to each other. In one embodiment, both of the ITR sequences of the ceDNA are hairpin (stem-loop) secondary structures. The wild-type AAV ITR sequences are from e.g., AAV1, AAV2, AAV3, AAV4, AAV5, AAV 5, AAV7, AAV8, AAV9, AAV10, AAV 11, AAV12, AAVrh8, AAVrh10, AAV-DJ, and AAV- DJ8 genome (NCBI: NC 002077; NC 001401; NC001729; NC001829; NC006152; NC 006260; NC 006261; see also Table 1, below) In some embodiments, an ITR of the ceDNA vector of the instant disclosure may be synthetic. In one embodiment, a synthetic ITR is based on ITR sequences that form the terminal loop portion of one of the ITR secondary structures (e.g., a hairpin (stem loop) secondary structure). In another embodiment, a synthetic ITR includes no AAV-based sequence lacking terminal resolution site (trs) and / or rep protein binding sequence (RBE). In yet another embodiment, a synthetic ITR preserves the ITR structure described above although having no AAV-sourced sequence. In one embodiment, the flanking ITRs are substantially symmetric to each other. In one embodiment, the flanking ITRs are the same and symmetric to each other. Any synthetic ITR can be used as an ITR (e.g., hairpin stem-loop structure, aptamer forming a secondary structure) or as a base ITR for modification. Table 1: Exemplary wt-ITRs from Different AAV Serotypes for Reference ceDNA Vectors44 ME148589913v.145 ME148589913v.1In certain embodiments of the present disclosure, the ceDNA vector of the disclosure does not have a wt-ITR consisting of the nucleotide sequence selected from any of the sequences in Table 1. In some embodiments, a ceDNA vector of the instant disclosure comprises a stem-loop structure having no more than 50% identity, 45% identity, 40% identity, 35% identity, 30% identity, 25% identity, 20% identity, 15% identity, 10% identity, or 5% identity with, for example, a viral ITR sequence as described above, or with any other viral ITR sequences known in the art. Those of skill in the art are readily able to determine the sequences known to be viral ITR sequences, and to determine percent identity between the ITR sequences used in the ceDNA vectors of the instant disclosure and known viral ITR sequences using routine methods of DNA sequence analysis. In one embodiment, the ceDNA vectors do not contain the trs and Rep protein binding element (RBE) and are defective with respect to Rep binding and Rep nicking. In one embodiment, the defect is completely lacking in function. The host cells do not express viral capsid proteins and the ceDNA vector is devoid of any viral capsid coding sequences. In one embodiment, the ceDNA vector and host cells are devoid of AAV capsid genes and the resultant protein also do not encode or express capsid genes of other viruses. In addition, in one embodiment, the ceDNA vector is devoid of AAV Rep protein coding sequences. In one embodiment, the entire ceDNA vector is completely devoid of any AAV-derived sequence. In some embodiments, the structural element of the stem-loop structure is devoid of any structural element that is involved in the functional interaction of an ITR with a large Rep protein (e.g., Rep 78 or Rep 68). The stem-loop structure can be modified structurally, for example, the stem-loop structure may be modified to include a functional sequence. In some embodiments, the stem-loop structure may be modified with an aptamer. In some embodiments, the compositions of the present disclosure comprise a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a stem-loop structure, wherein the stem-loop structures do not comprise any viral ITR sequences. In some embodiments of the aspects and embodiments herein, each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO: 1 (5’-CTCATCAGAATCACTTTGTGATTCTGA-3’), SEQ ID NO: 2 (5’- TCAGAATCACAAAGTGATTCTGATGAG-3’), and SEQ ID NO: 4 (5’- CACTCATCAGAATCACTTTGTGATTCTGATG-3’). In some embodiments of the aspects and embodiments herein, each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 46 ME148589913v.11 (5’-CTCATCAGAATCACTTTGTGATTCTGA-3’). In some embodiments, each IT stem-loop structure R independently consists of SEQ ID NO: 1. In some embodiments of the aspects and embodiments herein, each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 2 (5’-TCAGAATCACAAAGTGATTCTGATGAG-3’). In some embodiments, each stem-loop structure independently consists of SEQ ID NO: 2. In some embodiments of the aspects and embodiments herein, each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 3 (5’- TCAGAATCACAAAGTGATTCTGATGAG-3’). In some embodiments, each stem-loop structure independently consists of SEQ ID NO: 3. In some embodiments of the aspects and embodiments herein, each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 4 (5’-CACTCATCAGAATCACTTTGTGATTCTGATG-3’). In some embodiments, each stem-loop structure independently consists of SEQ ID NO: 4. In some embodiments of the aspects and embodiments herein, each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to SEQ ID NO: 12 (5’- TGAGCCTTGATACCACACTTACCTTTCAAGCTTAATACCTTTAGGAGAGCAATTGCAT- 3’). In some embodiments, each stem-loop structure independently consists of SEQ ID NO: 12. In some embodiments of the aspects and embodiments herein, each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, or at least 99% sequence identity to SEQ ID NO: 13 (5’- ATGCAATTGCTCTCCTAAAGGTATTAAGCTTGAAAGGTAAGTGTGGTATCAAGGCTCA- 3’). In some embodiments, each stem-loop structure independently consists of SEQ ID NO: 13. In some embodiments, at least one stem-loop structure comprises an aptamer. In other embodiments, each stem-loop structure independently comprises an aptamer. III. Regulatory Elements The ceDNA vectors of the present disclosure can be produced from expression constructs that further comprise a specific combination of cis-regulatory elements. The cis-regulatory elements include, but are not limited to, a promoter, an enhancer, a riboswitch, an insulator, a mir-regulatable element, a post-transcriptional regulatory element, a transcription factor binding site (or consensus 47 ME148589913v.1site), including but not limited to a tissue- and cell type-specific promoter and an enhancer. In some embodiments the ceDNA vectors of the present disclosure contain liver-specific regulatory elements. In some embodiments, the ceDNA vector comprises additional components to regulate expression of the transgene, for example, regulatory switches as described herein, to regulate the expression of the transgene, or a kill switch, which can kill a cell comprising the ceDNA vector. The ceDNA vectors can be produced from expression constructs that further comprise a specific combination of cis-regulatory elements such as WHP posttranscriptional regulatory element (WPRE) and BGH polyA. Suitable expression cassettes for use in expression constructs are not limited by the packaging constraint imposed by the viral capsid. A. Promoters Expression cassettes of the present disclosure include a promoter, which can influence overall expression levels as well as cell-specificity. For transgene expression, they can include a highly active virus-derived immediate early promoter. Expression cassettes can contain tissue-specific eukaryotic promoters to limit transgene expression to specific cell types and reduce toxic effects and immune responses resulting from unregulated, ectopic expression. Suitable promoters, including those described above, can be derived from viruses and can therefore be referred to as viral promoters, or they can be derived from any organism, including prokaryotic or eukaryotic organisms. Suitable promoters can be used to drive expression by any RNA polymerase (e.g., pol I, pol II, pol III). Exemplary promoters include, but are not limited to, the SV40 early promoter, mouse mammary tumor virus long terminal repeat (LTR) promoter; adenovirus major late promoter (Ad MLP); a herpes simplex virus (HSV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter region (CMVIE), a rous sarcoma virus (RSV) promoter, a human U6 small nuclear promoter (U6) (Miyagishi et al., Nature Biotechnology 20, 497- 500 (2002)), an enhanced U6 promoter (e.g., Xia et al., Nucleic Acids Res.2003 Sep.1; 31(17)), a human H1 promoter (H1), a CAG promoter, a human alpha 1-antitypsin (hAAT) promoter, and the like. In embodiments, these promoters are altered at their downstream intron containing end to include one or more nuclease cleavage sites. In embodiments, the DNA containing the nuclease cleavage site(s) is foreign to the promoter DNA. In one embodiment, a promoter may comprise one or more specific transcriptional regulatory sequences to further enhance expression and / or to alter the spatial expression and / or temporal expression of same. A promoter may also comprise distal enhancer or repressor elements, which may be located as much as several thousand base pairs from the start site of transcription. A promoter may be derived from sources including viral, bacterial, fungal, plants, insects, and animals. A promoter may regulate the expression of a gene component constitutively, or differentially with respect to the cell, tissue or organ in which expression occurs or, with respect to the developmental stage at which expression occurs, or in response to external stimuli such as physiological stresses, pathogens, metal 48 ME148589913v.1ions, or inducing agents. Representative examples of promoters include the bacteriophage T7 promoter, bacteriophage T3 promoter, SP6 promoter, lac operator-promoter, tac promoter, SV40 late promoter, SV40 early promoter, RSV-LTR promoter, CMV IE promoter, SV40 early promoter or SV40 late promoter and the CMV IE promoter, as well as the promoters listed below. Such promoters and / or enhancers can be used for expression of any gene of interest, e.g., the gene editing molecules, donor sequence, therapeutic proteins etc.). For example, the vector may comprise a promoter that is operably linked to the nucleic acid sequence encoding a therapeutic protein. The promoter operably linked to the therapeutic protein coding sequence may be a promoter from simian virus 40 (SV40), a mouse mammary tumor virus (MMTV) promoter, a human immunodeficiency virus (HIV) promoter such as the bovine immunodeficiency virus (BIV) long terminal repeat (LTR) promoter, a Moloney virus promoter, an avian leukosis virus (ALV) promoter, a cytomegalovirus (CMV) promoter such as the CMV immediate early promoter, Epstein Barr virus (EBV) promoter, or a Rous sarcoma virus (RSV) promoter. The promoter may also be a promoter from a human gene such as human ubiquitin C (hUbC), human actin, human myosin, human hemoglobin, human muscle creatine, or human metallothionein. The promoter may also be a tissue specific promoter, such as a liver specific promoter, such as human alpha 1-antitypsin (hAAT), natural or synthetic. In one embodiment, delivery to the liver can be achieved using endogenous ApoE specific targeting of the composition comprising a ceDNA vector to hepatocytes via the low-density lipoprotein (LDL) receptor present on the surface of the hepatocyte. In one embodiment, the promoter used is the native promoter of the gene encoding the therapeutic protein. The promoters and other regulatory sequences for the respective genes encoding the therapeutic proteins are known and have been characterized. The promoter region used may further include one or more additional regulatory sequences (e.g., native), e.g., enhancers. Non-limiting examples of suitable promoters for use in accordance with the present disclosure include the CAG promoter of, for example, the hAAT promoter, the human EF1-α promoter or a fragment of the EF1a promoter, IE2 promoter and the rat EF1-α promoter. In one embodiment, an expression cassette can contain a synthetic regulatory element, such as a CAG promoter. The CAG promoter comprises (i) the cytomegalovirus (CMV) early enhancer element, (ii) the promoter, the first exon and the first intron of chicken beta-actin gene, and (iii) the splice acceptor of the rabbit beta-globin gene. Alternatively, an expression cassette can contain an a hAAT promoter, Alpha-1-antitrypsin (AAT) promoter, a liver specific (LP1) promoter, a human elongation factor-1 alpha (EF1α) promoter, or a fragment thereof, a rat EF1α promoter or an IE2 promoter. In some embodiments, the expression cassette includes one or more constitutive promoters, for example, a retroviral Rous sarcoma virus (RSV) LTR promoter (optionally with the RSV enhancer), or a cytomegalovirus (CMV) immediate early promoter (optionally with the CMV enhancer). Alternatively, an inducible promoter, a native promoter for a transgene, a tissue-specific promoter, or various promoters known in the art can be used. 49 ME148589913v.1B. Polyadenylation Sequences A sequence encoding a polyadenylation sequence can be included in the ceDNA vector to stabilize the mRNA expressed from the ceDNA vector, and to aid in nuclear export and translation. In one embodiment, the ceDNA vector does not include a polyadenylation sequence. In other embodiments, the vector includes at least 1, at least 2, at least 3, at least 4, at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 40, least 45, at least 50 or more adenine dinucleotides. In some embodiments, the polyadenylation sequence comprises about 43 nucleotides, about 40-50 nucleotides, about 40-55 nucleotides, about 45-50 nucleotides, about 35-50 nucleotides, or any range there between. The expression cassettes can include a poly-adenylation sequence known in the art or a variation thereof, such as a naturally occurring sequence isolated from bovine BGHpA or a virus SV40pA, or a synthetic sequence. Some expression cassettes can also include SV40 late polyA signal upstream enhancer (USE) sequence. In some embodiments, the, USE can be used in combination with SV40pA or heterologous poly-A signal. The expression cassettes can also include a post-transcriptional element to increase the expression of a transgene. In some embodiments, Woodchuck Hepatitis Virus (WHP) posttranscriptional regulatory element (WPRE) is used to increase the expression of a transgene. Other post-transcriptional processing elements such as the post-transcriptional element from the thymidine kinase gene of herpes simplex virus, or hepatitis B virus (HBV) can be used. Secretory sequences can be linked to the transgenes, e.g., VH-02 and VK-A26 sequences. In one embodiment, the host cells do not express viral capsid proteins and the polynucleotide vector template is devoid of any viral capsid coding sequences. In one embodiment, the polynucleotide vector template is devoid of AAV capsid genes but also of capsid genes of other viruses). In one embodiment, the nucleic acid molecule is also devoid of AAV Rep protein coding sequences. Accordingly, in some embodiments, the nucleic acid molecule of the disclosure is devoid of both functional AAV cap and AAV rep genes. IV. Gene Editing Embodiments of the disclosure are based on methods and compositions comprising close ended linear duplexed (ceDNA) vectors as described herein that can express a transgene which is a gene editing molecule in a host cell (e.g., a transgene is a nuclease such as ZFN, TALEN, Cas; one or more guide RNA; CRISPR; a ribonucleoprotein (RNP), or any combination thereof) and result in more efficient genome editing. The ceDNA vectors described herein are not limited by size, thereby permitting, for example, expression of all of the components necessary for a gene editing system from a single vector (e.g., a CRISPR / Cas gene editing system (e.g., a Cas9 or modified Cas9 enzyme, a guide RNA and / or a homology directed repair template), or for a TALEN or Zinc Finger system). 50 ME148589913v.1However, it is also contemplated that having only one or two of such components encoded on a single vector, while the remaining component(s) can be expressed on a separate ceDNA vector or e.g., a traditional plasmid. One aspect herein relates to a ceDNA vector as described herein for DNA knock-in method(s), e.g., for the introduction of one or more exogenous donor sequences into a specific target site on a cellular chromosome with high efficiency. In some embodiments, a ceDNA vector described herein comprising the expression cassette with a transgene which is a gene editing molecule, or a gene editing nucleic acid sequence, can be operatively linked to one or more regulatory sequence(s) that allows or controls expression of the transgene. The expression cassette can comprise any transgene which is a gene editing molecule, or a gene editing nucleic acid sequence. The gene editing ceDNA vector edit any gene of interest in the subject, which includes but are not limited to, nucleic acids encoding polypeptides, or non-coding nucleic acids (e.g., RNAi, miRs etc.), as well as exogenous genes and nucleotide sequences, including virus sequences in a subjects’ genome, e.g., HIV virus sequences and the like. Preferably the gene editing ceDNA vector disclosed herein is used for therapeutic purposes (e.g., for medical, diagnostic, or veterinary uses) or immunogenic polypeptides. In certain embodiments, the gene editing ceDNA vector can edit any gene of interest in the subject, which includes one or more polypeptides, peptides, ribozymes, peptide nucleic acids, siRNAs, RNAis, antisense oligonucleotides, antisense polynucleotides, antibodies, antigen binding fragments, or any combination thereof. ceDNA expression cassette can include, for example, an expressible exogenous sequence (e.g., open reading frame) that encodes a protein that is either absent, inactive, or insufficient activity in the recipient subject or a gene that encodes a protein having a desired biological or a therapeutic effect. The exogenous sequence such as a donor sequence can encode a gene product that can function to correct the expression of a defective gene or transcript. The expression cassette can also encode corrective DNA strands, encode polypeptides, sense or antisense oligonucleotides, or RNAs (coding or non-coding; e.g., siRNAs, shRNAs, micro-RNAs, and their antisense counterparts (e.g., antagoMiR)). Expression cassettes can include an exogenous sequence that encodes a reporter protein to be used for experimental or diagnostic purposes, such as β-lactamase, β -galactosidase (LacZ), alkaline phosphatase, thymidine kinase, green fluorescent protein (GFP), chloramphenicol acetyltransferase (CAT), luciferase, and others well known in the art. In principle, the expression cassette can include any gene that encodes a protein, polypeptide or RNA that is either reduced or absent due to a mutation or which conveys a therapeutic benefit when overexpressed is considered to be within the scope of the disclosure. The ceDNA vector may comprise a template or donor nucleotide sequence used as a correcting DNA strand to be inserted after a double-strand break (or nick) provided by a nuclease. The ceDNA vector may include a template nucleotide sequence used as a correcting DNA strand to be inserted after a double-strand break (or 51 ME148589913v.1nick) provided by a guided RNA nuclease, meganuclease, or zinc finger nuclease. Preferably, non- inserted bacterial DNA is not present and preferably no bacterial DNA is present in the ceDNA compositions provided herein. In some instances, the protein can change a codon without a nick. Sequences provided in the expression cassette, expression construct, or donor sequence of a ceDNA vector described herein can be codon optimized for the host cell. As used herein, the term “codon optimized” or “codon optimization” refers to the process of modifying a nucleic acid sequence for enhanced expression in the cells of the vertebrate of interest, e.g., mouse or human, by replacing at least one, more than one, or a significant number of codons of the native sequence (e.g., a prokaryotic sequence) with codons that are more frequently or most frequently used in the genes of that vertebrate. Many organisms display a bias for use of particular codons to code for insertion of a particular amino acid in a growing peptide chain. Codon preference or codon bias, differences in codon usage between organisms, is afforded by degeneracy of the genetic code, and is well documented among many organisms. Codon bias often correlates with the efficiency of translation of messenger RNA (mRNA), which is in turn believed to be dependent on, inter alia, the properties of the codons being translated and the availability of particular transfer RNA (tRNA) molecules. In some embodiments, the gene editing gene (e.g., donor sequences) or guide RNA targets a therapeutic gene. In some embodiments, the guide RNA targets an antibody, or antibody fragment, or antigen-binding fragment thereof, e.g., a neutralizing antibody or antibody fragment and the like. In particular, the gene editing gene (e.g., donor sequences) or guide RNA targets one or more therapeutic agent(s), including, but not limited to, for example, protein(s), polypeptide(s), peptide(s), enzyme(s), antibodies, antigen binding fragments, as well as variants, and / or active fragments thereof, for use in the treatment, prophylaxis, and / or amelioration of one or more symptoms of a disease, dysfunction, injury, and / or disorder. Exemplary genes for targeting with the guide RNA are described herein in the section entitled “Method of Treatment”. A. Gene Editing Components - General In further embodiments, such as those including an RNA guided nuclease, the components required for gene editing may include a nuclease, a guide RNA (if Cas9 or the like is utilized), a donor sequence and one or more homology arms included within a single ceDNA vector of the present disclosure. Such embodiments increase the efficiency of gene editing compared to approaches that require distinct or various particles to deliver the gene editing components. In further embodiments, a nuclease can be inactivated / diminished after gene editing, reducing or eliminating off-target editing, if any, that would otherwise occur with the persistence of an added nuclease within cells. The methods and compositions described herein also provide for gene editing systems comprising a cellular switch. 52 ME148589913v.1It is also specifically contemplated herein that the methods and compositions described herein can be performed in a high-throughput manner using methods known in the art (see e.g., Shalem et al. Nat Rev Genet 16:299-311 (2015); Shalem et al. Science 343:84-88 (2014); the contents of each of which are incorporated herein by reference in their entirety. B. Knock-in of Desired Nucleic Acid Sequences The gene editing ceDNA vectors, methods and compositions described herein can be used to introduce a new nucleic acid sequence, correct a mutation of a genomic sequence or introduce a mutation into a target gene sequence in a host cell. Such methods can be referred to as “DNA knock- in systems.” The DNA knock-in system, as described herein, allows donor sequences to be inserted at any desired target site with high efficiency, making it feasible for many uses such as creation of transgenic animals expressing exogenous genes, preparing cell culture models of disease, preparing screening assay systems, modifying gene expression of engineered tissue constructs, modifying (e.g., mutating) a genomic locus, and gene editing, for example by adding an exogenous non-coding sequence (such as sequence tags or regulatory elements) into the genome. The cells and animals produced using methods provided herein can find various applications, for example as cellular therapeutics, as disease models, as research tools, and as humanized animals useful for various purposes. Accordingly, in one embodiment, a ceDNA vector can comprise an endonuclease (e.g., Cas9) that is transcriptionally regulated by an inducible promoter. In some embodiments, the endonuclease is on a separate ceDNA vector, which can be administered to a subject with a ceDNA comprising homology arms and a donor sequence, which can optionally also comprise guide RNA (sgRNAs). In alternative embodiments, the endonuclease can be on an all-in-one ceDNA vector as described herein. In some embodiments, the ceDNA encodes an endonuclease as described herein under control of a promoter. Non-limiting examples of inducible promoters include chemically-regulated promoters, which regulate transcriptional activity by the presence or absence of, for example, alcohols, tetracycline, steroids, metal, and pathogenesis-related proteins (e.g., salicylic acid, ethylene, and benzothiadiazole), and physically-regulated promoters, which regulate transcriptional activity by, for example, the presence or absence of light and low or high temperatures. Modulation of the inducible promoter allows for the turning off or on of gene-editing activity of a ceDNA vector. Inducible Cas9 promoters are further reviewed, for example in Cao J., et al. Nucleic Acids Research.44(19)2016, and Liu KI, et al. Nature Chemical Biol.12: 90-987 (2016), which are incorporated herein in their entireties. In one embodiment, the ceDNA vector described herein further comprises a second endonuclease that temporally targets and inhibits the activity of the first endonuclease (e.g., Cas9). Endonucleases that target and inhibit the activity of other endonucleases can be determined by those skilled in the art. In another embodiment, the ceDNA vector described herein further comprises 53 ME148589913v.1temporal expression of an “anti-CRISPR gene” (e.g., L. monocytogenes ArcIIa). As used herein, “anti-CRISPR gene” refers to a gene shown to inhibit the commonly used S. pyogenes Cas9. In another embodiment, the second endonuclease that targets and inhibits the activity of the first endonuclease activity, or the anti-CRISPR gene, is comprised in a second ceDNA vector that is administered after the desired gene-editing is complete. Alternatively, the second endonuclease targets and inhibits a gene of interest, for example, a gene that has been transcriptionally enhanced by a ceDNA vector as described herein. A ceDNA vector or composition thereof, as described herein, can include a nucleotide sequence encoding a transcriptional activator that activates a target gene. For example, the transcriptional activator may be engineered. For example, an engineered transcriptional activator may be a CRISPR / Cas9-based system, a zinc finger fusion protein, or a TALE fusion protein. The CRISPR / Cas9-based system, as described above, may be used to activate transcription of a target gene with RNA. The CRISPR / Cas9-based system may include a fusion protein, as described above, wherein the second polypeptide domain has transcription activation activity or histone modification activity. For example, the second polypeptide domain may include VP64 or p300. Alternatively, the transcriptional activator may be a zinc finger fusion protein. The zinc finger targeted DNA-binding domains, as described above, can be combined with a domain that has transcription activation activity or histone modification activity. For example, the domain may include VP64 or p300. TALE fusion proteins may be used to activate transcription of a target gene. The TALE fusion protein may include a TALE DNA-binding domain and a domain that has transcription activation activity or histone modification activity. For example, the domain may include VP64 or p300. C. Modified DNA endonucleases, Nuclease-dead Cas9 and Uses thereof Unlike viral vectors, the ceDNA vectors as described herein do not have a capsid that limits the size or number of nucleic acid sequences, effector sequences, regulatory sequences etc. that can be delivered to a cell. Accordingly, ceDNA vectors as described herein can comprise nucleic acids encoding nuclease-dead DNA endonucleases, nickases, or other DNA endonucleases with modified function (e.g., unique PAM binding sequence) for enhanced production of a desired vector and / or delivery of the vector to a cell. Such ceDNA vectors can also include promoter sequences and other regulatory or effector sequences as desired. Given the lack of size constraint, one of skill in the art will readily understand that, for example, that expression of a desired nuclease with modified function, and optionally, at least one guide RNA can be from nucleic acid sequences on the same vector and can be under the control of the same or different promoters. It is also contemplated herein that at least two different modified endonucleases can be encoded in the same vector, for example, for multiplexed gene expression modulation (see “Multiplexed gene expression modulation” section herein) and under the control of the same or different promoters. Thus, one of skill in the art could combine the desired functionality of at least two different Cas9 endonucleases (e.g., at least 3, at least 54 ME148589913v.14, at least 5, at least 6, at least 7, at least 8, at least 9, at least 10, or more) as desired including, for example, temporally regulated expression of at least two different modified endonucleases by one or more inducible promoters. In embodiments, ceDNA vectors in accordance with the present disclosure are suitable for use in nuclease free HDR systems such as those described in Porro et al., Promoterless gene targeting without nucleases rescues lethality of a Crigler-Najjar syndrome mouse model, EMBO Molecular Medicine, July 27, 2017 (herein incorporated by reference in its entirety). In such embodiments, in vivo gene targeting approaches are suitable for ceDNA application based on the insertion of a donor sequence, without the use of nucleases. In some embodiments, the donor sequence may be promoterless. Nucleic Acid-guided Endonucleases Different types of nucleic acid-guided endonucleases can be used in the compositions and methods of the disclosure to facilitate ceDNA-mediated gene editing. Exemplary, nonlimiting, types of nucleic acid-guided endonucleases suited for the compositions and methods of the disclosure include RNA-guided endonucleases, DNA-guided endonucleases, and single-base editors. In some embodiments, the nuclease can be an RNA-guided endonuclease. As used herein, the term “RNA-guided endonuclease” refers to an endonuclease that forms a complex with an RNA molecule that comprises a region complementary to a selected target DNA sequence, such that the RNA molecule binds to the selected sequence to direct endonuclease activity to the selected target DNA sequence. D. CRISPR / Cas systems As known in the art, a CRISPR-CAS9 system is a particular set of nucleic-acid guided- nuclease-based systems that includes a combination of protein and ribonucleic acid (“RNA”) that can alter the genetic sequence of an organism. The CRISPR-CAS9 system continues to develop as a powerful tool to modify specific deoxyribonucleic acid (“DNA”) in the genomes of many organisms such as microbes, fungi, plants, and animals. For example, mouse models of human disease can be developed quickly to study individual genes much faster, and easily change multiple genes in cells at once to study their interactions. One of ordinary skill in the art may select between a number of known CRISPR systems such as Type I, Type II, and Type III. Type II CRISPR-CAS system has a well-known mechanism including three components: (1) a crDNA molecule, which is called a “guide sequence” or “targeter-RNA”; (2) a “tracr RNA” or “activator-RNA”; and (3) a protein called Cas9. To alter the DNA molecule, a number of interactions occur in the system including: (1) the guide sequence binding by specific base pairing to a specific sequence of DNA of interest (“target DNA”), (2) the guide sequence binds by specific base pairing at another sequence to an activator- RNA, and (3) activator-RNA interacts with the Cas protein (e.g., Cas9 protein), which then acts as a 55 ME148589913v.1nuclease to cut the target DNA at a specific site. Suitable systems for use in accordance with ceDNA vectors in accordance with the present disclosure are further described in Van Nierop, et al. Stimulation of homology-directed gene targeting at an endogenous human locus by a nicking endonuclease, Nucleic Acid Research, August 2009 and Ran et al., Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity. ceDNA vectors in accordance with the present disclosure can be designed to include nucleotides encoding one or more components of these systems such as the guide sequence, tracr RNA, or Cas (e.g., Cas9). In certain embodiments, a single promoter drives expression of a guide sequence and tracr RNA, and a separate promoter drives Cas (e.g., Cas9) expression. One of skill in the art will appreciate that certain Cas nucleases require the presence of a protospacer adjacent motif (PAM) adjacent to a target nucleic acid sequence. In some embodiments, the PAM may be adjacent to or within 1, 2, 3, or 4 nucleotides of the 3’ end of the target sequence. The length and the sequence of the PAM can depend on the particular Cas protein. Exemplary PAM sequences include NGG, NGGNG, NG, NAAAAN, NNAAAAAW, NNNNACA, GNNNCNNA, TTN and NNNNGATT (wherein N is defined as any nucleotide and W is defined as either A or T). In some embodiments, the PAM sequence can be on the guide RNA, for example, when editing RNA. In some embodiments, RNA-guided nucleases including Cas and Cas9 are suitable for use in ceDNA vectors designed to provide one or more components for genome engineering using the CRISPR-Cas9 system See e.g., US publication 2014 / 0170753 herein incorporated by reference in its entirety. CRISPR-Cas 9 provides a set of tools for Cas9-mediated genome editing via non- homologous end joining (NHEJ) or homology-directed repair (HDR) in mammalian cells, as well as generation of modified cell lines for downstream functional studies. To minimize off-target cleavage, the CRISPR-Cas9 system may include a double-nicking strategy using the Cas9 nickase mutant with paired guide RNAs. This system is known in the art, and described in, for example, Ran et al., Genome engineering using the CRISPR-Cas9 system, Nature Protocols, 24 October 2013, and Zhang, et al., Efficient precise knockin with a double cut HDR donor after CRISPR / Cas9-mediated double- stranded DNA cleavage, Genome Biology, 2017 (both references are herein incorporated by reference in their entirety). In certain embodiments, the ceDNA system includes a nuclease and guide RNAs that are directed to a ceDNA sequence. For example, a nicking CAS, such as nCAS9 D10A can be used to increase the efficiency of gene editing. The guide RNAs can direct nCAS nicking of the ceDNA thereby releasing torsional constraints of ceDNA for more efficient gene repair and / or expression. Using a nicking nuclease relieves the torsional constraints while retaining sequence and structural integrity allowing the nicked DNA can persist in the nucleus. The guide RNAs can be directed to the same strand of DNA or the complementary strand. The guide RNAs can be directed to e.g., the ITRS, or sequences proceeding promoters, or homology domains etc. 56 ME148589913v.1In one embodiment, the RNA-guided endonuclease is a CRISPR enzyme, such as a Cas protein. Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5e (CasD), Cas6, Cas6e, Cas6f, Cas7, Cas8, Cas8a1, Cas8a2, Cas8b, Cas8c, Cas9 (also known as Csn1 and Csx12), Cas10, Cas10d, Cas13, Cas13a, Cas13c, CasF, CasH, Csy1, Csy2, Csy3, Cse1, Cse2, Cse3, Cse4, Csc1, Csc2, Csa5, Csn2, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx11, Csx16, CsaX, Csz1, Csx3, Csx1, Csx15, Csf1, Csf2, Csf3, Csf4, Cul966, Cpf1, C2c1, C2c3, homologs thereof, or modified versions thereof. In one embodiment, the Cas protein is Cas9. In another embodiment, the Cas protein is nuclease-dead Cas9 (dCas9) or a Cas9 nickase. In one embodiment, the Cas protein is a nicking Cas enzyme (nCas). In one embodiment, the Cas9 nickase comprises nCas9 D10A. For example, an aspartate-to- alanine substitution (D10A) in the RuvC I catalytic domain of Cas9 from S. pyogenes converts Cas9 from a nuclease that cleaves both strands to a nickase (cleaves a single strand). Other examples of mutations that render Cas9 a nickase include, without limitation, H840A, N854A, and N863A. In some embodiments, a Cas9 nickase can be used in combination with guide sequence(s), e.g., two guide sequences, which target respectively sense and antisense strands of the DNA target. This combination allows both strands to be nicked and used to induce non-homologous end joining (NHEJ) repair. In some embodiments, the ceDNA vectors of the present disclosure are suitable for use in systems and methods based on RNA-programmed Cas9 having gene-targeting and genome editing functionality. For example, the ceDNA vectors of the present disclosure are suitable for use with Clustered Regularly Interspaced Short Palindromic Repeats or the CRISPR associated (Cas) systems for gene targeting and gene editing. CRISPR cas9 systems are known in the art and described, e.g., in U.S. Patent Application No.13 / 842,859 filed on March 2013, and U.S. Patent Nos.8,697,359, 8771,945, 8795,965, 8,865,406, 8,871,445 all of which are herein incorporated by reference in their entirety. ceDNA vectors or compositions thereof can encode for modified DNA endonucleases as described in e.g., Fu et al. Nat Biotechnol 32:279-284 (2013); Ran et al. Cell 154:1380-1389 (2013); Mali et al. Nat Biotechnol 31:833-838 (2013); Guilinger et al. Nat Biotechnol 32:577-582 (2014); Slaymaker et al. Science 351:84-88 (2015); Klenstiver et al. Nature 523:481-485 (2015); Bolukbasi et al. Nat Methods 12:1-9 (2015); Gilbert et al. Cell 154;442-451 (2012); Anders et al. Mol Cell 61:895- 902 (2016); Wright et al. Proc Natl Acad Sci USA 112:2984-2989 (2015); Truong et al. Nucleic Acids Res 43:6450-6458 (2015); the contents of each of which are incorporated herein by reference in their entirety. E. MegaTALS In some embodiments, the endonuclease described herein can be a megaTAL. MegaTALs are engineered fusion proteins which comprise a transcription activator-like (TAL) effector domain and a 57 ME148589913v.1meganuclease domain. MegaTALs retain the ease of target specificity engineering of TALs while reducing off-target effects and overall enzyme size and increasing activity. MegaTAL construction and use is described in more detail in, e.g., Boissel et al.2014 Nucleic Acids Research 42(4):2591- 601 and Boissel 2015 Methods Mol Biol 1239:171-196; each of which is incorporated by reference herein in its entirety. Protocols for megaTAL-mediated gene knockout and gene editing are known in the art, see, e.g., Sather et al. Science Translational Medicine 20157(307):ra156 and Boissel et al. 2014 Nucleic Acids Research 42(4):2591-601; each of which is incorporated by reference herein in its entirety. MegaTALs can be used as an alternative endonuclease in any of the methods and compositions described herein. F. Guide RNAs (gRNAs) In general, a guide sequence is any polynucleotide sequence having sufficient complementarity with a target polynucleotide sequence to hybridize with the target sequence and direct sequence-specific targeting of an RNA-guided endonuclease complex to the selected genomic target sequence. In some embodiments, a guide RNA binds and e.g., a Cas protein can form a ribonucleoprotein (RNP), for example, a CRISPR / Cas complex. In some embodiments, the guide RNA (gRNA) sequence comprises a targeting sequence that directs the gRNA sequence to a desired site in the genome, fused to a crRNA and / or tracrRNA sequence that permit association of the guide sequence with the RNA-guided endonuclease. In some embodiments, the degree of complementarity between a guide sequence and its corresponding target sequence, when optimally aligned using a suitable alignment algorithm, is at least 50%, 60%, 75%, 80%, 85%, 90%, 95%, 97.5%, 99%, or more. Optimal alignment can be determined with the use of any suitable algorithm for aligning sequences, such as the Smith-Waterman algorithm, the Needleman-Wunsch algorithm, algorithms based on the Burrows-Wheeler Transform (e.g., the Burrows Wheeler Aligner), ClustalW, Clustal X, BLAT, Novoalign (Novocraft Technologies, ELAND (Illumina, San Diego, Calif.), SOAP, and Maq. In some embodiments, a guide sequence is 5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35, 40, 45, 50, 75, or more nucleotides in length. It is contemplated herein that the targeting sequence of the guide RNA and the target sequence on the target nucleic acid molecule can comprise 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mismatches. In some embodiments, the guide RNA sequence comprises a palindromic sequence, for example, the self-targeting sequence comprises a palindrome. The targeting sequence of the guide RNA is typically 19-21 base pairs long and directly precedes the hairpin that binds the entire guide RNA (targeting sequence + hairpin) to a Cas such as Cas9. Where a palindromic sequence is employed as the self-targeting sequence of the guide RNA, the inverted repeat element can be e.g., 9, 10, 11, 12, or more nucleotides in length. Where the targeting sequence of the guide RNA is most often 19-21 bp, a palindromic inverted repeat element of 9 or 10 nucleotides provides a targeting sequence of desirable length. The Cas9-guide RNA hairpin complex can then recognize and cut any 58 ME148589913v.1nucleotide sequence (DNA or RNA) e.g., a DNA sequence that matches the 19-21 base pair sequence and is followed by a “PAM” sequence e.g., NGG or NGA, or other PAM. The ability of a guide sequence to direct sequence-specific binding of an RNA-guided endonuclease complex to a target sequence can be assessed by any suitable assay. For example, the components of an RNA-guided endonuclease system sufficient to form an RNA-guided endonuclease complex can be provided to a host cell having the corresponding target sequence, such as by transfection with vectors encoding the components of the RNA-guided endonuclease sequence, followed by an assessment of preferential cleavage within the target sequence, such as by Surveyor assay (Transgenomic™, New Haven, CT). Similarly, cleavage of a target polynucleotide sequence can be evaluated in a test tube by providing the target sequence, components of an RNA-guided endonuclease complex, including the guide sequence to be tested and a control guide sequence different from the test guide sequence, and comparing binding or rate of cleavage at the target sequence between the test and control guide sequence reactions. One of ordinary skill in the art will appreciate that other assays can also be used to test gRNA sequences. A guide sequence can be selected to target any target sequence. In some embodiments, the target sequence is a sequence within a genome of a cell. In some embodiments, the target sequence is the sequence encoding a first guide RNA in a self-cloning plasmid, as described herein. Typically, the target sequence in the genome will include a protospacer adjacent (PAM) sequence for binding of the RNA-guided endonuclease. It will be appreciated by one of skill in the art that the PAM sequence and the RNA-guided endonuclease should be selected from the same (bacterial) species to permit proper association of the endonuclease with the targeting sequence. For example, the PAM sequence for CAS9 is different than the PAM sequence for cpF1. Design is based on the appropriate PAM sequence. To prevent degradation of the guide RNA, the sequence of the guide RNA should not contain the PAM sequence. In some embodiments, the length of the targeting sequence in the guide RNA is 12 nucleotides; in other embodiments, the length of the targeting sequence in the guide RNA is 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 35 or 40 nucleotides. The guide RNA can be complementary to either strand of the targeted DNA sequence. In some embodiments, when modifying the genome to include an insertion or deletion, the gRNA can be targeted closer to the N-terminus of a protein coding region. V. Regulatory Switches A molecular regulatory switch is one which generates a measurable change in state in response to a signal. Such regulatory switches can be usefully combined with the ceDNA vectors described herein to control the output of the ceDNA vector. In some embodiments, the ceDNA vector comprises a regulatory switch that serves to fine tune expression of the transgene. For example, it can serve as a biocontainment function of the ceDNA vector. In some embodiments, the switch is an “ON / OFF” switch that is designed to start or stop (i.e., shut down) expression of the gene of interest 59 ME148589913v.1in the ceDNA in a controllable and regulatable fashion. In some embodiments, the switch can include a “kill switch” that can instruct the cell comprising the ceDNA vector to undergo cell programmed death once the switch is activated. A. Binary Regulatory Switches In some embodiments, the ceDNA vector comprises a regulatory switch that can serve to controllably modulate expression of the transgene. In such an embodiment, the expression cassette located between the 5’ and 3’ stem-loop regions of the ceDNA vector may additionally comprise a regulatory region, e.g., a promoter, cis-element, repressor, enhancer etc., that is operatively linked to the gene of interest, where the regulatory region is regulated by one or more cofactors or exogenous agents. Accordingly, in one embodiment, only when the one or more cofactor(s) or exogenous agents are present in the cell will transcription and expression of the gene of interest from the ceDNA vector occur. In another embodiment, one or more cofactor(s) or exogenous agents may be used to de-repress the transcription and expression of the gene of interest. Any nucleic acid regulatory regions known by a person of ordinary skill in the art can be employed in a ceDNA vector designed to include a regulatory switch. By way of example only, regulatory regions can be modulated by small molecule switches or inducible or repressible promoters. Non-limiting examples of inducible promoters are hormone-inducible or metal-inducible promoters. Other exemplary inducible promoters / enhancer elements include, but are not limited to, an RU486-inducible promoter, an ecdysone-inducible promoter, a rapamycin-inducible promoter, and a metallothionein promoter. Classic tetracycline-based or other antibiotic-based switches are encompassed for use, including those disclosed in (Fussenegger et al., Nature Biotechnol.18: 1203- 1208 (2000)), incorporated by reference in its entirety herein. B. Small Molecule Regulatory Switches A variety of art-known small-molecule based regulatory switches are known in the art and can be combined with the ceDNA vectors disclosed herein to form a regulatory-switch controlled ceDNA vector. In some embodiments, the regulatory switch can be selected from any one or a combination of: an orthogonal ligand / nuclear receptor pair, for example retinoid receptor variant / LG335 and GRQCIMFI, along with an artificial promoter controlling expression of the operatively linked transgene, such as that as disclosed in Taylor, et al. BMC Biotechnology 10 (2010): 15; engineered steroid receptors, e.g., modified progesterone receptor with a C-terminal truncation that cannot bind progesterone but binds RU486 (mifepristone) (US Patent No.5,364,791); an ecdysone receptor from Drosophila and their ecdysteroid ligands (Saez, et al., PNAS, 97(26)(2000), 14512–14517; or a switch controlled by the antibiotic trimethoprim (TMP), as disclosed in Sando R 3rd; Nat Methods. 2013, 10(11):1085-8. 60 ME148589913v.1Other small molecule based regulatory switches known by an ordinarily skilled artisan are also envisioned for use to control transgene expression of the ceDNA and include, but are not limited to, those disclosed in Buskirk et al., Cell; Chem and Biol., 2005; 12(2); 151-161; an abscisic acid sensitive ON-switch; such as that disclosed in Liang, F.-S., et al., (2011) Science Signaling, 4(164);exogenous L-arginine sensitive ON-switches such as those disclosed in Hartenbach, et al. Nucleic Acids Research, 35(20), 2007, synthetic bile-acid sensitive ON-switches such as those disclosed in Rössger et al., Metab Eng.2014,21: 81–90;biotin sensitive ON-switches such as those disclosed in Weber et al., Metab. Eng.2009 Mar; 11(2): 117–124; dual input food additive benzoate / vanillin sensitive regulatory switches such as those disclosed in Xie et al., Nucleic Acids Research, 2014; 42(14);e116; 4-hydroxytamoxifen sensitive switches such as those disclosed in Giuseppe et al., Molecular Therapy , 6(5), 653 – 663; and flavinoid (phloretin) sensitive regulatory switches such as those disclosed in Gitzinger et al., Proc. Natl. Acad. Sci. U S A.2009 Jun 30; 106(26): 10638–10643. In some embodiments, the regulatory switch to control the transgene or expressed by the ceDNA vector is a pro-drug activation switch, such as that disclosed in US patents 8,771,679, and 6,339,070. Exemplary regulatory switches for use in the ceDNA vectors include, but are not limited to, those in Table 2. C. “Passcode” Regulatory Switches In some embodiments the regulatory switch can be a “passcode switch” or “passcode circuit”. Passcode switches allow fine tuning of the control of the expression of the transgene from the ceDNA vector when specific conditions occur – that is, a combination of conditions need to be present for transgene expression and / or repression to occur. For example, for expression of a transgene to occur at least conditions A and B must occur. A passcode regulatory switch can be any number of conditions, e.g., at least 2, or at least 3, or at least 4, or at least 5, or at least 6 or at least 7 or more conditions to be present for transgene expression to occur. In some embodiments, at least 2 conditions (e.g., A, B conditions) need to occur, and in some embodiments, at least 3 conditions need to occur (e.g., A, B and C, or A, B and D). By way of an example only, for gene expression from a ceDNA to occur that has a passcode “ABC” regulatory switch, conditions A, B and C must be present. Conditions A, B and C could be as follows; condition A is the presence of a condition or disease, condition B is a hormonal response, and condition C is a response to the transgene expression. As an exemplary example only, if the transgene is insulin, Condition A occurs if the subject has diabetes, Condition B is if the sugar level in the blood is high and Condition C is the level of endogenous insulin not being expressed at required amounts. Once the sugar level declines or the desired level of insulin is reached, the transgene (e.g., insulin), turns off again until the 3 conditions occur, turning it back on. In another exemplary example, if the transgene is EPO, Condition A is the presence of 61 ME148589913v.1Chronic Kidney Disease (CKD), Condition B occurs if the subject has hypoxic conditions in the kidney, Condition C is that Erythropoietin-producing cells (EPC) recruitment in the kidney is impaired; or alternatively, HIF-2 activation is impaired. Once the oxygen levels increase or the desired level of EPO is reached, the transgene (e.g., EPO) turns off again until 3 conditions occur, turning it back on. Passcode regulatory switches are useful to fine tune the expression of the transgene from the ceDNA vector. For example, the passcode regulatory switch can be modular in that it comprises multiple switches, e.g., a tissue specific, inducible promoter that is turned on only in the presence of a certain level of a metabolite. In such an embodiment, for transgene expression from the ceDNA vector to occur, the inducible agent must be present (condition A), in the desired cell type (condition B) and the metabolite is at, or above or below a certain threshold (Condition C). In alternative embodiments, the passcode regulatory switch can be designed such that the transgene expression is on when conditions A and B are present, but will turn off when condition C is present. Such an embodiment is useful when Condition C occurs as a direct result of the expressed transgene – that is Condition C serves as a positive feedback to loop to turn off transgene expression from the ceDNA vector when the transgene has had a sufficient amount of the desired therapeutic effect. In some embodiments, a passcode regulatory switch encompassed for use in the ceDNA vector is disclosed in International Patent Application Publication No. WO2017 / 059245, which describes a switch referred to as a “Passcode switch” or a “Passcode circuit” or “Passcode kill switch” which is a synthetic biological circuit that uses hybrid transcription factors (TFs) to construct complex environmental requirements for cell survival. The Passcode regulatory switches described in International Patent Application Publication No. WO2017 / 059245 are particularly useful for use in the ceDNA vectors, as they are modular and customizable, both in terms of the environmental conditions that control circuit activation and in the output modules that control cell fate. In addition, the Passcode circuit has particular utility to be used in ceDNA vectors, since without the appropriate “passcode” molecules it will allow transgene expression only in the presence of the required predetermined conditions. If something goes wrong with a cell or no further transgene expression is desired for any reason, then the related kill switch (i.e., deadman switch) can be triggered. In some embodiments, a passcode regulatory switch or “Passcode circuit” encompassed for use in the ceDNA vector comprises hybrid transcription factors (TFs) to expand the range and complexity of environmental signals used to define biocontainment conditions. As opposed to the deadman switch which triggers cell death on in the presence of a predetermined condition, the “passcode circuit” allows cell survival or transgene expression in the presence of a particular “passcode”, and can be easily reprogrammed to allow transgene expression and / or cell survival only when the predetermined environmental condition or passcode is present. In one aspect, a “passcode” system that restricts cell growth to the presence of a predetermined set of at least two selected agents, includes one or more nucleic acid constructs 62 ME148589913v.1encoding expression modules comprising: i) a toxin expression module that encodes a toxin that is toxic to a host cell, wherein sequence encoding the toxin is operably linked to a promoter P1 that is repressed by the binding of a first hybrid repressor protein hRP1; ii) a first hybrid repressor protein expression module that encodes the first hybrid repressor protein hRP1, wherein expression of hRP1 is controlled by an AND gate formed by two hybrid transcription factors hTF1 and hTF2, the binding or activity of which is responsive to agents A1 and A2, respectively, such that both agents A1 and A2 are required for expression of hRP1, wherein in the absence of either A1 or A2, hRP1 expression is insufficient to repress toxin promoter module P1 and toxin production, such that the host cell is killed. In this system, hybrid factors hTF1, hTF2 and hRP1 each comprise an environmental sensing module from one transcription factor and a DNA recognition module from a different transcription factor that renders the binding of the respective passcode regulatory switch sensitive to the presence of an environmental agent, A1, or A2, that is different from that which the respective subunits would typically bind in nature. Accordingly, a ceDNA vector can comprise a ‘Passcode regulatory circuit” that requires the presence and / or absence of specific molecules to activate the output module. In some embodiments, where genes that encode for cellular toxins are placed in the output module, this passcode regulatory circuit can not only be used to regulate transgene expression, but also can be used to create a kill switch mechanism in which the circuit kills the cell if the cell behaves in an undesired fashion (e.g., it leaves the specific environment defined by the sensor domains, or differentiates into a different cell type). In one non-limiting example, the modularity of the hybrid transcription factors, the circuit architecture, and the output module allows the circuit to be reconfigured to sense other environmental signals, to react to the environmental signals in other ways, and to control other functions in the cell in addition to induced cell death, as is understood in the art. Any and all combinations of regulatory switches disclosed herein, e.g., small molecule switches, nucleic acid-based switches, small molecule-nucleic acid hybrid switches, post- transcriptional transgene regulation switches, post-translational regulation, radiation-controlled switches, hypoxia-mediated switches and other regulatory switches known by persons of ordinary skill in the art as disclosed herein can be used in a passcode regulatory switch as disclosed herein. Regulatory switches encompassed for use are also discussed in the review article Kis et al., J R Soc Interface.12: 20141000 (2015), and summarized in Table 1 of Kis. In some embodiments, a regulatory switch for use in a passcode system can be selected from any or a combination of the switches in Table 2. D. Nucleic acid-based regulatory switches to control transgene expression In some embodiments, the regulatory switch to control the transgene expressed by the ceDNA is based on a nucleic-acid based control mechanism. Exemplary nucleic acid control mechanisms are known in the art and are envisioned for use. For example, such mechanisms include riboswitches, 63 ME148589913v.1such as those disclosed in, e.g., US2009 / 0305253, US2008 / 0269258, US2017 / 0204477, WO2018026762A1, US patent 9,222,093 and EP application EP288071, and also disclosed in the review by Villa JK et al., Microbiol Spectr.2018 May;6(3). Also included are metabolite-responsive transcription biosensors, such as those disclosed in WO2018 / 075486 and WO2017 / 147585. Other art- known mechanisms envisioned for use include silencing of the transgene with an siRNA or RNAi molecule (e.g., miR, shRNA). For example, the ceDNA vector can comprise a regulatory switch that encodes an RNAi molecule that is complementary to the transgene expressed by the ceDNA vector. When such RNAi is expressed even if the transgene is expressed by the ceDNA vector, it will be silenced by the complementary RNAi molecule, and when the RNAi is not expressed when the transgene is expressed by the ceDNA vector the transgene is not silenced by the RNAi. Such an example of a RNAi molecule controlling gene expression, or as a regulatory switch is disclosed in US2017 / 0183664. In some embodiments, the regulatory switch comprises a repressor that blocks expression of the transgene from the ceDNA vector. In some embodiments, the on / off switch is a Small transcription activating RNA (STAR)-based switch, for example, such as the one disclosed in Chappell J. et al., Nat Chem Biol.2015 Mar;11(3):214-20; and Chappell et al., Microbiol Spectr. 2018 May;6(3. In some embodiments, the regulatory switch is a toehold switch, such as that disclosed in US2009 / 0191546, US2016 / 0076083, WO2017 / 087530, US2017 / 0204477, WO2017 / 075486 and in Green et al, Cell, 2014; 159(4); 925-939. In some embodiments, the regulatory switch is a tissue-specific self-inactivating regulatory switch, for example as disclosed in US2002 / 0022018, whereby the regulatory switch deliberately switches transgene expression off at a site where transgene expression might otherwise be disadvantageous. In some embodiments, the regulatory switch is a recombinase reversible gene expression system, for example as disclosed in US2014 / 0127162 and US Patent 8,324,436. In some embodiments, the regulatory switch to control the transgene or gene of interest expressed by the ceDNA vector is a hybrid of a nucleic acid-based control mechanism and a small molecule regulator system. Such systems are well known to persons of ordinary skill in the art and are envisioned for use herein. Examples of such regulatory switches include, but are not limited to, an LTRi system or “Lac-Tet-RNAi” system, e.g., as disclosed in US2010 / 0175141 and in Deans T. et al., Cell., 2007, 130(2); 363-372, WO2008 / 051854 and US patent 9,388,425. In some embodiments, the regulatory switch to control the transgene or gene of interest expressed by the ceDNA vector involves circular permutation, as disclosed in US patent 8,338,138. In such an embodiment, the molecular switch is multistable, i.e., able to switch between at least two states, or alternatively, bistable, i.e., a state is either “ON” or “OFF,” for example, able to emit light or not, able to bind or not, able to catalyze or not, able to transfer electrons or not, and so forth. In another aspect, the molecular switch uses a fusion molecule, therefore the switch is able to switch between more than two states. For example, in response to a particular threshold state exhibited by an insertion sequence or acceptor sequence, the respective other sequence of the fusion may exhibit a 64 ME148589913v.1range of states (e.g., a range of binding activity, a range of enzyme catalysis, etc.). Thus, rather than switching from “ON” or “OFF,” the fusion molecule can exhibit a graded response to a stimulus. In some embodiments, a nucleic acid based regulatory switch can be selected from any or a combination of the switches in Table 2. E. Post-transcriptional and post-translational regulatory switches. In some embodiments, the regulatory switch to control the transgene or gene of interest expressed by the ceDNA vector is a post-transcriptional modification system. For example, such a regulatory switch can be an aptazyme riboswitch that is sensitive to tetracycline or theophylline, as disclosed in US2018 / 0119156, GB201107768, WO2001 / 064956A3, EP Patent 2707487 and Beilstein et al., ACS Synth. Biol., 2015, 4 (5), pp 526–534; Zhong et al., Elife.2016 Nov 2;5. Pii: e18858. In some embodiments, it is envisioned that a person of ordinary skill in the art could encode both the transgene and an inhibitory siRNA which contains a ligand sensitive (OFF-switch) aptamer, the net result being a ligand sensitive ON-switch. In some embodiments, the regulatory switch to control the transgene or gene of interest expressed by the ceDNA vector is a post-translational modification system. In alternative embodiments, the gene of interest or protein is expressed as pro-protein or pre-proprotein, or has a signal response element (SRE) or a destabilizing domain (DD) attached to the expressed protein, thereby preventing correct protein folding and / or activity until post-translation modification has occurred. In the case of a destabilizing domain (DD) or SRE, the de-stabilization domain is post- translationally cleaved in the presence of an exogenous agent or small molecule. One of ordinary skill in the art can utilize such control methods as disclosed in US patent 8,173,792 and PCT application WO2017180587. Other post-transcriptional control switches envisioned for use in the ceDNA vector for controlling functional transgene activity are disclosed in Rakhit et al., Chem Biol. 2014;21(9):1238-52 and Navarro et al., ACS Chem Biol.2016; 19; 11(8): 2101–2104A. In some embodiments, a regulatory switch to control the transgene or gene of interest expressed by the ceDNA vector is a post-translational modification system that incorporates ligand sensitive inteins into the transgene coding sequence, such that the transgene or expressed protein is inhibited prior to splicing. For example, this has been demonstrated using both 4-hydroxytamoxifen and thyroid hormone (see, e.g., US patents 7,541,450, 9,200,045; 7,192,739, Buskirk, et al, Proc Natl Acad Sci U S A.2004 Jul 20; 101(29): 10505–10510; ACS Synth Biol.2016 Dec 16; 5(12): 1475– 1484; and 2005 Feb; 14(2): 523–532. In some embodiments, a post-transcriptional based regulatory switch can be selected from any or a combination of the switches in Table 2. F. Other exemplary regulatory switches Any known regulatory switch can be used in the ceDNA vector to control the gene expression of the transgene expressed by the ceDNA vector, including those triggered by environmental changes. 65 ME148589913v.1Additional examples include, but are not limited to; the BOC method of Suzuki et al., Scientific Reports 8; 10051 (2018); genetic code expansion and a non-physiologic amino acid; radiation- controlled or ultra-sound controlled on / off switches (see, e.g., Scott S et al., Gene Ther.2000 Jul;7(13):1121-5; US patents 5,612,318; 5,571,797; 5,770,581; 5,817,636; and WO1999 / 025385A1. In some embodiments, the regulatory switch is controlled by an implantable system, e.g., as disclosed in US patent 7,840,263; US2007 / 0190028A1 where gene expression is controlled by one or more forms of energy, including electromagnetic energy, that activates promoters operatively linked to the transgene in the ceDNA vector. In some embodiments, a regulatory switch envisioned for use in the ceDNA vector is a hypoxia-mediated or stress-activated switch, e.g., such as those disclosed in WO1999060142A2, US patent 5,834,306; 6,218,179; 6,709,858; US2015 / 0322410; Greco et al., (2004) Targeted Cancer Therapies 9, S368, as well as FROG, TOAD and NRSE elements and conditionally inducible silence elements, including hypoxia response elements (HREs), inflammatory response elements (IREs) and shear-stress activated elements (SSAEs), e.g., as disclosed in U.S. Patent 9,394,526. Such an embodiment is useful for turning on expression of the transgene from the ceDNA vector after ischemia or in ischemic tissues, and / or tumors. In some embodiments, a regulatory switch envisioned for use in the ceDNA vector is an optogenetic (e.g., light controlled) regulatory switch, e.g., such as one of the switches reviewed in Polesskaya et al., BMC Neurosci.2018; 19(Suppl 1): 12, and are also envisioned for use herein. In such embodiments, a ceDNA vector can comprise genetic elements are light sensitive and can regulate transgene expression in response to visible wavelengths (e.g., blue, near IR). ceDNA vectors comprising optogenetic regulatory switches are useful when expressing the transgene in locations of the body that can receive such light sources, e.g., the skin, eye, muscle etc., and can also be used when ceDNA vectors are expressing transgenes in internal organs and tissues, where the light signal can be provided by a suitable means (e.g., implantable device as disclosed herein). Such optogenetic regulatory switches include use of the light responsive elements, or light-inducible transcriptional effector (LITE) (e.g., disclosed in 2014 / 0287938), a Light-On system (e.g., disclosed in Wang et al., Nat Methods.2012 Feb 12;9(3):266-9; which has reported to enable in vivo control of expression of an insulin transgene, the Cry2 / CIB1 system (e.g., disclosed on Kennedy et al., Nature Methods; 7, 973–975 (2010); and the FKF1 / GIGANTEA system (e.g., disclosed in Yazawa et al., Nat Biotechnol. 2009 Oct;27(10):941-5). G. Kill Switches Other embodiments of the disclosure relate to a ceDNA vector comprising a kill switch. A kill switch as disclosed herein enables a cell comprising the ceDNA vector to be killed or undergo programmed cell death as a means to permanently remove an introduced ceDNA vector from the subject’s system. It will be appreciated by one of ordinary skill in the art that use of kill switches in 66 ME148589913v.1the ceDNA vectors of the disclosure would be typically coupled with targeting of the ceDNA vector to a limited number of cells that the subject can acceptably lose or to a cell type where apoptosis is desirable (e.g., cancer cells). In all aspects, a “kill switch” as disclosed herein is designed to provide rapid and robust cell killing of the cell comprising the ceDNA vector in the absence of an input survival signal or other specified condition. Stated another way, a kill switch encoded by a ceDNA vector herein can restrict cell survival of a cell comprising a ceDNA vector to an environment defined by specific input signals. Such kill switches serve as a biological biocontainment function should it be desirable to remove the ceDNA vector from a subject or to ensure that it will not express the encoded transgene. Accordingly, kill switches are synthetic biological circuits in the ceDNA vector that couple environmental signals with conditional survival of the cell comprising the ceDNA vector. In some embodiments different ceDNA vectors can be designed to have different kill switches. This permits one to be able to control which transgene expressing cells are killed if cocktails of ceDNA vectors are used. In some embodiments, a ceDNA vector can comprise a kill switch which is a modular biological containment circuit. In some embodiments, a kill switch encompassed for use in the ceDNA vector is disclosed in WO2017 / 059245, which describes a switch referred to as a “Deadman kill switch” that comprises a mutually inhibitory arrangement of at least two repressible sequences, such that an environmental signal represses the activity of a second molecule in the construct (e.g., a small molecule-binding transcription factor is used to produce a ‘survival’ state due to repression of toxin production). In cells comprising a ceDNA vector comprising a deadman kill switch, upon loss of the environmental signal, the circuit switches permanently to the ‘death’ state, where the toxin is now derepressed, resulting in toxin production which kills the cell. In another embodiment, a synthetic biological circuit referred to as a “Passcode circuit” or “Passcode kill switch” that uses hybrid transcription factors (TFs) to construct complex environmental requirements for cell survival, is provided. The Deadman and Passcode kill switches described in WO2017 / 059245 are particularly useful for use in ceDNA vectors, as they are modular and customizable, both in terms of the environmental conditions that control circuit activation and in the output modules that control cell fate. With the proper choice of toxins, including, but not limited to an endonuclease, e.g., an EcoRI, Passcode circuits present in the ceDNA vector can be used to not only kill the host cell comprising the ceDNA vector, but also to degrade its genome and accompanying plasmids. Other kill switches known to a person of ordinary skill in the art are encompassed for use in the ceDNA vector as disclosed herein, e.g., as disclosed in US2010 / 0175141; US2013 / 0009799; US2011 / 0172826; US2013 / 0109568, as well as kill switches disclosed in Jusiak et al, Reviews in Cell Biology and molecular Medicine; 2014; 1-56; Kobayashi et al., PNAS, 2004; 101; 8419-9; Marchisio et al., Int. Journal of Biochem and Cell Biol., 2011; 43; 310-319; and in Reinshagen et al., Science Translational Medicine, 2018, 11. 67 ME148589913v.1Accordingly, in some embodiments, the ceDNA vector can comprise a kill switch nucleic acid construct, which comprises the nucleic acid encoding an effector toxin or reporter protein, where the expression of the effector toxin (e.g., a death protein) or reporter protein is controlled by a predetermined condition. For example, a predetermined condition can be the presence of an environmental agent, such as, e.g., an exogenous agent, without which the cell will default to expression of the effector toxin (e.g., a death protein) and be killed. In alternative embodiments, a predetermined condition is the presence of two or more environmental agents, e.g., the cell will only survive when two or more necessary exogenous agents are supplied, and without either of which, the cell comprising the ceDNA vector is killed. In some embodiments, the ceDNA vector is modified to incorporate a kill-switch to destroy the cells comprising the ceDNA vector to effectively terminate the in vivo expression of the transgene being expressed by the ceDNA vector (e.g., therapeutic gene, protein or peptide etc.). Specifically, the ceDNA vector is further genetically engineered to express a switch-protein that is not functional in mammalian cells under normal physiological conditions. Only upon administration of a drug or environmental condition that specifically targets this switch-protein, the cells expressing the switch- protein will be destroyed thereby terminating the expression of the therapeutic protein or peptide. For instance, it was reported that cells expressing HSV-thymidine kinase can be killed upon administration of drugs, such as ganciclovir and cytosine deaminase. See, for example, Dey and Evans, Suicide Gene Therapy by Herpes Simplex Virus-1 Thymidine Kinase (HSV-TK), in Targets in Gene Therapy, edited by You (2011); and Beltinger et al., Proc. Natl. Acad. Sci. USA 96(15):8699- 8704 (1999). In some embodiments the ceDNA vector can comprise a siRNA kill switch referred to as DISE (Death Induced by Survival gene Elimination) (Murmann et al., Oncotarget.2017; 8:84643- 84658. Induction of DISE in ovarian cancer cells in vivo). In some aspects, a deadman kill switch is a biological circuit or system rendering a cellular response sensitive to a predetermined condition, such as the lack of an agent in the cell growth environment, e.g., an exogenous agent. Such a circuit or system can comprise a nucleic acid construct comprising expression modules that form a deadman regulatory circuit sensitive to the predetermined condition, the construct comprising expression modules that form a regulatory circuit, the construct including: i) a first repressor protein expression module, wherein the first repressor protein binds a first repressor protein nucleic acid binding element and represses transcription from a coding sequence comprising the first repressor protein binding element, and wherein repression activity of the first repressor protein is sensitive to inhibition by a first exogenous agent, the presence or absence of the first exogenous agent establishing a predetermined condition; ii) a second repressor protein expression module, wherein the second repressor protein binds a second repressor protein nucleic acid binding element and represses transcription from a coding 68 ME148589913v.1sequence comprising the second repressor protein binding element, wherein the second repressor protein is different from the first repressor protein; and iii) an effector expression module, comprising a nucleic acid sequence encoding an effector protein, operably linked to a genetic element comprising a binding element for the second repressor protein, such that expression of the second repressor protein causes repression of effector expression from the effector expression module, wherein the second expression module comprises a first repressor protein nucleic acid binding element that permits repression of transcription of the second repressor protein when the element is bound by the first repressor protein, the respective modules forming a regulatory circuit such that in the absence of the first exogenous agent, the first repressor protein is produced from the first repressor protein expression module and represses transcription from the second repressor protein expression module, such that repression of effector expression by the second repressor protein is relieved, resulting in expression of the effector protein, but in the presence of the first exogenous agent, the activity of the first repressor protein is inhibited, permitting expression of the second repressor protein, which maintains expression of effector protein expression in the “off” state, such that the first exogenous agent is required by the circuit to maintain effector protein expression in the “off’ state, and removal or absence of the first exogenous agent defaults to expression of the effector protein. In some embodiments, the effector is a toxin or a protein that induces a cell death program. Any protein that is toxic to the host cell can be used. In some embodiments the toxin only kills those cells in which it is expressed. In other embodiments, the toxin kills other cells of the same host organism. Any of a large number of products that will lead to cell death can be employed in a deadman kill switch. Agents that inhibit DNA replication, protein translation or other processes or, e.g., that degrade the host cell’s nucleic acid, are of particular usefulness. To identify an efficient mechanism to kill the host cells upon circuit activation, several toxin genes were tested that directly damage the host cell’s DNA or RNA. The endonuclease ecoRI21, the DNA gyrase inhibitor ccdB22and the ribonuclease-type toxin mazF23were tested because they are well-characterized, are native to E. coli, and provide a range of killing mechanisms. To increase the robustness of the circuit and provide an independent method of circuit-dependent cell death, the system can be further adapted to express, e.g., a targeted protease or nuclease that further interferes with the repressor that maintains the death gene in the “off” state. Upon loss or withdrawal of the survival signal, death gene repression is even more efficiently removed by, e.g., active degradation of the repressor protein or its message. As non- limiting examples, mf-Lon protease was used to not only degrade LacI but also target essential proteins for degradation. The mf-Lon degradation tag pdt#1 can be attached to the 3’ end of five essential genes whose protein products are particularly sensitive to mf-Lon degradation20, and cell viability was measured following removal of Atc. Among the tested essential gene targets, the peptidoglycan biosynthesis gene murC provided the strongest and fastest cell death phenotype (survival ratio < 1 x 10-4within 6 hours). 69 ME148589913v.1As used herein, the term “predetermined input” refers to an agent or condition that influences the activity of a transcription factor polypeptide in a known manner. Generally, such agents can bind to and / or change the conformation of the transcription factor polypeptide to thereby modify the activity of the transcription factor polypeptide. Examples of predetermined inputs include, but are not limited to, environmental input agents that are not required for the survival of a given host organism (i.e., in the absence of a synthetic biological circuit as described herein). Conditions that can provide a predetermined input include, for example temperature, e.g., where the activity of one or more factors is temperature-sensitive, the presence or absence of light, including light of a given spectrum of wavelengths, and the concentration of a gas, salt, metal or mineral. Environmental input agents include, for example, a small molecule, biological agents such as pheromones, hormones, growth factors, metabolites, nutrients, and the like and analogs thereof; concentrations of chemicals, environmental byproducts, metal ions, and other such molecules or agents; light levels; temperature; mechanical stress or pressure; or electrical signals, such as currents and voltages. In some embodiments, reporters are used to quantify the strength or activity of the signal received by the modules or programmable synthetic biological circuits of the disclosure. In some embodiments, reporters can be fused in-frame to other protein coding sequences to identify where a protein is located in a cell or organism. Luciferases can be used as effector proteins for various embodiments described herein, for example, measuring low levels of gene expression, because cells tend to have little to no background luminescence in the absence of a luciferase. In other embodiments, enzymes that produce colored substrates can be quantified using spectrophotometers or other instruments that can take absorbance measurements including plate readers. Like luciferases, enzymes like β-galactosidase can be used for measuring low levels of gene expression because they tend to amplify low signals. In some embodiments, an effector protein can be an enzyme that can degrade or otherwise destroy a given toxin. In some embodiments, an effector protein can be an odorant enzyme that converts a substrate to an odorant product. In some embodiments, an effector protein can be an enzyme that phosphorylates or dephosphorylates either small molecules or other proteins, or an enzyme that methylates or demethylates other proteins or DNA. In some embodiments, an effector protein can be a receptor, ligand, or lytic protein. Receptors tend to have three domains: an extracellular domain for binding ligands such as proteins, peptides or small molecules, a transmembrane domain, and an intracellular or cytoplasmic domain which frequently can participate in some sort of signal transduction event such as phosphorylation. In some embodiments, transporter, channel, or pump gene sequences are used as effector proteins. Non- limiting examples and sequences of effector proteins for use with the kill switches as described herein can be found at the Registry of Standard Biological Parts on the world wide web at parts.igem.org. As used herein, a “modulator protein” is a protein that modulates the expression from a target nucleic acid sequence. Modulator proteins include, for example, transcription factors, including transcriptional activators and repressors, among others, and proteins that bind to or modify a 70 ME148589913v.1transcription factor and influence its activity. In some embodiments, a modulator protein includes, for example, a protease that degrades a protein factor involved in the regulation of expression from a target nucleic acid sequence. Preferred modulator proteins include modular proteins in which, for example, DNA-binding and input agent-binding or responsive elements or domains are separable and transferrable, such that, for example, the fusion of the DNA binding domain of a first modulator protein to the input agent-responsive domain of a second results in a new protein that binds the DNA sequence recognized by the first protein, yet is sensitive to the input agent to which the second protein normally responds. Accordingly, as used herein, the term “modulator polypeptide,” and the more specific “repressor polypeptide” include, in addition to the specified polypeptides, e.g., “a LacI (repressor) polypeptide,” variants, or derivatives of such polypeptides that responds to a different or variant input agent. Thus, for a LacI polypeptide, included are LacI mutants or variants that bind to agents other than lactose or IPTG. A wide range of such agents are known in the art. Table 2. Exemplary regulatory switches. bON switchability by an effector; other than removing the effector which confers the OFF state.cOFF switchability by an effector; other than removing the effector which confers the ON state.dA ligand or other physical stimuli (e.g., temperature, electromagnetic radiation, electricity) which stabilizes the switch either in its ON or OFF state.erefers to the reference number cited in Kis et al., J R Soc Interface.12:20141000 (2015), where both the article and the references cited therein are hereby incorporated by reference herein. Table 2: Example Regulatory Switches71 ME148589913v.172 ME148589913v.173 ME148589913v.1VI. Production of a ceDNA Vector Cell-Free Synthetic Production of Reference ceDNA Vectors and ceDNA Vectors of the Present Disclosure The cell-free synthetic production technology described herein is directed in general to methods for generating DNA vectors in the absence of cells or cell lines. As such, the resulting vectors have fewer impurities than comparable vectors made using conventional cell-based production methodologies, which may translate into better in vivo expression that is sustained a longer duration of time after administration (see e.g., FIG.16B of International Patent Application No. PCT / US2022 / 053868, filed December 22, 2022, incorporated herein by reference in its entirety). As exemplified here, this cell-free synthesis is also scalable, e.g., from small reactions (~1 mL) and up to a large scale (>40, 100, 200, 500, 1,000 mL) and further without compromising the purity (see e.g., FIG.15 of International Patent Application No. PCT / US2022 / 053868), therefore allowing the vectors 74 ME148589913v.1to prepared in large quantities for therapeutic uses. Moreover, while the cell-based methods could take up to weeks for the vectors to be produced, the cell-free methods described herein produce vectors in less than a week, such as 2-4 days depending on the scale. In one embodiment, the cell-free method described herein involves rolling circle and multiple strand displacement (MSD) amplification of DNA plasmid template by >1000 fold and subsequent conversion of the resultant products into ceDNA molecules using type II endonuclease, ligase, ITR oligonucleotides (for reference ceDNA vectors) or 5’ and 3’ oligonucleotides containing no viral ITR sequences (for ceDNA vectors of the present disclosure), and exonuclease enzymes. According to one aspect, the disclosure provides a method of producing a closed-ended DNA (ceDNA) vector, the method comprising (a) contacting a double-stranded DNA construct having a sense strand and an antisense strand with at least a first restriction endonuclease and at least a second restriction endonuclease, wherein the construct comprises a transgene expression cassette, a first non-palindromic restriction endonuclease recognition site and a corresponding first cleavage site upstream of the transgene expression cassette, and a second non-palindromic restriction endonuclease recognition site and a corresponding second cleavage site downstream of the transgene expression cassette; and wherein the first restriction endonuclease is capable of cleaving the double-stranded DNA construct at the first cleavage site, and wherein the second restriction endonuclease is capable of cleaving the double-stranded DNA construct at the second cleavage site, and wherein contacting the double-stranded DNA construct with the first restriction endonuclease and the second restriction endonuclease releases an insert having a first end comprising a first single-stranded overhang and a second end comprising a second single-stranded overhang; (b) ligating the first end to a first oligonucleotide comprising one or more hairpin structures; and (c) ligating the second end to a second oligonucleotide comprising one or more hairpin structures; thereby producing a ceDNA vector. In one embodiment, the first oligonucleotide comprises a stem-loop structure (e.g., a stem- loop structure devoid of viral ITR sequences). According to further embodiments, the second oligonucleotide comprises a stem-loop structure (e.g., a stem-loop structure devoid of viral ITR sequences). In one embodiment, the first oligonucleotide does not comprise a viral inverted terminal repeat (ITR). According to further embodiments, the second oligonucleotide does not comprise a viral ITR. In one embodiment, the first oligonucleotide comprises an artificial sequence. According to further embodiments, the second oligonucleotide comprises an artificial sequence. Oligonucleotides containing no viral ITR sequences are designed for the synthetic production of ceDNA vectors of the present disclosure that contain no viral ITRs. According to other embodiments, the first oligonucleotide and the second oligonucleotide are different. According to some other embodiments, the first oligonucleotide and the second oligonucleotide are the same. In some embodiments, reference ceDNA vectors comprising viral ITR sequences may be produced synthetically using similar oligonucleotides. 75 ME148589913v.1An overview of an exemplary embodiment of cell-free synthetic method of preparing a ceDNA vector is illustrated in FIG.4 of International Patent Application No. PCT / US2022 / 053868, incorporated by reference in its entirety herein. Briefly, the transgene expression cassette (in diagonal stripes in FIG.4 of International Patent Application No. PCT / US2022 / 053868) is excised from a double-stranded DNA construct using with at least one restriction endonuclease, followed up by ligation of the insert with inverted terminal repeat (ITR) oligonucleotides (e.g., 5’ and 3’ oligonucleotides that contain no viral ITR sequences) to form ceDNA. ITR oligonucleotides are single-stranded oligonucleotides that self-anneal to form an ITR-like three-dimensional configuration. In the case of ceDNA vectors of the present disclosure, the first and second oligonucleotides or the 5’ and 3’ oligonucleotides are single-stranded oligonucleotides that self-anneal to form a stem-loop region in the ceDNA vector that, In one embodiment, comprises a primary stem region and one or more loop structures, e.g., a hairpin loop structure (see FIGS.1A and 1B). Restriction endonucleases used in the methods described herein, such as but not necessarily limited to Type IIS restriction endonucleases, cleave the DNA at a site that is distinct and not within the recognition site. These restriction endonucleases used in the cell-free synthetic methods disclosed herein also recognize non- palindromic nucleotide sequences such that the recognition sequence (which is also the binding site) for the enzyme is only encoded on one strand (see e.g., FIG.5 of International Patent Application No. PCT / US2022 / 053868). Therefore, cleavage by this class of restriction endonucleases is directional, occurring either upstream or downstream of the recognition site, but not within the recognition site itself, unlike other restriction endonucleases that are most heavily used in molecular biology such as EcoRI (see FIG.5 of International Patent Application No. PCT / US2022 / 053868). The strand that encodes the recognition sequence dictates which side (i.e., downstream or upstream) of the sequence is cleaved. Taken together, the unique activity of the restriction endonucleases used in the methods described herein allows any sequence within a pre-determined distance from a specific recognition site to be cleaved by the restriction endonuclease and consequently, any overhang sequence to be generated. Digestion with the special restriction endonuclease(s) creates cohesive overhangs at both 5’ and 3’ ends of the excised insert that are compatible with the overhangs of the oligonucleotide. In other words, the design of the oligonucleotides and insert overhangs drives the high specificity of the ligation process such that the oligonucleotide overhangs and the insert overhangs are compatible with each other. Once ligated, the desired ceDNA product is not susceptible to digestion with the restriction endonuclease because the recognition site is not re-generated. However, in situations where the excised insert and the plasmid fragments re-ligate into the original construct, the recognition sites are re-generated and therefore allow the construct to be cleaved. Due to the unique activity of the restriction endonucleases used in the cell-free synthetic methods described herein, the generation of unique overhangs on the insert ends and the design of unique overhangs on the oligonucleotides that drive the high specificity of the sub-cloning process, the digestion and ligation can take place in a single reaction vessel without a need to purify the 76 ME148589913v.1digestion products prior to ligation. In some embodiments where the digestion / ligation is ensued by treatment with an exonuclease to degrade open-ended DNA fragments and intermediates, as shown in FIG.4 of International Patent Application No. PCT / US2022 / 053868, the restriction endonuclease digestion, ligation, and exonuclease degradation take place in a single reaction vessel and all the reactions can occur simultaneously. In addition, the unique activity of the restriction endonucleases used in the cell-free synthetic methods described herein allow the directionality of ligation reactions that utilize more than one oligonucleotides, thereby enabling preparation of reference ceDNA having asymmetric ITRs or ceDNA having asymmetric stem-loop regions. Cell-free synthetic production method in general Disclosed herein is a process for synthesis of closed-ended DNA vectors which does not require use of any microbiological steps. In some embodiments, the process allows for synthesis of closed-ended DNA vectors in a system using enzymatic cleavage steps using restriction endonucleases and ligation steps to generate the closed-ended DNA vectors. In nearly all embodiments, the synthetic system for DNA vector production is a cell-free system. It will be appreciated by one of ordinary skill in the art that one or more enzymes used in the synthetic production method or one or more of the oligonucleotide components can be produced from a cell and used in the methods of the disclosure in purified form. Accordingly, in some embodiments, the procedures themselves in synthetic production method are cell-free. However, the raw materials (i.e., the starting materials), such as the double-stranded DNA construct and oligonucleotides as well as enzymes such as restriction endonucleases and ligases may have been produced using methods and techniques utilizing cells. In one embodiment, a restriction endonuclease and / or a ligation-competent protein can be expressed or provided from an expression vector in a cell, e.g., bacterial cell. In one embodiment, a cell, such as a bacterial cell, comprising an expression vector expressing one or more of the restriction endonucleases or the ligase enzymes can be present. Therefore, while the methods disclosed herein are primarily directed to cell-free synthetic methods to generate the DNA vectors disclosed herein, also encompassed in one embodiment are synthetic production methods where a cell, e.g., bacterial cell but not an insect cell is present and can be used to express one or more of the enzymes required in the method. In such embodiments, the cell expressing a restriction endonuclease and / or ligation- competent protein is not an insect cell. In all embodiments where a cell is present and expresses one or more restriction endonucleases or ligation-competent proteins, the cell does not replicate the close- ended DNA vector. Stated differently, the intracellular machinery of the cell does not replicate, or is not involved in the replication of the DNA vector. In some embodiments, synthesis of DNA vectors (e.g., ceDNA vectors) described herein is carried out in an in vitro cell-free process starting from either a double-stranded DNA construct or one or more oligonucleotides. The double-stranded DNA construct or one or more oligonucleotides are 77 ME148589913v.1cleaved with restriction endonucleases and ligated to form the DNA molecules. In some embodiments, the oligonucleotides can be synthesized chemically, thus avoiding use of large starting templates encoding the entirety of the desired sequence which would typically need to be propagated in bacteria. Once a desired DNA sequence is synthesized, it can be cleaved and ligated with other oligonucleotides as disclosed herein. The use of multiple oligonucleotides in the generation of closed- ended DNA vectors using the methods disclosed herein allows for a modular approach to DNA vector generation, enabling tailoring and / or specific selection of the terminal repeats (e.g., ITRs) or stem- loop regions, as well as the spacing of the terminal repeats or stem-loop regions, and also selection of the heterologous nucleic acid sequence in the synthetically produced closed-ended DNA vectors. Cell-free synthetic production of DNA vectors The methods provided herein relate to a synthetic production method, e.g., in some embodiments, a cell-free production method, and is also referred to herein as “synthetic closed-ended DNA vector production” or “synthetic production”. In one aspect, a closed-ended DNA vector is generated by excising a transgene expression cassette from a double-stranded DNA construct, followed by ligation of the ends of the insert to a first oligonucleotide comprising one or more hairpin structures and a second oligonucleotide comprising one or more hairpin structures to form the ceDNA. In some embodiments, each of oligonucleotides independently includes 1, 2, 3, 4, or more stem-loop regions. In some embodiments, each of the oligonucleotides independently includes 2 or 3 stem-loop regions. In some embodiments, the first oligonucleotide comprising one or more hairpin structures and the second oligonucleotide comprising one or more hairpin structures are each a single-stranded oligonucleotide that self-anneals to form a three-dimensional configuration. In further embodiments, the three-dimensional configuration is a T- or Y-shaped stem-loop structure. In another aspect, a closed-ended DNA vector is generated by excising a transgene expression cassette from a double-stranded DNA construct, followed by ligation of the ends of the insert to stem- loop oligonucleotides to form the ceDNA. The ligation may be effected by a ligase (e.g., T4 ligase). In one embodiment, the reaction mixture is not purified prior to ligation. In such an embodiment, the excision of the transgene expression cassette (e.g., with one or more restriction endonucleases) and ligation take place simultaneously in a single reaction vessel. In an alternative embodiment, the reaction mixture is purified prior to ligation. The resultant closed-ended DNA vector as prepared by the cell-free synthetic methods described herein comprises at least about 85%, at least about 90%, at least about 95%, at least about 96%, at least about 97%, at least about 98%, or at least about 99% of the monomeric species of the vector. The resultant closed-ended DNA vector as prepared by the cell-free synthetic methods described herein comprises less than about 15%, less than about 10%, less than about 5%, less than about 4%, less than about 3%, less than about 2%, or less than about 1% of the sub-monomeric species of the vector. 78 ME148589913v.1In one embodiment, the double-stranded DNA construct is selected from a bacmid, a plasmid, a minicircle, and a linear double-stranded DNA molecule. In such an embodiment, the double- stranded DNA construct is provided with at least, in 5’ to 3’ order: a first non-palindromic restriction endonuclease recognition site and a corresponding first cleavage site upstream of the transgene expression cassette; a transgene expression cassette; and a second non-palindromic restriction endonuclease recognition site and a corresponding second cleavage site downstream of the transgene expression cassette. In one embodiment, the first restriction endonuclease is capable of cleaving the double-stranded DNA construct at the first cleavage site, and wherein the second restriction endonuclease is capable of cleaving the double-stranded DNA construct at the second cleavage site, and wherein contacting the double-stranded DNA construct with the first restriction endonuclease and the second restriction endonuclease releases an insert having a first end comprising a first single- stranded overhang and a second end comprising a second single-stranded overhang. In further embodiments, the first restriction endonuclease and the second restriction endonuclease are different restriction endonucleases. In other embodiments, the first restriction endonuclease and the second restriction endonuclease are the same restriction endonuclease. In another embodiment, the double- stranded DNA construct for the synthetic production of a reference ceDNA is provided with at least, in 5’ to 3’ order: a first non-palindromic restriction endonuclease recognition site and a corresponding first cleavage site upstream of the transgene expression cassette; a first partial stem-loop structure; a transgene expression cassette; a second partial stem-loop structure; and a second non-palindromic restriction endonuclease recognition site and a corresponding second cleavage site downstream of the transgene expression cassette. In another embodiment, the double-stranded DNA construct for the synthetic production of a ceDNA vector of the present disclosure is provided with at least, in 5’ to 3’ order: a first non-palindromic restriction endonuclease recognition site and a corresponding first cleavage site upstream of the transgene expression cassette; a 5’ secondary stem region; a transgene expression cassette; a 3’ secondary stem region; and a second non-palindromic restriction endonuclease recognition site and a corresponding second cleavage site downstream of the transgene expression cassette. In another embodiment, the double-stranded DNA construct for the synthetic production of a ceDNA vector of the present disclosure is provided with at least, in 5’ to 3’ order: a first non-palindromic restriction endonuclease recognition site and a corresponding first cleavage site upstream of the transgene expression cassette; a 5’ secondary stem region; 5’ spacer; a transgene expression cassette; a 3’ spacer; a 3’ secondary stem region; and a second non-palindromic restriction endonuclease recognition site and a corresponding second cleavage site downstream of the transgene expression cassette (see e.g., ceDNA 384 in FIG.1A). In another embodiment, the double-stranded DNA construct for the synthetic production of a ceDNA vector of the present disclosure is provided with at least, in 5’ to 3’ order: a first non-palindromic restriction endonuclease recognition site and a corresponding first cleavage site upstream of the transgene expression cassette; a 5’ spacer; a transgene expression cassette; a 3’ spacer; and a second non-palindromic restriction endonuclease 79 ME148589913v.1recognition site and a corresponding second cleavage site downstream of the transgene expression cassette (see e.g., ceDNA 558 in FIG.1B). The double-stranded DNA construct is contacted with at least one restriction endonuclease is capable of cleaving the construct at the first and second cleavage sites to release an insert having single-stranded overhangs at the 5’ and 3’ ends (i.e., cohesive ends) of the insert. These ends of the insert are then ligated to a first inverted terminal repeat oligonucleotide and a second oligonucleotide to form the ceDNA vector. In one embodiment, one or both of the single-stranded overhangs at the 5’ and 3’ ends of the inserts is a 5’ overhang. In one embodiment, one or both of the single-stranded overhangs at the 5’ and 3’ ends of the inserts is a 3’ overhang. In one embodiment, these overhangs are about 1 to about 30 nucleotides in length, e.g., about 1 to about 25 nucleotides, or about 1 to about 20 nucleotides, or about 1 to about 18 nucleotides, or about 1 to about 15 nucleotides, or about 1 to about 12 nucleotides, or about 1 to about 10 nucleotides, or about 1 to about 8 nucleotides, or about 2 to about 8 nucleotides, or about 2 to about 7 nucleotides, or about 2 to about 6 nucleotides, or about 1 nucleotide, or about 2 nucleotides, or about 3 nucleotides, or about 4 nucleotides, or about 5 nucleotides, or about 6 nucleotides, or about 7 nucleotides, or about 8 nucleotides, or about 9 nucleotides, or about 10 nucleotides in length. Use of restriction endonucleases that recognize non-palindromic nucleotide sequences and have cleavage sites distinct from their recognition and binding sites Of note, the restriction endonuclease(s) used in the synthetic methods provided herein recognizes non-palindromic nucleotide sequences. As used herein, the term “non-palindromic” when referring to a double-stranded polynucleotide or oligonucleotide having different 5’→3’ nucleotide sequences between the sense strand and the anti-sense strand; whereas the term “palindromic” when referring to a double-stranded polynucleotide or oligonucleotide having identical 5’→3’ nucleotide sequences between the sense strand and the anti-sense strand. Accordingly, as illustrated in FIG.5 of International Patent Application No. PCT / US2022 / 053868, incorporated by reference in its entirety herein, such a restriction endonuclease recognizes a double-stranded polynucleotide or oligonucleotide having different 5’→3’ nucleotide sequences between the sense strand and the anti-sense strand. This means that the recognition sequence for the restriction endonuclease, such as 5’-GGTCTC-3’ for the example illustrated in FIG. 5 of International Patent Application No. PCT / US2022 / 053868, is encoded only one of the strands. Another prominent feature about restriction endonuclease(s) used in the synthetic methods described herein is that the enzyme cleaves the DNA at a cleavage site that is either upstream or downstream of the recognition sequence, but not within the recognition site itself. The strand that encodes the recognition site dictates which side (i.e., downstream or upstream) of the recognition sequence is cleaved. 80 ME148589913v.1In certain embodiments, the first non-palindromic restriction endonuclease recognition site and the corresponding first cleavage site are separate and distinct sites from each other that are located upstream of the transgene expression cassette. The first cleavage site is about 1 to 35 nucleotides away from the first non-palindromic restriction endonuclease recognition site in at least one of the sense and the antisense strands of the construct, e.g., about 1 to about 22 nucleotides away, or about 1 to about 20 nucleotides away, or about 1 to about 15 nucleotides away, or about 1 to about 12 nucleotides away, or about 1 to about 10 nucleotides away, or about 1 to about 8 nucleotides away, or about 1, or about 2, or about 3, or about 4, or about 5, or about 6, or about 7, or about 8, or about 9, or about 10 nucleotides away from the first non-palindromic restriction endonuclease recognition site in at least one of the sense and the antisense strands of the construct. In certain embodiments, the second non-palindromic restriction endonuclease recognition site and the corresponding second cleavage site are separate and distinct sites from each other that are located downstream of the expression cassette. The second cleavage site is about 1 to 35 nucleotides away from the second non-palindromic restriction endonuclease recognition site in at least one of the sense and the antisense strands of the construct, e.g., about 1 to about 22 nucleotides away, or about 1 to about 20 nucleotides away, or about 1 to about 15 nucleotides away, or about 1 to about 12 nucleotides away, or about 1 to about 10 nucleotides away, or about 1 to about 8 nucleotides away, or about 1, or about 2, or about 3, or about 4, or about 5, or about 6, or about 7, or about 8, or about 9, or about 10 nucleotides away from the second non-palindromic restriction endonuclease recognition site in at least one of the sense and the antisense strands of the construct. A single restriction endonuclease can target both the first and second non-palindromic restriction endonuclease recognition sites and their corresponding cleavage sites. Alternatively, two different restriction endonucleases target both the first and second non-palindromic restriction endonuclease recognition sites and their corresponding cleavage sites. Type IIS restriction endonucleases In one embodiment, the restriction endonuclease(s) used in the synthetic methods provided herein, which recognizes non-palindromic nucleotide sequences and cleaves a DNA outside of the recognition site is a Type IIS restriction endonuclease. Non-limiting examples of Type IIS restriction endonucleases include AcuI, AlwI, Alw26I, BasI, BbsI, BbvI, BceAI, BcgI, BCiVI, BcoDI, BruAI, BmrI, BpiI, BpuEI, BsaI, BsaXI, BseGI, BseRI, BsgI, BsmAI, BsmBI, BsmFI, BsmI, BspCNI, BspMI, BspQI, BsrDI, BsrI, BtgZI, BtsCI, BtsI, MutI, CspCI, EarI, EciI, Eco31I, Esp3I, FauI, FokI, HgaI, HphI, HpyAV, LguI, MboII, MlyI, MmeI, MnlI, Mva1269I, NmeAIII, PaqCI, PleI, SapI, SfaNI, and an isoschizomer of any of the foregoing. Isoschizomers are pairs of restriction endonucleases that are specific to the same recognition sequence. For example, BcoDI and BsmAI are isoschizomers of each other, both being specific to the recognition sequence of 5’-GTCTC-3’. In one embodiment, the Type IIS endonuclease(s) is selected from BbsI, BsaI, BsmBI, Esp3I, and SapI, and an isoschizomer thereof. In one embodiment, the Type IIS endonuclease is BbsI or an isoschizomer thereof. In one 81 ME148589913v.1embodiment, the Type IIS endonuclease is BsaI or an isoschizomer thereof. In one embodiment, the Type IIS endonuclease is BsmBI or an isoschizomer thereof. In one embodiment, the Type IIS endonuclease is BbsI or an isoschizomer thereof. In one embodiment, the Type IIS endonuclease is Esp3I or an isoschizomer thereof. In one embodiment, the Type IIS endonuclease is SapI or an isoschizomer thereof. First and second oligonucleotides (or 5’ and 3’ oligonucleotides) The first and second oligonucleotides to which the 5’ and 3’ ends of the insert are ligated to in the cell-free synthetic methods disclosed herein are each a single-stranded oligonucleotide that self- anneals to form a three-dimensional configuration, such has a three-dimensional structure like a hairpin structure or a T- or Y-shaped stem-loop structure. In one embodiment, one or both of the first and second oligonucleotides are synthetic or synthesized. In some embodiments, in addition to the three-dimensional structure, the oligonucleotides each self-anneal to further form a single-stranded overhang at either the 5’ or the 3’ end of the oligonucleotide. In such embodiments, the single-stranded overhangs of the insert are ligated to the single-stranded overhangs of the oligonucleotides. The stem-loop structureoligonucleotide overhangs are about 1 to about 30 nucleotides in length, e.g., about 1 to about 25 nucleotides, or about 1 to about 20 nucleotides, or about 1 to about 18 nucleotides, or about 1 to about 15 nucleotides, or about 1 to about 12 nucleotides, or about 1 to about 10 nucleotides, or about 1 to about 8 nucleotides, or about 2 to about 8 nucleotides, or about 2 to about 7 nucleotides, or about 2 to about 6 nucleotides, or about 1 nucleotide, or about 2 nucleotides, or about 3 nucleotides, or about 4 nucleotides, or about 5 nucleotides, or about 6 nucleotides, or about 7 nucleotides, or about 8 nucleotides, or about 9 nucleotides, or about 10 nucleotides in length. In a particular embodiment, the oligonucleotide overhang comprises a 5’ ^3’ nucleotide sequence of CTCT, CTCA, CACT, CTC, or GCT. The overhangs of the first and second oligonucleotides comprise non-complementary 5’ ^3’ nucleotide sequences to each other. In one embodiment, overhangs of the first and second oligonucleotides comprise or have identical sequences, i.e., the same 5’ ^3’ nucleotide sequence and in a further embodiment, the first and second oligonucleotides are the same oligonucleotide. In such an embodiment, the overhangs at the 5’ and 3’ ends of the insert comprise or have the same 5’ ^3’ nucleotide sequence. The overhangs of the oligonucleotides are complementary to either and both of the overhangs of the insert. Such an embodiment whereby a single oligonucleotide is used in the cell- free synthesis of ceDNA is useful for preparing reference ceDNA having symmetric ITRs or ceDNA having symmetric stem-loop regions as defined herein. As used herein, the term “stem-loop region” when referring to ceDNA vector of the present disclosure refers to a region of a ceDNA vector of the present disclosure, which may be found upstream of the 5’ end of the at least one transgene expression cassette in the ceDNA vector and / or a second stem-loop region downstream of the 3’ end of the at least one transgene expression cassette. 82 ME148589913v.1The stem-loop region comprises an artificial nucleic acid sequence and does not comprise a viral ITR sequence. In some embodiments, each stem-loop region comprises a double-stranded primary stem region and a single-stranded region. In some embodiments, each stem-loop region is formed from a 5’ oligonucleotide or a 3’ oligonucleotide, or a first oligonucleotide or a second oligonucleotide, or a left oligonucleotide or a right oligonucleotide, that self-anneals to form the double-stranded primary stem region (where there is complimentarity in the nucleotides) and the single-stranded region (where there is no complimentarity in the nucleotides). In some embodiments of a ceDNA vector of the present disclosure, each double-stranded primary stem region comprises about 1 to about 50 bp, or about 1 to about 40 bp, or about 1 to about 30 bp, or about 1 to about 25 bp, or about 1 to about 20 bp, or about 1 to about 15 bp, or about 2 to about 20 bp, or about 2 to about 15 bp, or about 3 to about 20 bp, or about 3 to about 15 bp, or about 4 to about 20 bp, or about 4 to about 15 bp, or about 5 to about 20 bp, or about 5 to about 15 bp, or about 1 bp, or about 2 bp, or about 3 bp, or about 4 bp, or about 5 bp, or about 6 bp, or about 7 bp, or about 8 bp, or about 9 bp, or about 10 bp, or about 11 bp, or about 12 bp, or about 13 bp, or about 14 bp, or about 15 bp. In some embodiments of a ceDNA vector of the present disclosure, each single-stranded region comprises about 2 to about 100 nt, about 2 to about 90 nt, about 2 to about 80 nt, about 2 to about 70 nt, about 2 to about 60 nt, about 2 to about 50 nt, about 2 to about 40 nt, about 2 to about 30 nt, about 2 to about 20 nt, about 2 to about 15 nt, about 2 to about 12 nt, about 2 to about 10 nt, about 2 to about 8 nt, about 3 to about 20 nt, about 3 to about 15 nt, about 3 to about 12 nt, about 3 to about 10 nt, about 3 to about 8 nt, or about 2 nt, or about 3 nt, or about 4 nt, or about 5 nt, or about 6 nt, or about 7 nt, or about 8 nt, or about 9 nt, or about 10 nt, or about 11 nt, or about 12 nt, or about 13 nt, or about 14 nt, or about 15 nt. In some embodiments of a ceDNA vector of the present disclosure, each single-stranded region comprises at least one loop structure. In some embodiments of a ceDNA vector of the present disclosure, each single-stranded region comprises an aptamer. In alternative embodiments, overhangs of the first and second oligonucleotides comprise or have different sequences, i.e., different 5’ ^3’ nucleotide sequences and hence, the first and second oligonucleotides are different oligonucleotides. In such an embodiment, the overhangs at the 5’ and 3’ ends of the insert comprise or have different 5’ ^3’ nucleotide sequences. The overhangs of the oligonucleotides are each complementary to only one of the overhangs of the insert. In some embodiments of a ceDNA vector of the present disclosure, the first stem-loop region and the second stem-loop region each independently comprise a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence similarity to any one of SEQ ID NO: 1 (5’-CTCATCAGAATCACTTTGTGATTCTGA-3’), SEQ ID NO: 2 (5’-TCAGAATCACAAAGTGATTCTGATGAG-3’), and SEQ ID NO: 4 (5’- CACTCATCAGAATCACTTTGTGATTCTGATG-3’). 83 ME148589913v.1Accordingly, in some embodiments of a ceDNA vector of the present disclosure, the first stem-loop region and the second stem-loop region are each independently formed from an oligonucleotide comprising a nucleic acid sequence having at least 80%, at least 85%, at least 90%, 95%, at least 95%, at least 96%, at least 97%, at least 98% or at least 99% sequence identity to any one of SEQ ID NO: 1 (5’-CTCATCAGAATCACTTTGTGATTCTGA-3’), SEQ ID NO: 2 (5’- TCAGAATCACAAAGTGATTCTGATGAG-3’), and SEQ ID NO: 4 (5’- CACTCATCAGAATCACTTTGTGATTCTGATG-3’). To enhance ligation efficiency, the 5’ ends of the oligonucleotide may be phosphorylated. In one embodiment, the first ITR and the second ITR in a reference ceDNA vector each comprise a hairpin structure and / or a T- or Y-shaped stem-loop structure. In another embodiment, the first ITR and the second ITR each comprise a T- or Y-shaped stem-loop structure. In another embodiment, the first ITR and the second ITR are symmetric or substantially symmetric to each other. In another embodiment, the first ITR and the second ITR are asymmetric ITRs. In some embodiments, the T- or Y-shaped stem-loop structure (e.g., single stem + two loops or single stem + two loops) of the first ITR oligonucleotide and the second ITR oligonucleotide comprises a stem region that is at least about 4 base pairs (nucleotides) in length, e.g., about 4 base pairs to about 30 base pairs, or 4 base pairs to about 25 base pairs, or 4 base pairs to about 22 base pairs, or 4 base pairs to about 20 base pairs, or 4 base pairs to about 18 base pairs, or 4 base pairs to about 15 base pairs, or 4 base pairs to about 12 base pairs, or 4 base pairs to about 10 base pairs, or 4 base pairs to about 8 base pairs, or 4 base pairs to about 7 base pairs, or 4 base pairs to about 6 base pairs or 6 base pairs to about 8 base pairs, or about 4 base pairs, or about 5 base pairs, or about 6 base pairs, or about 7 base pairs, or about 8 base pairs, or about 9 base pairs, or about 10 base pairs, or about 11 base pairs, or about 12 base pairs, or about 13 base pairs, or about 14 base pairs, or about 15 base pairs. In one embodiment, this stem region length does not include the overhang length. Partial ITRs in reference ceDNA, secondary stem regions in ceDNA of the present disclosure, and spacers In some embodiments, the ceDNA vectors of the present disclosure, such as ceDNA 384 (see FIG.1A), contain one or more “secondary stem regions” such as 5’ secondary stem region and 3’ secondary stem region that flank the transgene expression cassette. In some embodiments, 5’ secondary stem region is adjacent to the primary stem region of the 5’ stem-loop region and the 3’ secondary stem region is adjacent to the primary stem region of the 3’ stem-loop region. Both of the secondary stem regions, if incorporated in a ceDNA vector of the present disclosure such as in ceDNA 384, contain only artificial sequences and no viral ITR sequences, and the length of each of these artificial secondary stem regions is corresponds to the A, A’, D, and D’ regions of a reference ceDNA having 5’ and 3’ AAV derived wt-ITRs such as reference ceDNA 382 or the A, A’ and D regions of an AAV derived wt-ITRs. As an example only, the 5’ secondary stem region (SEQ ID NO: 12) and a 3’ secondary stem region (SEQ ID NO: 13), which are reverse complement of each other, 84 ME148589913v.1each contains 58 bp. Without being bound by theory, the presence of the artificial secondary stem regions may provide some beneficial properties to the vector, such as improving or enhancing the genetic stability of the vector. In other embodiments the double-stranded primary stem region in the stem-loop accounts partially for the entire stem region of a ceDNA of the present disclosure, while the remaining and continuing sequence of the stem region is found in the secondary stem regions on the insert. Accordingly, in some embodiments of a ceDNA of the present disclosure, the double-stranded DNA construct (e.g., a plasmid or a linear double-stranded DNA molecule) from which the transgene expression cassette is excised in the cell-free synthetic methods disclosed herein further comprises a least a first secondary stem region and a second secondary stem region each flanking the transgene expression cassette. In one embodiment, the first secondary stem region is upstream of the transgene expression cassette and downstream of the first non-palindromic restriction endonuclease recognition site and the corresponding first cleavage site. The second secondary stem region is downstream of the transgene expression cassette and upstream of the second non-palindromic restriction endonuclease recognition site and the corresponding second cleavage site. In one embodiment, the first cleavage site is adjacent to the first secondary stem region and the second cleavage site is adjacent to the second secondary stem region (i.e., no spacer between the cleavage site and the secondary stem region). In some embodiments, the first secondary stem region and the second secondary stem region each comprise about 1 to about 100 bp, or about 1 to about 90 bp, or about 1 to about 80 bp, or about 1 to about 70 bp, or about 2 to about 70 bp, or about 3 to about 70 bp, or about 5 to about 70 bp, or about 10 to about 70 bp, or about 15 to about 70 bp, or about 20 to about 70 bp, or about 25 to about 70 bp, or about 30 to about 70 bp, or about 35 to about 70 bp, or about 40 to about 70 bp, or about 45 to about 70 bp, or about 50 to about 70 bp, or about 50 bp, or about 51 bp, or about 52 bp, or about 53 bp, or about 54 bp, or about 55 bp, or about 56 bp, or about 57 bp, or about 58 bp, or about 59 bp, or about 60 bp, or about 61 bp, or about 62 bp, or about 63 bp, or about 64 bp, or about 65 bp, or about 66 bp, or about 67 bp, or about 68 bp, or about 69 bp, or about 70 bp. In certain embodiments, the double-stranded DNA construct or the excised insert further comprises one or more spacer regions. In one embodiment, the double-stranded DNA construct (e.g., a plasmid or a linear double-stranded DNA molecule) or the insert further comprises a first spacer between the first restriction endonuclease cleavage site and the transgene expression cassette. In another embodiment, the double-stranded DNA construct further comprises a second spacer between the second restriction endonuclease cleavage site and the transgene expression cassette. Each spacer region or sequence is about 1-50 nucleotides in length, e.g., about 2, 5, 7, 8, 10, 11, 12, 13, 15, 17, 18, 20, 22, 23, 25, 27, 28, 30, 32, 33, 35, 37, 38, 40, 42, 43, 45, 47, 48, or 50 nucleotides. In some embodiments, the spacer between a first (or left) restriction endonuclease cleavage site or the second (or right) restriction endonuclease cleavage site and the transgene expression cassette is selected from the spacers comprising the sequences as shown in Table 2 of International Patent Application No. 85 ME148589913v.1PCT / US2022 / 053868, which are incorporated by reference in their entireties herein. In one embodiment, the spacer comprises a nucleic acid sequence that is at least 95%, 96%, 97%, 98% or 99% identical to a nucleic acid sequence selected from the group consisting of: SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40 of International Patent Application No. PCT / US2022 / 053868; SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11 in Table 3 below. In one embodiment, the spacer consists of a nucleic acid sequence selected from the group consisting of: SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, SEQ ID NO: 39, and SEQ ID NO: 40 of International Patent Application No. PCT / US2022 / 053868; SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12 in Table 3 below. Table 3. Exemplary spacer sequencesIn some aspects, the disclosure provides a method of producing a double-stranded DNA construct from a plasmid template via rolling-circle amplification, comprising the steps of (a) contacting the plasmid template with a thermostable polymerase having strand-displacement activity, wherein the ratio of plasmid template concentration (in ng / µl) to polymerase concentration (in U / µl) is greater than about 1; (b) contacting the plasmid template with an oligonucleotide primer and dNTPs; (c) incubating the plasmid template, the polymerase, the oligonucleotide primer, and the dNTPs at a temperature of about 40℃ or less, for a time period of at least about 5 hours; thereby producing a double-stranded DNA construct. In some embodiments, the ratio of plasmid template concentration (in ng / µl) to polymerase concentration (in U / µl) is greater than about 1, about 2, about 3, about 4, about 5, about 6, about 7, about 8, about 9, about 10, about 11, about 12, about 13, about 14, about 15, about 16, about 17, about 18, about 19, or about 20. In some embodiments, the plasmid template concentration is about 0.01 ng / µl, about 0.05 ng / µl, about 0.1 ng / µl, about 0.15 ng / µl, about 0.2 ng / µl, about 0.21 ng / µl, about 0.22 ng / µl, about 0.23 ng / µl, about 0.24 ng / µl, about 0.2 ng / µl 5, about 0.26 ng / µl, about 0.27 ng / µl, about 0.28 ng / µl, about 0.29 ng / µl, about 0.3 ng / µl, about 0.35 ng / µl, about 0.4 ng / µl, about 0.45 ng / µl, about 0.5 ng / µl, about 0.6 ng / µl, about 0.7 ng / µl, about 0.8 ng / µl, about 0.9 ng / µl, or about 1.0 ng / µl. In other embodiments, the polymerase concentration is about 0.01 U / µl, 86 ME148589913v.1about 0.02 U / µl, about 0.03 U / µl, about 0.04 U / µl, about 0.05 U / µl, about 0.06 U / µl, about 0.07 U / µl, about 0.08 U / µl, about 0.09 U / µl, about 0.1 U / µl, about 0.15 U / µl, about 0.2 U / µl, about 0.25 U / µl, about 0.3 U / µl, about 0.35 U / µl, about 0.4 U / µl, or about 0.45 U / µl. In further embodiments, the temperature in step (c) is less than about 40℃, about 39℃, about 38℃, about 37℃, about 36℃, about 35℃, about 34℃, about 33℃, about 32℃, about 31℃, about 30℃, about 29℃, about 28℃, about 27℃, about 26℃, about 25℃, about 24℃, about 23℃, about 22℃, or about 21℃. In some embodiments, the time period is at least about 5 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, about 30 hours, about 31 hours, about 21 hours, about 33 hours, about 34 hours, about 35 hours, about 36 hours, about 37 hours, about 38 hours, about 39 hours, or about 40 hours. In some embodiments, the time period is less than about 6 hours, about 6 hours, about 7 hours, about 8 hours, about 9 hours, about 10 hours, about 11 hours, about 12 hours, about 13 hours, about 14 hours, about 15 hours, about 16 hours, about 17 hours, about 18 hours, about 19 hours, about 20 hours, about 21 hours, about 22 hours, about 23 hours, about 24 hours, about 25 hours, about 26 hours, about 27 hours, about 28 hours, about 29 hours, about 30 hours, about 31 hours, about 21 hours, about 33 hours, about 34 hours, about 35 hours, about 36 hours, about 37 hours, about 38 hours, about 39 hours, or about 40 hours. In some embodiments, the plasmid template concentration is about 0.25 ng / µl, the temperature is about 30℃, the polymerase concentration is about 0.05 U / µl, and the time period is about 18-26 hours. In further embodiments, the oligonucleotide primer concentration is less than about 50 µM. In other embodiments, the oligonucleotide primer concentration is at least about 10 µM. In further embodiments, the oligonucleotide primer concentration is at least about 10 µM and less than about 50 µM. In further embodiments, the thermostable polymerase is Phi29 DNA polymerase or a derivative or variant thereof. In other further embodiments, the thermostable polymerase is EQUIPHI29TM. In other embodiments, the method is performed in a total reaction volume of at least about 100 µl. In other further embodiments, the method is performed in a total reaction volume of at least about 100 µl, about 200 µl, about 300 µl, about 400 µl, about 500 µl, about 600 µl, about 700 µl, about 800 µl, about 900 µl, about 1 ml, about 2 ml, about 3 ml, about 4 ml, about 5 ml, about 6 ml, about 7 ml, about 8 ml, about 9 ml, about 10 ml, about 15 ml, about 20 ml, about 25 ml, about 30 ml, about 35 ml, about 40 ml, about 45 ml, about 50 ml, about 55 ml, about 60 ml, about 65 ml, about 70 ml, about 75 ml, about 80 ml, about 85 ml, about 90 ml, about 95 ml, about 100 ml, about 200 ml, about 300 ml, about 400 ml, about 500 ml, about 600 ml, about 700 ml, about 800 ml, about 900 ml, about 1 L, about 2 L, about 3 L, 4 L, about 5 L, about 6 L, about 7 L, about 8 L, about 9 L, about 10 L, about 20 L, about 30 L, about 40 L, about 50 L, about 60 L, about 70 L, about 80 L, about 90 L, about 100 L, 87 ME148589913v.1about 200 L, about 300 L, about 400 L, about 500 L, about 600 L, about 700 L, about 800 L, about 900 L, or about 1000 L. In some embodiments, the method is performed in a reaction vessel that has a capacity of at least twice the total reaction volume. In some embodiments, the oligonucleotide primer hybridizes to a backbone sequence in the plasmid template. In some embodiments, the oligonucleotide primer is a universal primer. In some embodiments, the dNTP concentration is about 4 mM. In some embodiments, the dNTP concentration is between about 3.8-4.2 mM. Isolation and Purification Methods to generate and isolate a ceDNA vector, which is an exemplary closed-ended DNA vector, are described herein. For example, a closed-ended DNA vector, e.g., ceDNA vector produced by the synthetic methods described herein can be harvested or collected at an appropriate time after the last ligation reaction and can be optimized to achieve a high-yield production of the ceDNA vectors. The closed-ended DNA vector, e.g., ceDNA vectors can be purified by any means known to those of skill in the art for purification of DNA. In one embodiment, ceDNA vectors are purified as DNA molecules. Generally, any art-known nucleic acid purification methods can be adopted, as well as commercially available DNA extraction kits. Alternatively, purification can be implemented by subjecting a reaction mixture to chromatographic separation. As one non-limiting example, the process can be performed by loading the reaction mixture on an ion exchange column (e.g., SARTOBIND Q®) which retains nucleic acids, and then eluting (e.g., with a 1.2 M NaCl solution) and performing a further chromatographic purification on a gel filtration column (e.g., 6 fast flow GE). The DNA vector, e.g., ceDNA vector is then recovered by, e.g., precipitation. The presence of the ceDNA vector can be confirmed by digesting the vector DNA isolated from the cells with a restriction enzyme having a single recognition site on the DNA vector and analyzing both digested and undigested DNA material using gel electrophoresis to confirm the presence of characteristic bands of linear and continuous DNA as compared to linear and non- continuous DNA. In some embodiments, the closed-ended DNA vectors produced by the synthetic production methods disclosed herein can be delivered to a target cell in vitro or in vivo by various suitable methods as discussed herein. Vectors alone can be applied or injected. Vectors can be delivered to a cell without the help of a transfection reagent or other physical means. Alternatively, vectors can be delivered using a transfection reagent or other physical means that facilitates entry of DNA into a cell, e.g., liposomes, alcohols, polylysine- rich compounds, arginine-rich compounds calcium phosphate, microvesicles, microinjection, and the like. 88 ME148589913v.1Circular DNA vectors produced using the synthetic production method Provided herein are various methods of in vitro production of DNA molecules and closed- ended DNA vectors. In some embodiments, the closed-ended DNA vector is a ceDNA vector, as described herein. In alternative embodiments, the closed-ended DNA vector is, e.g., a dumbbell DNA vector or a doggybone DNA vector (see e.g., International Patent Application Publication No. WO2010 / 0086626, incorporated by reference in its entirety herein). VII. Pharmaceutical Compositions In another aspect, pharmaceutical compositions are provided. The pharmaceutical composition comprises a ceDNA vector as disclosed herein and a pharmaceutically acceptable carrier or diluent. The DNA-vectors disclosed herein can be incorporated into pharmaceutical compositions suitable for administration to a subject for in vivo delivery to cells, tissues, or organs of the subject. Typically, the pharmaceutical composition comprises a ceDNA-vector as disclosed herein and a pharmaceutically acceptable carrier. For example, the ceDNA vectors described herein can be incorporated into a pharmaceutical composition suitable for a desired route of therapeutic administration (e.g., parenteral administration). Passive tissue transduction via high pressure intravenous or intraarterial infusion, as well as intracellular injection, such as intranuclear microinjection or intracytoplasmic injection, are also contemplated. Pharmaceutical compositions for therapeutic purposes can be formulated as a solution, microemulsion, dispersion, liposomes, or other ordered structure suitable to high ceDNA vector concentration. Sterile injectable solutions can be prepared by incorporating the ceDNA vector compound in the required amount in an appropriate buffer with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Pharmaceutically active compositions comprising a ceDNA vector can be formulated to deliver a transgene in the nucleic acid to the cells of a recipient, resulting in the therapeutic expression of the transgene therein. The composition can also include a pharmaceutically acceptable carrier. A ceDNA vector as disclosed herein can be incorporated into a pharmaceutical composition suitable for topical, systemic, intra-amniotic, intrathecal, intracranial, intraarterial, intravenous, intralymphatic, intraperitoneal, subcutaneous, tracheal, intra-tissue (e.g., intramuscular, intracardiac, intrahepatic, intrarenal, intracerebral), intrathecal, intravesical, conjunctival (e.g., extra-orbital, intraorbital, retroorbital, intraretinal, subretinal, choroidal, sub-choroidal, intrastromal, intracameral and intravitreal), intracochlear, and mucosal (e.g., oral, rectal, nasal) administration. Passive tissue transduction via high pressure intravenous or intraarterial infusion, as well as intracellular injection, such as intranuclear microinjection or intracytoplasmic injection, are also contemplated. 89 ME148589913v.1Pharmaceutical compositions for therapeutic purposes typically must be sterile and stable under the conditions of manufacture and storage. The composition can be formulated as a solution, microemulsion, dispersion, liposomes, or other ordered structure suitable to high ceDNA vector concentration. Sterile injectable solutions can be prepared by incorporating the ceDNA vector compound in the required amount in an appropriate buffer with one or a combination of ingredients enumerated above, as required, followed by filtered sterilization. Various techniques and methods are known in the art for delivering nucleic acids to cells. For example, nucleic acids, such as ceDNA can be formulated into lipid nanoparticles (LNPs), lipidoids, liposomes, lipid nanoparticles, lipoplexes, or core-shell nanoparticles. Typically, LNPs are composed of nucleic acid (e.g., ceDNA) molecules, one or more ionizable or cationic lipids (or salts thereof), one or more non-ionic or neutral lipids (e.g., a phospholipid), a molecule that prevents aggregation (e.g., PEG or a PEG-lipid conjugate), and optionally a sterol (e.g., cholesterol). Another method for delivering nucleic acids, such as ceDNA to a cell is by conjugating the nucleic acid with a ligand that is internalized by the cell. For example, the ligand can bind a receptor on the cell surface and internalized via endocytosis. The ligand can be covalently linked to a nucleotide in the nucleic acid. Exemplary conjugates for delivering nucleic acids into a cell are described, example, in International Patent Application Publication Nos. WO2015 / 006740, WO2014 / 025805, WO2012 / 037254, WO2009 / 082606, WO2009 / 073809, WO2009 / 018332, WO2006 / 112872, WO2004 / 090108, WO2004 / 091515 and WO2017 / 177326, the contents of all of which are incorporated by reference in their entireties herein. Nucleic acids, such as ceDNA, can also be delivered to a cell by transfection. Useful transfection methods include, but are not limited to, lipid-mediated transfection, cationic polymer- mediated transfection, or calcium phosphate precipitation. Transfection reagents are well known in the art and include, but are not limited to, TurboFect Transfection Reagent (Thermo Fisher Scientific), Pro-Ject Reagent (Thermo Fisher Scientific), TRANSPASS™ P Protein Transfection Reagent (New England Biolabs), CHARIOT™ Protein Delivery Reagent (Active Motif), PROTEOJUICE™ Protein Transfection Reagent (EMD Millipore), 293fectin, LIPOFECTAMINE™ 2000, LIPOFECTAMINE™ 3000 (Thermo Fisher Scientific), LIPOFECTAMINE™ (Thermo Fisher Scientific), LIPOFECTIN™ (Thermo Fisher Scientific), DMRIE-C, CELLFECTIN™ (Thermo Fisher Scientific), OLIGOFECTAMINE™ (Thermo Fisher Scientific), LIPOFECTACE™, FUGENE™ (Roche, Basel, Switzerland), FUGENE™ HD (Roche), TRANSFECTAM™(Transfectam, Promega, Madison, Wis.), TFX-10™ (Promega), TFX-20™ (Promega), TFX-50™ (Promega), TRANSFECTIN™ (BioRad, Hercules, Calif.), SILENTFECT™ (Bio-Rad), Effectene™ (Qiagen, Valencia, Calif.), DC-chol (Avanti Polar Lipids), GENEPORTER™ (Gene Therapy Systems, San Diego, Calif.), DHARMAFECT 1™ (Dharmacon, Lafayette, Colo.), DHARMAFECT 2™ (Dharmacon), DHARMAFECT 3™ (Dharmacon), DHARMAFECT 4™ (Dharmacon), ESCORT™ 90 ME148589913v.1III (Sigma, St. Louis, Mo.), and ESCORT™ IV (Sigma Chemical Co.). Nucleic acids, such as ceDNA, can also be delivered to a cell via microfluidics methods known to those of skill in the art. Methods of non-viral delivery of nucleic acids in vivo or ex vivo include electroporation, lipofection (see, U.S. Pat. No.5,049,386; 4,946,787 and commercially available reagents such as Transfectam™ and Lipofectin™), microinjection, biolistics, virosomes, liposomes (see, e.g., Crystal, Science 270:404-410 (1995); Blaese et al., Cancer Gene Ther.2:291-297 (1995); Behr et al., Bioconjugate Chem.5:382-389 (1994); Remy et al., Bioconjugate Chem.5:647-654 (1994); Gao et al., Gene Therapy 2:710-722 (1995); Ahmad et al., Cancer Res.52:4817-4820 (1992); U.S. Pat. Nos. 4,186,183, 4,217,344, 4,235,871, 4,261,975, 4,485,054, 4,501,728, 4,774,085, 4,837,028, and 4,946,787), immunoliposomes, microbubbles (Frenkel et al., Ultrasound Med. Biol. (2002) 28(6): 817-22; Tsutsui et al., Cardiovasc. Ultrasound (2004) 2:23), polycation or lipid:nucleic acid conjugates, naked DNA, and agent-enhanced uptake of DNA. Sonoporation using, e.g., the Sonitron 2000 system (Rich-Mar) can also be used for delivery of nucleic acids. ceDNA vectors as described herein can also be administered directly to an organism for transduction of cells in vivo. Administration is by any of the routes normally used for introducing a molecule into ultimate contact with blood or tissue cells including, but not limited to, injection, infusion, topical application and electroporation. Suitable methods of administering such nucleic acids are available and well known to those of skill in the art, and, although more than one route can be used to administer a particular composition, a particular route can often provide a more immediate and more effective reaction than another route. Methods for introduction of a nucleic acid vector ceDNA vector as disclosed herein can be delivered into hematopoietic stem cells, for example, by the methods as described, for example, in U.S. Pat. No.5,928,638. Various delivery methods known in the art or modification thereof can be used to deliver ceDNA vectors in vitro or in vivo. For example, in some embodiments, ceDNA vectors are delivered by making transient penetration in cell membrane by mechanical, electrical, ultrasonic, hydrodynamic, or laser-based energy so that DNA entrance into the targeted cells is facilitated. For example, a ceDNA vector can be delivered by transiently disrupting cell membrane by squeezing the cell through a size-restricted channel or by other means known in the art. In some cases, a ceDNA vector alone is directly injected as naked DNA into skin, thymus, cardiac muscle, skeletal muscle, or liver cells. In some cases, a ceDNA vector is delivered by gene gun. Gold or tungsten spherical particles (1–3 μm diameter) coated with capsid-free AAV vectors can be accelerated to high speed by pressurized gas to penetrate into target tissue cells. In some embodiments, electroporation is used to deliver ceDNA vectors. Electroporation causes temporary destabilization of the cell membrane target cell tissue by insertion of a pair of electrodes into the tissue so that DNA molecules in the surrounding media of the destabilized 91 ME148589913v.1membrane would be able to penetrate into cytoplasm and nucleoplasm of the cell. Electroporation has been used in vivo for many types of tissues, such as skin, lung, and muscle. In some cases, a ceDNA vector is delivered by hydrodynamic injection, which is a simple and highly efficient method for direct intracellular delivery of any water-soluble compounds and particles into internal organs and skeletal muscle in an entire limb. In some cases, ceDNA vectors are delivered by ultrasound by making nanoscopic pores in membrane to facilitate intracellular delivery of DNA particles into cells of internal organs or tumors, so the size and concentration of plasmid DNA have great role in efficiency of the system. In some cases, ceDNA vectors are delivered by magnetofection by using magnetic fields to concentrate particles containing nucleic acid into the target cells. In some cases, chemical delivery systems can be used, for example, by using nanomeric complexes, which include compaction of negatively charged nucleic acid by polycationic nanomeric particles, belonging to cationic liposome / micelle or cationic polymers. Cationic lipids used for the delivery method includes, but not limited to monovalent cationic lipids, polyvalent cationic lipids, guanidine containing compounds, cholesterol derivative compounds, cationic polymers, (e.g., poly(ethylenimine), poly-L-lysine, protamine, other cationic polymers), and lipid-polymer hybrid. A. Exosomes In some embodiments, a ceDNA vector as disclosed herein is delivered by being packaged in an exosome. Exosomes are small membrane vesicles of endocytic origin that are released into the extracellular environment following fusion of multivesicular bodies with the plasma membrane. Their surface consists of a lipid bilayer from the donor cell's cell membrane, they contain cytosol from the cell that produced the exosome, and exhibit membrane proteins from the parental cell on the surface. Exosomes are produced by various cell types including epithelial cells, B and T lymphocytes, mast cells (MC) as well as dendritic cells (DC). Some embodiments, exosomes with a diameter between 10nm and 1μm, between 20nm and 500nm, between 30nm and 250nm, between 50nm and 100nm are envisioned for use. Exosomes can be isolated for delivery to target cells using either their donor cells or by introducing specific nucleic acids into them. Various approaches known in the art can be used to produce exosomes containing capsid-free AAV vectors of the present disclosure. B. Microparticle / Nanoparticles In some embodiments, a ceDNA vector as disclosed herein is delivered by a lipid nanoparticle. Generally, lipid nanoparticles comprise an ionizable amino lipid (e.g., heptatriaconta- 6,9,28,31-tetraen-19-yl 4-(dimethylamino)butanoate, DLin-MC3-DMA, a phosphatidylcholine (1,2- distearoyl-sn-glycero-3-phosphocholine, DSPC), cholesterol and a coat lipid (polyethylene glycol- 92 ME148589913v.1dimyristolglycerol, PEG-DMG), for example as disclosed by Tam et al. (2013). Advances in Lipid Nanoparticles for siRNA delivery. Pharmaceuticals 5(3): 498-507. Generally, the LNPs of the disclosure have a mean diameter selected to provide an intended therapeutic effect. For example, the LNPs of the disclosure have a mean diameter that is compatible with a target organ, such that the LNPs of the disclosure are able to diffuse through the fenestrations of a target organ (e.g., liver) or a target cell subpopulation (e.g., hepatocytes). Lipid particles of the disclosure are characterized by an average diameter of about 70-80 nm or less, making them particularly useful for therapeutic administration. In one embodiment, lipid particles of the disclosure typically have a mean diameter of from about 20 nm to about 75 nm, about 20 nm to about 70 nm, about 25 nm to about 75 nm, about 25 nm to about 70 nm, from about 30 nm to about 75 nm, from about 30 nm to about 70 nm, from about 35 nm to about 75 nm, from about 35 nm to about 70 nm, from about 40 nm to about 75 nm, from about 40 nm to about 70 nm, from about 45 nm to about 75 nm, from about 50 nm to about 75 nm, from about 50 nm to about 70 nm, from about 60 nm to about 75 nm, from about 60 nm to about 70 nm, from about 65 nm to about 75 nm, from about 65 nm to about 70 nm, or about 20 nm, about 25 nm, about 30 nm, about 35 nm, about 40 nm, about 45 nm, about 50 nm, about 51 nm, about 52 nm, about 53 nm, about 54 nm, about 55 nm, about 56 nm, about 57 nm, about 58 nm, about 59 nm about 60 nm, about 61 nm, about 62 nm, about 63 nm, about 64 nm, about 65 nm, about 66 nm, about 67 nm, about 68 nm, about 69 nm, about 70 nm, about 71 nm, about 72 nm, about 73 nm, about 74 nm, or about 75 nm (± 3 nm) in size. Various lipid nanoparticles known in the art can be used to deliver ceDNA vector disclosed herein. For example, various delivery methods using lipid nanoparticles are described in U.S. Patent Nos.9,404,127, 9,006,417 and 9,518,272. In some embodiments, a ceDNA vector disclosed herein is delivered by a gold nanoparticle. Generally, a nucleic acid can be covalently bound to a gold nanoparticle or non-covalently bound to a gold nanoparticle (e.g., bound by a charge-charge interaction), for example as described by Ding et al. (2014). Gold Nanoparticles for Nucleic Acid Delivery. Mol. Ther.22(6); 1075-1083. In some embodiments, gold nanoparticle-nucleic acid conjugates are produced using methods described, for example, in U.S. Patent No.6,812,334. C. Conjugates In some embodiments, a ceDNA vector as disclosed herein is conjugated (e.g., covalently bound to an agent that increases cellular uptake. An “agent that increases cellular uptake” is a molecule that facilitates transport of a nucleic acid across a lipid membrane. For example, a nucleic acid can be conjugated to a lipophilic compound (e.g., cholesterol, tocopherol, etc.), a cell penetrating peptide (CPP) (e.g., penetratin, TAT, Syn1B, etc.), and polyamines (e.g., spermine). Further examples of agents that increase cellular uptake are disclosed, for example, in Winkler (2013). Oligonucleotide conjugates for therapeutic applications. Ther. Deliv.4(7); 791-809. 93 ME148589913v.1In some embodiments, a ceDNA vector as disclosed herein is conjugated to a polymer (e.g., a polymeric molecule) or a folate molecule (e.g., folic acid molecule). Generally, delivery of nucleic acids conjugated to polymers is known in the art, for example as described in WO2000 / 34343 and WO2008 / 022309. In some embodiments, a ceDNA vector as disclosed herein is conjugated to a poly(amide) polymer, for example as described by U.S. Patent No.8,987,377. In some embodiments, a nucleic acid described by the disclosure is conjugated to a folic acid molecule as described in U.S. Patent No.8,507,455. In some embodiments, a ceDNA vector as disclosed herein is conjugated to a carbohydrate, for example as described in U.S. Patent No.8,450,467. D. Nanocapsule Alternatively, nanocapsule formulations of a ceDNA vector as disclosed herein can be used. Nanocapsules can generally entrap substances in a stable and reproducible way. To avoid side effects due to intracellular polymeric overloading, such ultrafine particles (sized around 0.1 µm) should be designed using polymers able to be degraded in vivo. Biodegradable polyalkyl-cyanoacrylate nanoparticles that meet these requirements are contemplated for use. E. Liposomes The ceDNA vectors in accordance with the present disclosure can be added to liposomes for delivery to a cell or target organ in a subject. Liposomes are vesicles that possess at least one lipid bilayer. Liposomes are typical used as carriers for drug / therapeutic delivery in the context of pharmaceutical development. They work by fusing with a cellular membrane and repositioning its lipid structure to deliver a drug or active pharmaceutical ingredient (API). Liposome compositions for such delivery are composed of phospholipids, especially compounds having a phosphatidylcholine group, however these compositions may also include other lipids. The formation and use of liposomes is generally known to those of skill in the art. Liposomes have been developed with improved serum stability and circulation half-times (U.S. Pat. No. 5,741,516). Further, various methods of liposome and liposome like preparations as potential drug carriers have been described (U.S. Pat. Nos.5,567,434; 5,552,157; 5,565,213; 5,738,868 and 5,795,587). Liposomes have been used successfully with a number of cell types that are normally resistant to transfection by other procedures. In addition, liposomes are free of the DNA length constraints that are typical of viral-based delivery systems. Liposomes have been used effectively to introduce genes, drugs, radiotherapeutic agents, viruses, transcription factors and allosteric effectors into a variety of cultured cell lines and animals. In addition, several successful clinical trials examining the effectiveness of liposome-mediated drug delivery have been completed. 94 ME148589913v.1Liposomes are formed from phospholipids that are dispersed in an aqueous medium and spontaneously form multilamellar concentric bilayer vesicles (also termed multilamellar vesicles (MLVs). MLVs generally have diameters of from 25 nm to 4 µm. Sonication of MLVs results in the formation of small unilamellar vesicles (SUVs) with diameters in the range of 200 to 500 ANG, containing an aqueous solution in the core. In some embodiments, a liposome comprises cationic lipids. The term “cationic lipid” includes lipids and synthetic lipids having both polar and non-polar domains and which are capable of being positively charged at or around physiological pH and which bind to polyanions, such as nucleic acids, and facilitate the delivery of nucleic acids into cells. In some embodiments, cationic lipids include saturated and unsaturated alkyl and alicyclic ethers and esters of amines, amides, or derivatives thereof. In some embodiments, cationic lipids comprise straight-chain, branched alkyl, alkenyl groups, or any combination of the foregoing. In some embodiments, cationic lipids contain from 1 to about 25 carbon atoms (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 carbon atoms. In some embodiments, cationic lipids contain more than 25 carbon atoms. In some embodiments, straight chain or branched alkyl or alkene groups have six or more carbon atoms. A cationic lipid can also comprise, in some embodiments, one or more alicyclic groups. Non-limiting examples of alicyclic groups include cholesterol and other steroid groups. In some embodiments, cationic lipids are prepared with one or more counter ions. Examples of counter ions (anions) include, but are not limited to, Cl−, Br−, I−, F−, acetate, trifluoroacetate, sulfate, nitrite, and nitrate. In some aspects, the disclosure provides for a liposome formulation that includes one or more compounds with a polyethylene glycol (PEG) functional group (so-called “PEG-ylated compounds”) which can reduce the immunogenicity / antigenicity of, provide hydrophilicity and hydrophobicity to the compound(s) and reduce dosage frequency. Or the liposome formulation simply includes polyethylene glycol (PEG) polymer as an additional component. In such aspects, the molecular weight of the PEG or PEG functional group can be from 62 Da to about 5,000 Da. In some aspects, the disclosure provides for a liposome formulation that will deliver an API with extended release or controlled release profile over a period of hours to weeks. In some related aspects, the liposome formulation may comprise aqueous chambers that are bound by lipid bilayers. In other related aspects, the liposome formulation encapsulates an API with components that undergo a physical transition at elevated temperature which releases the API over a period of hours to weeks. In some aspects, the liposome formulation comprises sphingomyelin and one or more lipids disclosed herein. In some aspects, the liposome formulation comprises optisomes. In some aspects, the disclosure provides for a liposome formulation that includes one or more lipids selected from: N-(carbonyl-methoxypolyethylene glycol 2000)-1,2-distearoyl-sn-glycero-3- phosphoethanolamine sodium salt, (distearoyl-sn-glycero-phosphoethanolamine), MPEG (methoxy polyethylene glycol)-conjugated lipid, HSPC (hydrogenated soy phosphatidylcholine); PEG 95 ME148589913v.1(polyethylene glycol); DSG (distearoyl-rac-glycerol); DSPE (distearoyl-sn-glycero- phosphoethanolamine); DSPC (distearoylphosphatidylcholine); DOPC (dioleoylphosphatidylcholine); DPPG (dipalmitoylphosphatidylglycerol); EPC (egg phosphatidylcholine); DOPS (dioleoylphosphatidylserine); POPC (palmitoyloleoylphosphatidylcholine); SM (sphingomyelin); MPEG (methoxy polyethylene glycol); DMPC (dimyristoyl phosphatidylcholine); DMPG (dimyristoyl phosphatidylglycerol); DSPG (distearoylphosphatidylglycerol); DEPC (dierucoylphosphatidylcholine); DOPE (dioleoly-sn-glycero-phophoethanolamine). cholesteryl sulphate (CS), dipalmitoylphosphatidylglycerol (DPPG), DOPC (dioleoly-sn-glycero- phosphatidylcholine) or any combination thereof. In some aspects, the disclosure provides for a liposome formulation comprising phospholipid, cholesterol and a PEG-ylated lipid in a molar ratio of 56:38:5. In some aspects, the liposome formulation’s overall lipid content is from 2-16 mg / mL. In some aspects, the disclosure provides for a liposome formulation comprising a lipid containing a phosphatidylcholine functional group, a lipid containing an ethanolamine functional group and a PEG-ylated lipid. In some aspects, the disclosure provides for a liposome formulation comprising a lipid containing a phosphatidylcholine functional group, a lipid containing an ethanolamine functional group and a PEG-ylated lipid in a molar ratio of 3:0.015:2 respectively. In some aspects, the disclosure provides for a liposome formulation comprising a lipid containing a phosphatidylcholine functional group, cholesterol and a PEG-ylated lipid. In some aspects, the disclosure provides for a liposome formulation comprising a lipid containing a phosphatidylcholine functional group and cholesterol. In some aspects, the PEG-ylated lipid is PEG-2000-DSPE. In some aspects, the disclosure provides for a liposome formulation comprising DPPG, soy PC, MPEG-DSPE lipid conjugate and cholesterol. In some aspects, the disclosure provides for a liposome formulation comprising one or more lipids containing a phosphatidylcholine functional group and one or more lipids containing an ethanolamine functional group. In some aspects, the disclosure provides for a liposome formulation comprising one or more: lipids containing a phosphatidylcholine functional group, lipids containing an ethanolamine functional group, and sterols, e.g., cholesterol. In some aspects, the liposome formulation comprises DOPC / DEPC; and DOPE. In some aspects, the disclosure provides for a liposome formulation further comprising one or more pharmaceutical excipients, e.g., sucrose and / or glycine. In some aspects, the disclosure provides for a liposome formulation that is wither unilamellar or multilamellar in structure. In some aspects, the disclosure provides for a liposome formulation that comprises multi-vesicular particles and / or foam-based particles. In some aspects, the disclosure provides for a liposome formulation that are larger in relative size to common nanoparticles and about 150 to 250 nm in size. In some aspects, the liposome formulation is a lyophilized powder. In some aspects, the disclosure provides for a liposome formulation that is made and loaded with ceDNA vectors disclosed or described herein, by adding a weak base to a mixture having the 96 ME148589913v.1isolated ceDNA outside the liposome. This addition increases the pH outside the liposomes to approximately 7.3 and drives the API into the liposome. In some aspects, the disclosure provides for a liposome formulation having a pH that is acidic on the inside of the liposome. In such cases the inside of the liposome can be at pH 4-6.9, and more preferably pH 6.5. In other aspects, the disclosure provides for a liposome formulation made by using intra-liposomal drug stabilization technology. In such cases, polymeric or non-polymeric highly charged anions and intra-liposomal trapping agents are utilized, e.g., polyphosphate or sucrose octasulfate. In other aspects, the disclosure provides for a liposome formulation comprising phospholipids, lecithin, phosphatidylcholine and phosphatidylethanolamine. Non-limiting examples of cationic lipids include polyethylenimine, polyamidoamine (PAMAM) starburst dendrimers, Lipofectin (a combination of DOTMA and DOPE), Lipofectase, LIPOFECTAMINE™ (e.g., LIPOFECTAMINE™ 2000), DOPE, Cytofectin (Gilead Sciences, Foster City, Calif.), and Eufectins (JBL, San Luis Obispo, Calif.). Exemplary cationic liposomes can be made from N-[1-(2,3-dioleoloxy)-propyl]-N,N,N-trimethylammonium chloride (DOTMA), N-[1 - (2,3-dioleoloxy)-propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP), 3β-[N-(N′,N′- dimethylaminoethane)carbamoyl]cholesterol (DC-Chol), 2,3,-diol...
Claims
CLAIMS 1. A composition comprising: a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise a viral inverted terminal repeat (ITR) sequence, and a lipid.
2. The composition of claim 1, further comprising a pharmaceutically acceptable excipient or carrier.
3. A pharmaceutical composition comprising: a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise a viral inverted terminal repeat (ITR) sequence, an LNP, and a pharmaceutically acceptable excipient or carrier.
4. The composition of claim 2 or claim 3, wherein the ceDNA vector is encapsulated by or associated with the LNP.
5. The composition or pharmaceutical composition of any one of claims 1 to 4, wherein the stem-loop structures do not comprise a viral ITR sequence comprising a sequence selected from the group consisting of a Rep binding element (RBE), a RBE’, a terminal resolution site (trs), an A ITR region, an A’ ITR region, a B ITR region, a B’ ITR region, a C ITR region, a C’ ITR region, a D ITR region, a D’ ITR region, and a combination thereof.
6. The composition or pharmaceutical composition of any one of claims 1 to 5, wherein the at least one transgene expression cassette comprises at least one liver-specific regulatory element operably linked to at least one transgene.
7. The composition or pharmaceutical composition of any one of claims 1 to 6, wherein the first stem-loop structure is located upstream of the 5’ end of the at least one transgene expression cassette 139 ME148589913v.1and the second stem-loop structure is located downstream of the 3’ end of the at least one transgene expression cassette.
8. The composition or pharmaceutical composition of claim 7, wherein the first stem-loop structure and the second stem-loop structure are symmetric with respect to each other.
9. The composition or pharmaceutical composition of claim 7, wherein the first stem-loop structure and the second stem-loop structure are asymmetric with respect to each other.
10. The composition or pharmaceutical composition of any one of claims 7 to 9, wherein the first stem-loop structure and the second stem-loop structure each comprise at least one double-stranded stem region and at least one single-stranded loop region.
11. The composition or pharmaceutical composition of claim 10, wherein each partial duplex comprises about 1 to about 50 base pairs (bp), or about 1 to about 40 bp, or about 1 to about 30 bp, or about 1 to about 25 bp, or about 1 to about 20 bp, or about 1 to about 15 bp, or about 2 to about 20 bp, or about 2 to about 15 bp, or about 3 to about 20 bp, or about 3 to about 15 bp, or about 4 to about 20 bp, or about 4 to about 15 bp, or about 5 to about 20 bp, or about 5 to about 15 bp, or about 1 bp, or about 2 bp, or about 3 bp, or about 4 bp, or about 5 bp, or about 6 bp, or about 7 bp, or about 8 bp, or about 9 bp, or about 10 bp, or about 11 bp, or about 12 bp, or about 13 bp, or about 14 bp, or about 15 bp.
12. The composition or pharmaceutical composition of claim 10 or claim 11, wherein each single- stranded loop comprises about 2 to about 100 nucleotides (nt), about 2 to about 90 nt, about 2 to about 80 nt, about 2 to about 70 nt, about 2 to about 60 nt, about 2 to about 50 nt, about 2 to about 40 nt, about 2 to about 30 nt, about 2 to about 20 nt, about 2 to about 15 nt, about 2 to about 12 nt, about 2 to about 10 nt, about 2 to about 8 nt, about 3 to about 20 nt, about 3 to about 15 nt, about 3 to about 12 nt, about 3 to about 10 nt, about 3 to about 8 nt, or about 2 nt, or about 3 nt, or about 4 nt, or about 5 nt, or about 6 nt, or about 7 nt, or about 8 nt, or about 9 nt, or about 10 nt, or about 11 nt, or about 12 nt, or about 13 nt, or about 14 nt, or about 15 nt.
13. The composition or pharmaceutical composition of any one of claims 1 to 12, wherein each stem-loop structure comprises at least one loop structure.
14. The composition or pharmaceutical composition of any one of claims 1 to 13, wherein at least one stem-loop structure comprises an aptamer. 140 ME148589913v.
115. The composition or pharmaceutical composition of any one of claims 1 to 14, wherein each stem-loop structure comprises an aptamer.
16. The composition or pharmaceutical composition of any one of claims 1 to 15, wherein each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO:1 (5’-CTCATCAGAATCACTTTGTGATTCTGA-3’), SEQ ID NO:2 (5’-TCAGAATCACAAAGTGATTCTGATGAG-3’), and SEQ ID NO:4 (5’- CACTCATCAGAATCACTTTGTGATTCTGATG-3’).
17. The composition or pharmaceutical composition of any one of claims 1 to 16, wherein each stem-loop structure independently comprises a nucleic acid sequence having at least 80%, at least 85%, at least 90%, at least 95%, or at least 99% sequence identity to a sequence selected from the group consisting of SEQ ID NO:12 (5’- TGAGCCTTGATACCACACTTACCTTTCAAGCTTAATACCTTTAGGAGAGCAATTGCAT-3’) and SEQ ID NO:13 (5’- ATGCAATTGCTCTCCTAAAGGTATTAAGCTTGAAAGGTAAGTGTGGTATCAAGGCTCA- 3’).
18. The composition or pharmaceutical composition of any one of claims 1 to 17, wherein the ceDNA vector further comprises at least one spacer region, wherein the at least one spacer region comprises an artificial nucleic acid sequence and does not comprise a viral ITR sequence.
19. The composition or pharmaceutical composition of claim 18, wherein the at least one spacer region is adjacent to the 5’ end of the at least one transgene expression cassette, or the at least one spacer region is adjacent to the 3’ end of the at least one transgene expression cassette, or both.
20. The composition or pharmaceutical composition of claim 18 or claim 19, wherein the at least one spacer region comprises about 1 to 200 bp, or about 5 to 150 bp, or about 10 to 100 bp, or about 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100 bp.
21. The composition or pharmaceutical composition of any one of claims 6 to 20, wherein the at least one liver-specific regulatory element is selected from the group consisting of a liver-specific promoter, a liver-specific enhancer, a liver-specific riboswitch, a liver-specific insulator, a liver- specific mir-regulatable element, a liver-specific post-transcriptional regulatory element, a liver- specific transcription factor binding site (or consensus site), and a combination thereof. 141 ME148589913v.
122. The composition or pharmaceutical composition of claim 21, wherein the at least one liver- specific transcription factor consensus site is FoxA, HNF4, or both.
23. The composition or pharmaceutical composition of claim 21, wherein the at least one liver- specific promoter is selected from the group consisting of: a transthyretin (TTR) promoter, minimal TTR promotor (TTRm), an AAT promoter, an albumin (ALB) promotor or minimal promoter, an apolipoprotein A1 (APOA1) promoter or minimal promoter, a complement factor B (CFB) promoter, a ketohexokinase (KHK) promoter, a hemopexin (HPX) promoter or minimal promoter, a nicotinamide N-methyltransferase (NNMT) promoter or minimal promoter, a carboxylesterase 1 (CES1) promoter or minimal promoter, a protein C (PROC) promoter or minimal promoter, an apolipoprotein C3 (APOC3) promoter or minimal promoter, a mannan-binding lectin serine protease 2 (MASP2) promoter or minimal promoter, a hepcidin antimicrobial peptide (HAMP) promoter or minimal promoter, and a serpin peptidase inhibitor, clade C (antithrombin), member 1 (SERPINCl) promoter or minimal promoter.
24. The composition or pharmaceutical composition of any one of claims 1 to 23, wherein the ceDNA vector produces an in vivo expression level of the at least one transgene expression cassette that is equivalent to or higher than the in vivo expression level produced by a reference ceDNA vector comprising a viral ITR sequence.
25. The composition or pharmaceutical composition of claim 24, wherein the ceDNA vector produces an in vivo liver expression level of the at least one transgene that is equivalent to or higher than the in vivo liver expression level produced by a reference ceDNA vector comprising a viral ITR sequence.
26. The composition or pharmaceutical composition of claim 24 or claim 25, wherein the ceDNA vector elicits an equivalent or lower pro-inflammatory cytokine response than a reference ceDNA vector comprising a viral ITR sequence.
27. The composition or pharmaceutical composition of any one of claims 1 to 26, wherein the ceDNA vector produces an expression level of the at least one transgene in a cell that is equivalent to or higher than the expression level of the at least one transgene produced by a reference ceDNA vector comprising the same transgene expression cassette and at least one stem-loop structure comprising a viral ITR sequence. 142 ME148589913v.
128. The composition or pharmaceutical composition of claim 27, wherein the cell is selected from the group consisting of a liver cell, a muscle cell, a T cell, a B cell, a natural killer (NK) cell, and a dendritic cell.
29. The composition or pharmaceutical composition of claim 28, wherein the cell is in vitro.
30. The composition or pharmaceutical composition of claim 28, wherein the cell is in vivo.
31. The composition or pharmaceutical composition of claim 28, wherein the cell is ex vivo.
32. The composition or pharmaceutical composition of any one of claims 1 to 31, wherein the ceDNA vector is synthetically produced in a cell-free environment.
33. The composition or pharmaceutical composition of any one of claims 1 to 32, wherein the ceDNA vector is produced using a method comprising: (a) contacting a double-stranded DNA construct having a sense strand and an antisense strand with at least a first restriction endonuclease and at least a second restriction endonuclease, wherein: the double-stranded DNA construct comprises: a transgene expression cassette, a first non-palindromic restriction endonuclease recognition site and a corresponding first cleavage site upstream of the transgene expression cassette, and a second non-palindromic restriction endonuclease recognition site and a corresponding second cleavage site downstream of the transgene expression cassette; and wherein the first restriction endonuclease is capable of cleaving the double-stranded DNA construct at the first cleavage site, and wherein the second restriction endonuclease is capable of cleaving the double-stranded DNA construct at the second cleavage site, and wherein contacting the double-stranded DNA construct with the first restriction endonuclease and the second restriction endonuclease releases an insert having a first end comprising a first single-stranded overhang and a second end comprising a second single- stranded overhang; (b) ligating the first end to a first oligonucleotide comprising one or more stem-loop structures, wherein the first oligonucleotide does not comprise a viral inverted terminal repeat (ITR) sequence; and (c) ligating the second end to a second oligonucleotide comprising one or more stem- loop structures, wherein the second oligonucleotide does not comprise a viral ITR sequence; 143 ME148589913v.1thereby producing the ceDNA vector.
34. The composition or pharmaceutical composition of claim 33, wherein the first oligonucleotide and the second oligonucleotide are symmetric with respect to each other.
35. The composition or pharmaceutical composition of claim 33, wherein the first oligonucleotide and the second oligonucleotide are asymmetric with respect to each other.
36. The composition or pharmaceutical composition of any one of claims 33 to 35, wherein the first oligonucleotide and the second oligonucleotide each self-anneal to form the one or more stem- loop structures and a single-stranded overhang at the 5’ end of each oligonucleotide or the 3’ end of each oligonucleotide.
37. The composition or pharmaceutical composition of any one of claims 33 to 35, wherein the single-stranded overhang of the first oligonucleotide and / or the single-stranded overhang of the second oligonucleotide each comprise a 5’ to 3’ nucleic acid sequence selected from the group consisting of CTCT, CTCA, CACT, CTC, and GCT.
38. The composition or pharmaceutical composition of any one of claims 33 to 37, wherein the first oligonucleotide corresponds to the first stem-loop region in the ceDNA vector and the second oligonucleotide corresponds to the second stem-loop region in the ceDNA vector.
39. The composition or pharmaceutical composition of any one of claims 33 to 38, wherein at least one of the first and second restriction endonucleases or wherein each of the first and second restriction endonucleases is a Type IIS restriction endonuclease.
40. The composition or pharmaceutical composition of any one of claims 33 to 39, wherein the first restriction endonuclease and the second restriction endonuclease are the same restriction endonuclease.
41. The composition or pharmaceutical composition of any one of claims 33 to 40, wherein the first restriction endonuclease and the second restriction endonuclease are different restriction endonucleases.
42. The composition or pharmaceutical composition of any one of claims 39 to 41, wherein the Type IIS restriction endonuclease is selected from group consisting of AcuI, AlwI, Alw26I, BasI, BbsI, BbvI, BceAI, BcgI, BciVI, BcoDI, BruAI, BmrI, BpiI, BpuEI, BsaI, BsaXI, BseGI, BseRI, BsgI, 144 ME148589913v.1BsmAI, BsmBI, BsmFI, BsmI, BspCNI, BspMI, BspQI, BsrDI, BsrI, BtgZI, BtsCI, BtsI, MutI, CspCI, EarI, EciI, Eco31I, Esp3I, FauI, FokI, HgaI, HphI, HpyAV, LguI, MboII, MlyI, MmeI, MnlI, Mva1269I, NmeAIII, PaqCI, PleI, SapI, SfaNI, and an isoschizomer thereof.
43. The composition or pharmaceutical composition of any one of claims 39 to 42, wherein the Type IIS restriction endonuclease is selected from group consisting of BbsI, BsaI, BsmBI, Esp3I, and SapI, and an isoschizomer thereof.
44. The composition or pharmaceutical composition of any one of claims 39 to 43, wherein the Type IIS restriction endonuclease is BsmBI or an isoschizomer thereof; or wherein each of the first and second restriction endonucleases is BsmBI or an isoschizomer thereof.
45. The composition or pharmaceutical composition of any one of claims 1 to 44, wherein the lipid or LNP comprises at least one lipid selected from the group consisting of an ionizable lipid, a sterol, non-cationic lipid, and a lipid-anchored polymer.
46. The composition or pharmaceutical composition of any one of claims 2 to 45, wherein the LNP comprises a sterol.
47. The composition or pharmaceutical composition of claim 46, wherein the sterol is cholesterol or beta-sitosterol.
48. The composition or pharmaceutical composition of any one of claims 2 to 47, wherein the LNP comprises a non-cationic lipid.
49. The composition or pharmaceutical composition of claim 48, wherein the non-cationic lipid is selected from the group consisting of distearoyl-sn-glycero-phosphoethanolamine (DSPE), distearoylphosphatidylcholine (DSPC), dioleoylphosphatidylcholine (DOPC), dipalmitoylphosphatidylcholine (DPPC), dioleoylphosphatidylglycerol (DOPG), dipalmitoylphosphatidylglycerol (DPPG), dioleoyl-phosphatidylethanolamine (DOPE), palmitoyloleoylphosphatidylcholine (POPC), palmitoyloleoylphosphatidylethanolamine (POPE), dioleoyl-phosphatidylethanolamine 4-(N-maleimidomethyl)-cyclohexane-1-carboxylate (DOPE-mal), dipalmitoyl phosphatidyl ethanolamine (DPPE), dimyristoylphosphoethanolamine (DMPE), distearoyl-phosphatidyl-ethanolamine (DSPE), monomethyl-phosphatidylethanolamine (such as 16- O-monomethyl PE), dimethyl-phosphatidylethanolamine (such as 16-O-dimethyl PE), 18-1-trans PE, 1-stearoyl-2-oleoyl-phosphatidyethanolamine (SOPE), hydrogenated soy phosphatidylcholine (HSPC), egg phosphatidylcholine (EPC), dioleoylphosphatidylserine (DOPS), sphingomyelin (SM), 145 ME148589913v.1dimyristoyl phosphatidylcholine (DMPC), dimyristoyl phosphatidylglycerol (DMPG), distearoylphosphatidylglycerol (DSPG), dierucoylphosphatidylcholine (DEPC), palmitoyloleyolphosphatidylglycerol (POPG), dielaidoyl-phosphatidylethanolamine (DEPE), 1,2- dilauroyl-sn-glycero-3 -pho sphoethanolamine (DLPE); 1,2-diphytanoyl-sn-glycero-3- phosphoethanolamine (DPHyPE); lecithin, phosphatidylethanolamine, lysolecithin, lysophosphatidylethanolamine, phosphatidylserine, phosphatidylinositol, sphingomyelin, egg sphingomyelin (ESM), cephalin, cardiolipin, phosphatidicacid, cerebrosides, dicetylphosphate, lysophosphatidylcholine, dilinoleoylphosphatidylcholine, and mixtures thereof.
50. The composition or pharmaceutical composition of claim 48 or claim 49, wherein the non- cationic lipid is selected from the group consisting of dioleoylphosphatidylcholine (DOPC), distearoylphosphatidylcholine (DSPC), and dioleoyl-phosphatidylethanolamine (DOPE).
51. The composition or pharmaceutical composition of any one of claims 48 to 50, wherein the non-cationic lipid is DSPC.
52. The composition or pharmaceutical composition of any one of claims 2 to 51, wherein the LNP comprises a lipid-anchored polymer.
53. The composition or pharmaceutical composition of claim 52, wherein the lipid-anchored polymer is a PEGylated lipid.
54. The composition or pharmaceutical composition of claim 53, wherein the PEGylated lipid is selected from the group consisting of PEG-dilauryloxypropyl; PEG-dimyristyloxypropyl; PEG- dipalmityloxypropyl, PEG-distearyloxypropyl; l-(monomethoxy-polyethyleneglycol)-2,3- dimyristoylglycerol (DMG-PEG); PEG-dilaurylglycerol; PEG-dipalmitoylglycerol; PEG- disterylglycerol; PEG-dilaurylglycamide; PEG-dimyristylglycamide; PEG-dipalmitoylglycamide; PEG-disterylglycamide; (l-[8’-(Cholest-5-en-3[beta]-oxy)carboxamido-3’,6’-dioxaoctanyl] carbamoyl-[omega]-methyl-poly(ethylene glycol) (PEG-cholesterol); 3,4-ditetradecoxylbenzyl- [omega]- methyl-poly(ethylene glycol) ether (PEG-DMB), and l,2-dimyristoyl-sn-glycero-3- phosphoethanolamine-N- [methoxy(polyethylene glycol) (DSPE-PEG).
55. The composition or pharmaceutical composition of claim 53 or claim 54, wherein the PEGylated lipid is DMG-PEG, DSPE-PEG, or both.
56. The composition or pharmaceutical composition of any one of claims 53 to 55, wherein the PEGylated lipid is DMG-PEG2000, DSPE-PEG2000, or both. 146 ME148589913v.
157. The composition or pharmaceutical composition of any one of claims 2 to 56, wherein the LNP comprises an ionizable lipid, a sterol, and a lipid-anchored polymer.
58. The composition or pharmaceutical composition of any one of claims 2 to 57, wherein the LNP comprises an ionizable lipid, a sterol, a non-cationic lipid, and a lipid-anchored polymer.
59. The composition or pharmaceutical composition of any one of claims 2 to 58, wherein the LNP comprise a tissue-specific targeting ligand.
60. The composition or pharmaceutical composition of claim 59, wherein the tissue-specific targeting ligand is N-acetylgalactosamine (GalNAc) or a GalNAc derivative.
61. The composition or pharmaceutical composition of claim 59 or claim 60, wherein the tissue- specific targeting ligand is covalently linked to the PEGylated lipid to form a PEGylated lipid conjugate.
62. The composition or pharmaceutical composition of claim 61, wherein the PEGylated lipid conjugate comprises tetra- or tri-antennary GalNAc covalently linked to the PEGylated lipid.
63. The composition or pharmaceutical composition of claim 61 or claim 62, wherein the PEGylated lipid is DSPE-PEG2000 64. The composition or pharmaceutical composition of any one of claims 45 to 63, wherein the ionizable lipid is present in the LNP at a molar percentage of about 30% to about 70%.
65. The composition or pharmaceutical composition of any one of claims 45 to 64, wherein the sterol is present in the LNP at a molar percentage of about 20% to about 50%.
66. The composition or pharmaceutical composition of any one of claims 45 to 65, wherein the non-cationic lipid is present in the LNP at a molar percentage of about 2% to about 20%.
67. The composition or pharmaceutical composition of any one of claims 45 to 66, wherein the lipid-anchored polymer or PEGylated lipid is present in the LNP at a molar percentage of about 2.1% to about 10%. 147 ME148589913v.
168. The composition or pharmaceutical composition of any one of claims 55, 56, or 61 to 67, wherein the PEGylated lipid conjugate is present in the LNP at a molar percentage of about 0.1% to about 10%.
69. The composition or pharmaceutical composition of any one of claims 45 to 63, wherein the LNP comprises an ionizable lipid, a sterol, a non-cationic lipid, a PEGylated lipid, and a PEGylated lipid conjugate.
70. The composition or pharmaceutical composition of any one of claims 2 to 69, wherein the LNP has an average diameter ranging from about 40 nm to about 120 nm.
71. The composition or pharmaceutical composition of any one of claims 2 to 70, wherein the LNP has an average diameter of less than about 100 nm.
72. The composition or pharmaceutical composition of any one of claims 2 to 71, wherein the LNP has an average diameter of about 50 nm to about 80 nm.
73. An isolated host cell comprising the ceDNA vector of the composition or pharmaceutical composition any one of claims 1 to 72.
74. An isolated host cell comprising: a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise any viral ITR sequences.
75. A transgenic animal comprising the ceDNA vector of any one of claims 1 to 72 or the isolated host cell of claim 73 or claim 74.
76. A transgenic animal comprising: a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise any viral ITR sequences. 148 ME148589913v.
177. A method of treating a disorder, disease, or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of the composition or pharmaceutical composition of any one of claims 1 to 72.
78. A method of treating a disorder, disease, or condition in a subject, the method comprising administering to the subject a therapeutically effective amount of a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise any viral ITR sequence, wherein the ceDNA vector is encapsulated by an LNP.
79. The method of claim 77 or claim 78, wherein the disorder, disease, or condition is a genetic disorder, disease, or condition.
80. A method of delivering a therapeutic protein to a subject, the method comprising administering to the subject a therapeutically effective amount of the composition or pharmaceutical composition of any one of claims 1 to 72.
81. A method of delivering a therapeutic protein to a subject, the method comprising administering to the subject a therapeutically effective amount of a non-viral, capsid-free DNA vector with covalently-closed ends (ceDNA vector), wherein the ceDNA vector comprises at least one transgene expression cassette flanked by a first stem-loop structure and a second stem-loop structure, each stem-loop structure comprising a partial duplex and at least one loop, wherein the stem-loop structures do not comprise any viral ITR sequences, and wherein the ceDNA vector is encapsulated by an LNP.
82. The method of claim 80 or claim 81, wherein the therapeutic protein is selected from the group consisting of an enzyme, a coagulation factor or co-factor, an antibody or an antigen-binding fragment thereof, an antigen, a gene-editing protein, and a cytotoxic protein.
83. A method of producing the ceDNA vector of any one of claims 1 to 72, the method comprising: (a) contacting a double-stranded DNA construct having a sense strand and an antisense strand with at least a first restriction endonuclease and at least a second restriction endonuclease, wherein: the construct comprises: 149 ME148589913v.1a transgene expression cassette, a first non-palindromic restriction endonuclease recognition site and a corresponding first cleavage site upstream of the transgene expression cassette, and a second non-palindromic restriction endonuclease recognition site and a corresponding second cleavage site downstream of the transgene expression cassette; and wherein the first restriction endonuclease is capable of cleaving the double-stranded DNA construct at the first cleavage site, and wherein the second restriction endonuclease is capable of cleaving the double-stranded DNA construct at the second cleavage site, and wherein contacting the double-stranded DNA construct with the first restriction endonuclease and the second restriction endonuclease releases an insert having a first end comprising a first single-stranded overhang and a second end comprising a second single- stranded overhang; (b) ligating the first end to a first oligonucleotide comprising one or more stem-loop structures, wherein the first oligonucleotide does not comprise a viral inverted terminal repeat (ITR) sequence; and (c) ligating the second end to a second oligonucleotide comprising one or more stem- loop structures, wherein the second oligonucleotide does not comprise a viral ITR sequence; thereby producing the ceDNA vector.
84. The method of claim 83, wherein the first oligonucleotide and the second oligonucleotide are symmetric with respect to each other.
85. The method of claim 83, wherein the first oligonucleotide and the second oligonucleotide are asymmetric with respect to each other.
86. The method of any one of claims 83 to 85, wherein the first oligonucleotide and the second oligonucleotide each self-anneal to form the one or more stem-loop structures and a single-stranded overhang at the 5’ end of each oligonucleotide or the 3’ end of each oligonucleotide.
87. The composition or pharmaceutical composition of any one of claims 83 to 85, wherein the single-stranded overhang of the first oligonucleotide and / or the single-stranded overhang of the second oligonucleotide each comprise a 5’ to 3’ nucleic acid sequence selected from the group consisting of CTCT, CTCA, CACT, CTC, and GCT. 150 ME148589913v.
188. The composition or pharmaceutical composition of any one of claims 83 to 87, wherein the first oligonucleotide corresponds to the first stem-loop region in the ceDNA vector and the second oligonucleotide corresponds to the second stem-loop region in the ceDNA vector.
89. The composition or pharmaceutical composition of any one of claims 83 to 88, wherein at least one of the first and second restriction endonucleases or wherein each of the first and second restriction endonucleases is a Type IIS restriction endonuclease.
90. The composition or pharmaceutical composition of any one of claims 83 to 89, wherein the first restriction endonuclease and the second restriction endonuclease are the same restriction endonuclease.
91. The composition or pharmaceutical composition of any one of claims 83 to 90, wherein the first restriction endonuclease and the second restriction endonuclease are different restriction endonucleases.
92. The composition or pharmaceutical composition of any one of claims 89 to 91, wherein the Type IIS restriction endonuclease is selected from group consisting of AcuI, AlwI, Alw26I, BasI, BbsI, BbvI, BceAI, BcgI, BciVI, BcoDI, BruAI, BmrI, BpiI, BpuEI, BsaI, BsaXI, BseGI, BseRI, BsgI, BsmAI, BsmBI, BsmFI, BsmI, BspCNI, BspMI, BspQI, BsrDI, BsrI, BtgZI, BtsCI, BtsI, MutI, CspCI, EarI, EciI, Eco31I, Esp3I, FauI, FokI, HgaI, HphI, HpyAV, LguI, MboII, MlyI, MmeI, MnlI, Mva1269I, NmeAIII, PaqCI, PleI, SapI, SfaNI, and an isoschizomer thereof.
93. The composition or pharmaceutical composition of any one of claims 89 to 92, wherein the Type IIS restriction endonuclease is selected from group consisting of BbsI, BsaI, BsmBI, Esp3I, and SapI, and an isoschizomer thereof.
94. The composition or pharmaceutical composition of any one of claims 89 to 93, wherein the Type IIS restriction endonuclease is BsmBI or an isoschizomer thereof; or wherein each of the first and second restriction endonucleases is BsmBI or an isoschizomer thereof. 151 ME148589913v.1
